var title_f29_37_30288="mBODE and survival postLVRS";
var content_f29_37_30288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 625px\">",
"   <div class=\"ttl\">",
"    mBODE and survival post-LVRS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 605px; height: 422px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curves (starting at 6 months after randomization [F06]) for the surgically treated patients in the National Emphysema Treatment Trial who survived and were able to provide data to calculate mBODE (",
"    <strong>",
"     m",
"    </strong>",
"    odified",
"    <strong>",
"     B",
"    </strong>",
"    ody mass index, airflow",
"    <strong>",
"     O",
"    </strong>",
"    bstruction,",
"    <strong>",
"     D",
"    </strong>",
"    yspnea, and",
"    <strong>",
"     E",
"    </strong>",
"    xercise capacity) 6 (F06) months after randomization. Survival curves are segregated by groups who experienced a decrease in mBODE &gt; 1 (",
"    <span class=\"blue\">",
"     blue",
"    </span>",
"    ), a rise in mBODE &gt; 1 (",
"    <span class=\"red\">",
"     red",
"    </span>",
"    ), no change in mBODE (-1 to 1 point change) (",
"    <span class=\"green\">",
"     green",
"    </span>",
"    ), or missing data (black) from baseline to the starting time point.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission of the American Thoracic Society. Copyright &copy; 2008 American Thoracic Society. Martinez, FJ, Han, MK, Andrei, AC, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. American Journal of Respiratory and Critical Care Medicine 2008; 178:491. Official journal of the American Thoracic Society. Diane Gern, Publisher.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30288=[""].join("\n");
var outline_f29_37_30288=null;
var title_f29_37_30289="Patient information: Acute cerebellar ataxia (The Basics)";
var content_f29_37_30289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/57/27538\">",
"         Patient information: Chickenpox (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/31/1522\">",
"         Patient information: Roseola (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/40/2691\">",
"         Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Acute cerebellar ataxia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/acute-cerebellar-ataxia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2296148\">",
"      <span class=\"h1\">",
"       What is acute cerebellar ataxia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Acute cerebellar ataxia is a condition that causes people to suddenly become unable to coordinate their movements. It most often affects children between the ages of 2 and 5, but it can affect older people, too.",
"     </p>",
"     <p>",
"      Acute cerebellar ataxia usually happens in response to an infection that causes fever. For example, some children get it after having chickenpox.",
"     </p>",
"     <p>",
"      The symptoms of acute cerebellar ataxia usually go away on their own within 2 to 3 weeks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2296163\">",
"      <span class=\"h1\">",
"       What are the symptoms of acute cerebellar ataxia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is usually trouble walking, but other movement problems can also occur. Some children also develop:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Jumpy or flicking eyeball movements",
"       </li>",
"       <li>",
"        Trouble speaking clearly",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2296178\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. If your child has symptoms of acute cerebellar ataxia, the doctor or nurse will want to make sure those symptoms are not caused by a more serious problem, such as brain damage. He or she will ask a lot of questions about your child&rsquo;s symptoms and medical history. As part of the exam, the doctor or nurse will also need to watch how your child responds to different things and how he or she moves.",
"     </p>",
"     <p>",
"      The doctor or nurse might also order:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests to check for poisons or drugs (for example, if there is a chance the child accidentally swallowed something)",
"       </li>",
"       <li>",
"        Blood tests to check for low blood sugar, or other problems",
"       </li>",
"       <li>",
"        Imaging tests to check for problems in the brain",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2296193\">",
"      <span class=\"h1\">",
"       How is acute cerebellar ataxia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Acute cerebellar ataxia usually gets better on its own without treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2296208\">",
"      <span class=\"h1\">",
"       Is there anything I can do to help my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Give your child a lot of support. Let him or her know that things will get better. Also, keep a close watch on your child&rsquo;s symptoms and let the doctor know if they get worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2296223\">",
"      <span class=\"h1\">",
"       Can acute cerebellar ataxia be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can lower the chances that your child will get acute cerebellar ataxia by making sure he or she has all the right vaccines. Some of the infections that lead to acute cerebellar ataxia (such as chickenpox, measles, and mumps) can be prevented with vaccines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2296238\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=see_link\">",
"       Patient information: Chickenpox (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1522?source=see_link\">",
"       Patient information: Roseola (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/40/2691?source=see_link\">",
"       Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/37/30289?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83073 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30289=[""].join("\n");
var outline_f29_37_30289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2296148\">",
"      What is acute cerebellar ataxia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2296163\">",
"      What are the symptoms of acute cerebellar ataxia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2296178\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2296193\">",
"      How is acute cerebellar ataxia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2296208\">",
"      Is there anything I can do to help my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2296223\">",
"      Can acute cerebellar ataxia be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2296238\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=related_link\">",
"      Patient information: Chickenpox (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/40/2691?source=related_link\">",
"      Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1522?source=related_link\">",
"      Patient information: Roseola (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_37_30290="Patient information: High blood pressure in children (The Basics)";
var content_f29_37_30290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/28/38337\">",
"         Patient information: High blood pressure in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/58/931\">",
"         Patient information: High blood pressure treatment in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: High blood pressure in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/high-blood-pressure-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1240667263\">",
"      <span class=\"h1\">",
"       How do I know if my child has high blood pressure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;At your child&rsquo;s regular checkup, your doctor or nurse will check your child&rsquo;s blood pressure. He or she will compare your child&rsquo;s blood pressure to the blood pressure of other children of the same age, sex, and height. If your child&rsquo;s blood pressure is much greater than the blood pressure of other children of the same age, sex, and height, your doctor or nurse will check it again on one or more other days.",
"     </p>",
"     <p>",
"      Children have high blood pressure if their blood pressure is much greater than that of other children on 3 or more different days. Another word for high blood pressure is &ldquo;hypertension.&rdquo;",
"     </p>",
"     <p>",
"      Some children have a condition called &ldquo;pre-hypertension.&rdquo; These children have blood pressure that is greater than normal, but is not yet high blood pressure.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1240667270\">",
"      <span class=\"h1\">",
"       What are the symptoms of high blood pressure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;High blood pressure does not usually cause any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1240667277\">",
"      <span class=\"h1\">",
"       Why does my child have high blood pressure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes, high blood pressure is caused by a medical condition. Other times, there is no known cause. High blood pressure can run in families.",
"     </p>",
"     <p>",
"      Your doctor or nurse will want to figure out if a medical condition is causing your child&rsquo;s high blood pressure. He or she will talk with you and do an exam. During the exam, he or she will check the blood pressure in your child&rsquo;s arms and legs. Your doctor or nurse might also do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lab tests",
"       </li>",
"       <li>",
"        Ultrasounds of the heart and kidneys, or other imaging tests &ndash; Imaging tests can create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1240667284\">",
"      <span class=\"h1\">",
"       Why does high blood pressure need to be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;High blood pressure needs to be treated, because it can lead to future problems.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Children with high blood pressure can have high blood pressure as adults. Adults with high blood pressure have a greater chance of having a heart attack or stroke.",
"       </li>",
"       <li>",
"        A few children with very high blood pressure can have seizures or heart failure. Heart failure is a type of heart problem in which the heart cannot pump normally.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The goal of treatment is to reduce your child&rsquo;s high blood pressure until it is at a normal level. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1240667291\">",
"      <span class=\"h1\">",
"       How is high blood pressure treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, doctors treat any medical conditions that might be causing the high blood pressure.",
"     </p>",
"     <p>",
"      But treating the cause does not always reduce high blood pressure. Or there might not be a known cause. In these cases, high blood pressure is treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lifestyle changes",
"       </li>",
"       <li>",
"        Medicines",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1240667298\">",
"      <span class=\"h1\">",
"       What lifestyle changes might be part of treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lifestyle changes that might be part of treatment include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Losing weight (if your child is overweight) &ndash; Your doctor or nurse might recommend that you work with a &ldquo;nutritionist.&rdquo; A nutritionist is an expert on food and eating.",
"       </li>",
"       <li>",
"        Diet changes, such as eating healthier foods or reducing the amount of salt in your child&rsquo;s food. Healthy foods include fruits, vegetables, and low-fat dairy foods.",
"       </li>",
"       <li>",
"        Getting regular exercise &ndash; Most children should get &ldquo;aerobic&rdquo; exercise for 20 to 30 minutes a day, most days of the week. Aerobic exercise includes activities such as walking, running, swimming, or biking. Your doctor or nurse will tell you if there are activities your child should not do.",
"       </li>",
"       <li>",
"        Not spending a lot of time sitting, watching TV, or playing computer games",
"       </li>",
"       <li>",
"        Not smoking or drinking alcohol &ndash; Doctors also recommend that family members not smoke. Children who breathe in smoke can get heart problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1240667305\">",
"      <span class=\"h1\">",
"       What medicines might be part of treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can use different types of medicines to treat high blood pressure. The medicines work in different ways and can have different side effects. Your doctor will work with you to find the medicine that is right for your child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1240667312\">",
"      <span class=\"h1\">",
"       When do I follow up with my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will follow up with you and your child on a regular basis. On each visit, he or she will check your child&rsquo;s blood pressure. Let your doctor or nurse know if you have any problems with treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1240667319\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=see_link\">",
"       Patient information: High blood pressure in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=see_link\">",
"       Patient information: High blood pressure treatment in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/37/30290?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15659 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-0DF129FE3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30290=[""].join("\n");
var outline_f29_37_30290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240667263\">",
"      How do I know if my child has high blood pressure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240667270\">",
"      What are the symptoms of high blood pressure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240667277\">",
"      Why does my child have high blood pressure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240667284\">",
"      Why does high blood pressure need to be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240667291\">",
"      How is high blood pressure treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240667298\">",
"      What lifestyle changes might be part of treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240667305\">",
"      What medicines might be part of treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240667312\">",
"      When do I follow up with my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240667319\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=related_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=related_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_37_30291="Fusidic acid and hydrocortisone: Patient drug information";
var content_f29_37_30291=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fusidic acid and hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/36/11843?source=see_link\">",
"     see \"Fusidic acid and hydrocortisone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12887458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fucidin H",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12990685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12990682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3473200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fusidic acid, hydrocortisone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3474102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a very bad skin infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12990677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12990679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12990683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12990686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12990678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12990681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12990684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16822 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30291=[""].join("\n");
var outline_f29_37_30291=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12887458\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990685\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990682\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990677\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990679\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990683\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990686\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990678\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990681\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990684\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/36/11843?source=related_link\">",
"      Fusidic acid and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_37_30292="Primaquine: Patient drug information";
var content_f29_37_30292=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Primaquine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     see \"Primaquine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/26/14757?source=see_link\">",
"     see \"Primaquine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be watched closely by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat malaria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat",
"       <i>",
"        Pneumocystis jirovecii",
"       </i>",
"       pneumonia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to primaquine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697188",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bone marrow disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705456",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Malaria:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other measures are needed along with this drug including using screens, bed netting, insect repellent (10% to 35% DEET), and permethrin spray on clothing and nets. Avoid spraying most insect repellents on children. Lower evening and night-time outdoor activity.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a pregnant woman and traveling to a malaria infested place, talk to your doctor about the risks first.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever that happens while in or after coming back from the malaria area.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Start this drug before travel to the high risk place. Keep using after leaving.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11410 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-197.136.42.3-6F5635152F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30292=[""].join("\n");
var outline_f29_37_30292=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022240\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022242\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022241\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022246\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022247\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022249\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022244\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022245\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022250\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022251\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=related_link\">",
"      Primaquine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/26/14757?source=related_link\">",
"      Primaquine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_37_30293="Leiomyosarcoma gross appearance";
var content_f29_37_30293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leiomyosarcoma: gross appearance compared with leiomyoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Leiomyoma and leiomyosarcoma. The small nodule on the left is well circumscribed, with the bulging, white, firm and whorled cut surface, typical of leiomyoma. The large, soft, hemorrhagic, and fleshy mass represents a leiomyosarcoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berek, JS, Hacker, NF. Practical Gynecologic Oncology, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30293=[""].join("\n");
var outline_f29_37_30293=null;
var title_f29_37_30294="Lisinopril and hydrochlorothiazide: Patient drug information";
var content_f29_37_30294=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lisinopril and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/60/23495?source=see_link\">",
"     see \"Lisinopril and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prinzide&reg;;",
"     </li>",
"     <li>",
"      Zestoretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lisinopril&reg;/Hctz;",
"     </li>",
"     <li>",
"      Mylan-Lisinopril/Hctz;",
"     </li>",
"     <li>",
"      Novo-Lisinopril/Hctz;",
"     </li>",
"     <li>",
"      Prinzide&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Lisinopril/Hctz;",
"     </li>",
"     <li>",
"      Teva-Lisinopril/Hctz (Type P);",
"     </li>",
"     <li>",
"      Teva-Lisinopril/Hctz (Type Z);",
"     </li>",
"     <li>",
"      Zestoretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given to you for other reasons. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lisinopril, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ever had a very bad reaction called angioedema. Signs may be swelling of the hands, face, lips, eyes, tongue, or throat; trouble breathing; trouble swallowing; unusual hoarseness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking dofetilide.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194403",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This is not a list of all drugs or health problems that interact with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4201327",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To lower the chance of feeling dizzy or passing out, rise slowly over a few minutes when sitting or lying down. Be careful climbing stairs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you drink wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may affect certain lab tests. Be sure your doctor and lab workers know you take this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The chance of a very bad or sometimes deadly reaction called angioedema may be higher in black patients. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 65 or older, use this drug with care. You could have more side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4192387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4193750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of fluid and electrolyte problems like mood changes, confusion, muscle pain or weakness, a heartbeat that does not feel normal, very bad dizziness or passing out, fast heartbeat, more thirst, seizures, feeling very tired or weak, not hungry, unable to pass urine or change in the amount of urine produced, dry mouth, dry eyes, or very bad upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4230803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Restlessness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain or loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4192394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A burning, numbness, or tingling feeling that is not normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain when passing urine or blood in urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4230804",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug can cause certain eye problems. If left untreated, this can lead to lasting eyesight loss. If eye problems happen, signs like change in eyesight or eye pain most often happen within hours to weeks of starting this drug. Call your doctor right away if you have these signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at",
"       <a href=\"file://www.fda.gov/medwatch\" target=\"_blank\">",
"        file://www.fda.gov/medwatch",
"       </a>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to Health Canada's Canada Vigilance Program at 1-866-234-2345.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10812 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30294=[""].join("\n");
var outline_f29_37_30294=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189274\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189275\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020165\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020167\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020166\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020171\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020172\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020174\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020169\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020170\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020175\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020176\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/60/23495?source=related_link\">",
"      Lisinopril and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_37_30295="Treatment of paracoccidioidomycosis";
var content_f29_37_30295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of paracoccidioidomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/37/30295/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/37/30295/contributors\">",
"     Marcio Nucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/37/30295/contributors\">",
"     Arnaldo L Colombo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/37/30295/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/37/30295/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/37/30295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/37/30295/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/37/30295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracoccidioidomycosis is a systemic endemic mycotic disease caused by the thermally dimorphic fungus, Paracoccidioides brasiliensis. The fungus has a geographic distribution limited to Central and South America, and paracoccidioidomycosis is the most frequent systemic endemic mycosis in this region. Primary infection is usually transient and almost always devoid of clinical manifestations. If the infection is not contained by the host, the disease may evolve into one of two patterns: the chronic form, which represents reactivation of the primary infection and is most common, and the",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    form [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of paracoccidioidomycosis will be reviewed here. The mycology, epidemiology, clinical manifestations and diagnosis of paracoccidioidomycosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41268?source=see_link\">",
"     \"Mycology and epidemiology of paracoccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40756?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. brasiliensis is sensitive to most antifungal agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , the azoles (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    , and even sulfonamides [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/2\">",
"     2",
"    </a>",
"    ]. Of these agents, itraconazole has been studied most extensively and is used most commonly. Sulfonamides, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , are used in some cases, but require prolonged therapy to prevent relapse. Amphotericin B is reserved for patients with severe disease.",
"   </p>",
"   <p>",
"    Despite the fact that paracoccidioidomycosis has a high incidence and morbidity in Central and South America, few studies have been conducted to define its optimal treatment. Only two randomized trials have been published, neither of which had sufficient power to assess response or cure rates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    has been used extensively in the treatment of paracoccidioidomycosis and results in high response rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    was first shown in a single-center noncomparative study, in which 47 patients (45 with chronic disease) received itraconazole for a median duration of 6 months (range 3 to 24 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/5\">",
"     5",
"    </a>",
"    ]. The overall response rate (complete resolution or marked improvement) was 91 percent. Of 15 patients who were followed for 12 months post-therapy, none had a relapse.",
"   </p>",
"   <p>",
"    In a randomized trial that included 42 patients with paracoccidioidomycosis (35 with chronic disease, 7 with acute disease), &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    capsules (50 to 100 mg per day) were compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    (200 to 400 mg per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    (100 to 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/3\">",
"     3",
"    </a>",
"    ]. One of these agents was given for four to six months as determined by clinical response, followed by slow release sulfa (sulfamethoxypyridazine) until serologic testing became negative. The mean duration of therapy with the initial antifungal agent was 170 days for the itraconazole group, 164 days for the sulfadiazine group, and 154 days for the ketoconazole group. The mean total duration of therapy (including maintenance sulfa therapy) was 24, 28, and 31 months, respectively. Clinical responses were observed in all patients receiving itraconazole or sulfadiazine, and in all but one patient receiving ketoconazole. As expected with such a small sample size, no differences were observed among the three agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is generally well tolerated. Adverse effects include hepatotoxicity, hypokalemia, pedal edema, and, rarely, heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacology of azoles\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are important pharmacokinetic differences between the capsule and liquid preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . Absorption of the capsule formulation is highly variable, requires gastric acidity, and is enhanced when the agent is taken with food. Thus, in patients who receive concomitant medications that decrease gastric acidity, blood levels are reduced. In contrast, the liquid formulation has better bioavailability, does not require an acidic environment, and is taken on an empty stomach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H5#H5\">",
"     \"Pharmacology of azoles\", section on 'Pharmacokinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The factors that affect",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    pharmacokinetics, including drug interactions, absorption, and drug formulation, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has excellent in vitro activity against P. brasiliensis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/6\">",
"     6",
"    </a>",
"    ], it has only been evaluated for the treatment of paracoccidioidomycosis in one small randomized open-label trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/4\">",
"     4",
"    </a>",
"    ]. Thirty-five patients with paracoccidioidomycosis received voriconazole (400 mg twice daily on the first day and 200 mg twice daily thereafter) and 18 received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    capsules (100 mg twice daily). All but one patient had the chronic form of paracoccidioidomycosis. The median duration of treatment was 169 days for patients treated with voriconazole and 200 days for patients treated with itraconazole. The response rates were similar in patients who received at least one dose of treatment (89 percent with voriconazole versus 94 percent with itraconazole) and in patients receiving &gt;6 months of treatment (100 percent in both groups). Thus, voriconazole appears to be as effective as itraconazole for the treatment of chronic paracoccidioidomycosis, although the small size of the study limits these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    include hepatotoxicity, photosensitivity skin rash, and transient visual disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) has been used extensively in the treatment of paracoccidioidomycosis, but it has not been evaluated in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the response rates seem to be similar to those obtained with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , treatment with TMP-SMX is more prolonged (usually two years) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study compared treatment outcomes in 71 patients with paracoccidioidomycosis who received TMP-SMX and 19 who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/8\">",
"     8",
"    </a>",
"    ]. The groups were comparable with regards to age, gender, and the form of disease (acute or chronic). The cure rates were similar (94 and 95 percent for patients receiving TMP-SMX and itraconazole, respectively), but the median duration of treatment was shorter in patients receiving itraconazole (7 versus 24 months). Furthermore, compliance was better in patients receiving itraconazole; no patients receiving itraconazole discontinued treatment early compared with 23 patients receiving TMP-SMX.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) is generally well tolerated in non-HIV-infected patients in whom adverse reactions occur in approximately 6 to 8 percent. In comparison, the adverse reaction rate is as high as 25 to 50 percent in HIV-infected patients, with many of the reactions being severe.",
"   </p>",
"   <p>",
"    The more common adverse reactions to TMP-SMX involve the gastrointestinal tract (nausea, vomiting) and skin (rash, Steven-Johnson syndrome, and pruritus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38438?source=see_link&amp;anchor=H8#H8\">",
"     \"Trimethoprim-sulfamethoxazole: An overview\", section on 'Adverse effects and precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the toxicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate, as well as the good clinical results obtained with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , amphotericin B is used infrequently. Amphotericin B deoxycholate is generally given only to patients with severe infection, such as those who require hospitalization due to the presence of respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate for paracoccidioidomycosis has been limited to small observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Amphotericin B deoxycholate is often avoided due to nephrotoxicity and the availability of less toxic agents. However, amphotericin B is the drug of choice for treating patients with sepsis due to P. brasiliensis (occasionally seen with the acute or subacute form of paracoccidioidomycosis) and patients with respiratory failure. It is not possible to estimate the response rate to amphotericin B in patients with severe paracoccidioidomycosis because there are inadequate data.",
"   </p>",
"   <p>",
"    Clinical experience with the lipid formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is scarce, but they are expected to be at least as effective as amphotericin B deoxycholate and have the benefit of lower nephrotoxicity. In addition, one of the lipid formulations (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    ; AmBisome) had better central nervous system (CNS) penetration in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/12\">",
"     12",
"    </a>",
"    ]. In a report of four patients with acute paracoccidioidomycosis treated with amphotericin B colloidal dispersion, three had complete response, and one responded partially after &gt;28 days of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/13\">",
"     13",
"    </a>",
"    ]. The lipid formulations of amphotericin B are given at a dose of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate therapy is frequently complicated by significant toxicity, such as reduced renal function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infusion-related systemic reactions. The lipid formulations of amphotericin B are associated with less nephrotoxicity than amphotericin B deoxycholate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    are active against P. brasiliensis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, because of the very limited clinical experience with these drugs for the treatment of paracoccidioidomycosis, they cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brazilian guidelines for the management of paracoccidioidomycosis were published in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/9\">",
"     9",
"    </a>",
"    ]. Our recommendations are generally in keeping with these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mild to moderate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    capsules (100 mg once or twice daily) is the drug of choice for the treatment of mild and moderate paracoccidioidomycosis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/9\">",
"     9",
"    </a>",
"    ]. For children who cannot swallow capsules, the oral solution of itraconazole (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily) or TMP-SMX (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day based on the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component divided into two daily doses) should be used. The oral solution of itraconazole is not available in some countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Severe",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with severe paracoccidioidomycosis (hypotension, respiratory failure, severe malnutrition), we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). An alternative is intravenous TMP-SMX (8 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of the TMP component divided into three daily doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other options for severe disease are intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). However, there are few data on the use of these agents for the treatment of severe paracoccidioidomycosis. Although the optimal dose of voriconazole has not been determined for the treatment of severe paracoccidioidomycosis, it would be reasonable to use doses similar to those used for other invasive fungal infections in patients with contraindications to the other possible agents, or for step-down therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H20#H20\">",
"     \"Pharmacology of azoles\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients treated initially with an intravenous drug can be switched to an oral agent once significant improvement in the clinical condition has been observed (resolution of hypotension, reduction of ascites, improvement of respiratory function and nutritional status). Such improvements are usually achieved after 20 to 40 days of intravenous therapy. The transition to an oral regimen should be made cautiously in patients with extensive abdominal involvement because oral absorption can be impaired due to edema of the intestinal wall, involvement of abdominal lymph nodes and fibrosis. In these cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    capsules should be avoided because of their erratic oral absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Central nervous system involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both TMP-SMX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate are effective for treating CNS infection. Thus, either one may be used for patients with CNS involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DURATION AND MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of treatment is a matter of debate, since no randomized trials have compared different treatment durations. It is generally accepted that azoles require a shorter treatment course than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are usually given for approximately 6 to 12 months, whereas TMP-SMX requires a longer period of treatment to prevent relapse (usually &ge;2 years). Patients with severe disease often require longer courses of therapy (&gt;2 years), even when itraconazole is used. Patients with central nervous system involvement, as well as immunocompromised hosts (eg, HIV infection, cancer, transplantation) may also require a longer duration of therapy.",
"   </p>",
"   <p>",
"    The main therapeutic challenges in the management of paracoccidioidomycosis are the long duration of treatment, and the high frequency of relapse and sequelae (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Relapse'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36935?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis\", section on 'Sequelae'",
"    </a>",
"    ). In addition, patients may have comorbidities that complicate the management of the disease. These include tuberculosis (in approximately 8 percent of patients with paracoccidioidomycosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/16\">",
"     16",
"    </a>",
"    ], enteric parasitic diseases, and others.",
"   </p>",
"   <p>",
"    Treatment is usually continued until the clinical and radiological signs of paracoccidioidomycosis have improved substantially or resolved (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64929 \" href=\"UTD.htm?8/62/9185\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61380 \" href=\"UTD.htm?25/28/26053\">",
"     image 2",
"    </a>",
"    ), and until there has been a significant reduction in antibody titers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the presence of sequelae may complicate the interpretation of clinical and radiologic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial serologic testing by quantitative immunodiffusion is useful for monitoring the response to therapy since a good response to antifungal therapy is often associated with a reduction in the titer of serum antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/17\">",
"     17",
"    </a>",
"    ]. Serologic testing should be performed prior to the initiation of therapy, after three months of therapy, and every six months thereafter until the completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/9\">",
"     9",
"    </a>",
"    ]. Serologies should also be requested if recurrence is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36935?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis\", section on 'Serologic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A typical serologic response is that of progressive reduction in the titers of antibodies after 1 to 3 months of treatment until stabilization at a low titer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/18\">",
"     18",
"    </a>",
"    ]. However, antibodies titers do not always correlate with either the clinical status of the patient or with response to therapy. Some patients exhibit a transient increase in antibody titers after starting antifungal therapy, in spite of a good clinical response. Thus, serologic testing should be used in combination with other factors such as clinical and radiographic improvement in order to determine the treatment response and total duration of antifungal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for laboratory studies during therapy depends upon the organs involved and the therapy used. Patients receiving an azole, for example, require close monitoring of liver function tests given the risk of hepatotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with lung involvement, chest radiographs should be performed at the time of diagnosis and during follow-up evaluations (eg, every one or two months during the first six to nine months of therapy, and every six months thereafter until the completion of therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/9\">",
"     9",
"    </a>",
"    ]. Chest CT scanning is indicated when clinical response cannot be assessed adequately by chest x-ray (eg, in those with coexisting lung abnormalities such as tuberculosis or chronic obstructive pulmonary disease) and for evaluation of pulmonary sequelae.",
"   </p>",
"   <p>",
"    Follow-up CT scanning is also indicated in patients with abdominal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central nervous system involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse typically occurs in patients with chronic paracoccidioidomycosis that has disseminated, especially if the treatment was discontinued earlier than recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/1\">",
"     1",
"    </a>",
"    ]. Relapse occurs in fewer than 5 percent of patients with chronic paracoccidioidomycosis who have received a full treatment course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Relapse has also been seen with acute or subacute paracoccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    has been associated with a rate of relapse of up to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/21\">",
"     21",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is associated with a rate of relapse of approximately 20 to 30 percent unless followed by step-down therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunocompromised patients are at particular risk of relapse. As an example, in a retrospective case-control study of patients treated for paracoccidioidomycosis, relapse occurred in 5 of 27 (19 percent) HIV-infected patients by 24 months after diagnosis compared with 2 of 61 (3 percent) HIV-negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PARADOXICAL REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two cases of acute paracoccidioidomycosis were reported in which immunocompetent adolescents exhibited persistent signs and symptoms of disease (fever, weight loss, and draining lymph nodes) despite long periods of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/23\">",
"     23",
"    </a>",
"    ]. Examination of clinical material showed few or no fungal elements, and the patients improved with systemic glucocorticoids. While this report does not provide enough evidence to support a diagnosis of a paradoxical reaction, this entity should be considered in the differential diagnosis of patients with acute paracoccidioidomycosis who remain symptomatic despite appropriate treatment; paradoxical reactions have been likened to the immune reconstitution inflammatory syndrome seen in AIDS patients. Further studies will need to be performed before glucocorticoids can be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of paracoccidioidomycosis depends on the clinical form of the disease. In a series of 63 children with acute paracoccidioidomycosis who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    as primary treatment, six patients died [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30295/abstract/24\">",
"     24",
"    </a>",
"    ]. Five of these six patients were severely malnourished. In adults with the chronic form of paracoccidioidomycosis, the mortality rate is lower, but the morbidity of patients with severe sequelae, especially in patients with extensive lung involvement, is high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36935?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis\", section on 'Sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with mild or moderate paracoccidioidomycosis, we suggest oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      rather than another azole or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The usual dose of itraconazole is 100 to 200 mg per day. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Mild to moderate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe paracoccidioidomycosis, we suggest initial therapy with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative is TMP-SMX. The usual dose of amphotericin B deoxycholate is 0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily, and the usual dose of TMP-SMX is 8 to 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the TMP component divided into three daily doses. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Severe'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CNS involvement, we suggest either TMP-SMX or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Central nervous system involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated initially with an intravenous drug can be switched to an oral agent once significant improvement in the clinical condition has been observed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Severe'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      are usually given for approximately 6 to 12 months, whereas TMP-SMX requires a longer period of treatment to prevent relapse (usually &ge;2 years). Patients with severe disease often require longer courses of therapy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is usually continued until the clinical and radiological signs of paracoccidioidomycosis have improved substantially or resolved and there has been a significant reduction in antibody titers (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Duration'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients with paracoccidioidomycosis should be monitored closely during therapy with laboratory studies including serologies, and imaging. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Duration and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relapse typically occurs in patients with chronic paracoccidioidomycosis that has disseminated, especially if a long treatment course is not given. Relapse occurs in fewer than 5 percent of patients with chronic paracoccidioidomycosis who have received a full treatment course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      , but is more common in patients receiving TMP-SMX or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate not followed by therapy with oral drugs. Relapse may also occur among patients with acute or subacute paracoccidioidomycosis. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Relapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/1\">",
"      Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther 2008; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/2\">",
"      Menezes VM, Soares BG, Fontes CJ. Drugs for treating paracoccidioidomycosis. Cochrane Database Syst Rev 2006; :CD004967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/3\">",
"      Shikanai-Yasuda MA, Benard G, Higaki Y, et al. Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. Med Mycol 2002; 40:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/4\">",
"      Queiroz-Telles F, Goldani LZ, Schlamm HT, et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007; 45:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/5\">",
"      Naranjo MS, Trujillo M, Munera MI, et al. Treatment of paracoccidioidomycosis with itraconazole. J Med Vet Mycol 1990; 28:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/6\">",
"      McGinnis MR, Pasarell L, Sutton DA, et al. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997; 41:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/7\">",
"      Barraviera B, Mendes RP, Machado JM, et al. Evaluation of treatment of paracoccidioidomycosis with cotrimazine (combination of sulfadiazine and trimetoprim). Preliminary report. Rev Inst Med Trop Sao Paulo 1989; 31:53.",
"     </a>",
"    </li>",
"    <li>",
"     Queiroz-Telles, F, Colombo, AL, Nucci, M. Comparative efficacy of cotrimoxazole and itraconazole in the treatment of paracoccidioidomycosis. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego) Washington, DC: American Society for Microbiology, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/9\">",
"      Shikanai-Yasuda MA, Telles Filho Fde Q, Mendes RP, et al. [Guidelines in paracoccidioidomycosis]. Rev Soc Bras Med Trop 2006; 39:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/10\">",
"      Dillon NL, Sampaio SA, Habermann MC, et al. Delayed results of treatment of paracoccidioidomycosis with amphotericin B plus sulfamides versus amphotericin B alone. Rev Inst Med Trop Sao Paulo 1986; 28:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/11\">",
"      de Campos EP, Sartori JC, Hetch ML, de Franco MF. Clinical and serologic features of 47 patients with paracoccidioidomycosis treated by amphotericin B. Rev Inst Med Trop Sao Paulo 1984; 26:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/12\">",
"      Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/13\">",
"      Dietze R, Fowler VG Jr, Steiner TS, et al. Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis. Am J Trop Med Hyg 1999; 60:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/14\">",
"      Martinez R, Malta MH, Verceze AV, Arantes MR. Comparative efficacy of fluconazole and amphotericin B in the parenteral treatment of experimental paracoccidioidomycosis in the rat. Mycopathologia 1999; 146:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/15\">",
"      Hahn RC, Fontes CJ, Batista RD, Hamdan JS. In vitro comparison of activities of terbinafine and itraconazole against Paracoccidioides brasiliensis. J Clin Microbiol 2002; 40:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/16\">",
"      Quagliato J&uacute;nior R, Grangeia Tde A, Massucio RA, et al. Association between paracoccidioidomycosis and tuberculosis: reality and misdiagnosis. J Bras Pneumol 2007; 33:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/17\">",
"      Del Negro GM, Pereira CN, Andrade HF, et al. Evaluation of tests for antibody response in the follow-up of patients with acute and chronic forms of paracoccidioidomycosis. J Med Microbiol 2000; 49:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/18\">",
"      de Camargo ZP. Serology of paracoccidioidomycosis. Mycopathologia 2008; 165:289.",
"     </a>",
"    </li>",
"    <li>",
"     Restrepo A, Tobon AM, Agudelo CA. Paracoccidioidomycosis. In: Diagnosis and Treatment of Human Mycoses, 1st edition, Hospenthal, DR, Rinaldi, MG (Eds), Humana Press, Totowa, NJ 2008. p.331.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/20\">",
"      Tob&oacute;n AM, Agudelo CA, Osorio ML, et al. Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy. Clin Infect Dis 2003; 37:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/21\">",
"      Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993; 6:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/22\">",
"      Morej&oacute;n KM, Machado AA, Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case-control study. Am J Trop Med Hyg 2009; 80:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/23\">",
"      Gryschek RC, Pereira RM, Kono A, et al. Paradoxical reaction to treatment in 2 patients with severe acute paracoccidioidomycosis: a previously unreported complication and its management with corticosteroids. Clin Infect Dis 2010; 50:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30295/abstract/24\">",
"      Pereira RM, Bucaretchi F, Barison Ede M, et al. Paracoccidioidomycosis in children: clinical presentation, follow-up and outcome. Rev Inst Med Trop Sao Paulo 2004; 46:127.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2422 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30295=[""].join("\n");
var outline_f29_37_30295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIFUNGAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mild to moderate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Severe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Central nervous system involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DURATION AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PARADOXICAL REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2422\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2422|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/62/9185\" title=\"diagnostic image 1\">",
"      CNS PCM CT scans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/28/26053\" title=\"diagnostic image 2\">",
"      Pulmonary PCM images",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40756?source=related_link\">",
"      Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic paracoccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41268?source=related_link\">",
"      Mycology and epidemiology of paracoccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38438?source=related_link\">",
"      Trimethoprim-sulfamethoxazole: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_37_30296="Immunizations in patients with cancer";
var content_f29_37_30296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunizations in patients with cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/37/30296/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/37/30296/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/37/30296/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/37/30296/contributors\">",
"     Michael Boeckh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/37/30296/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/37/30296/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/37/30296/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/37/30296/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of infection is of paramount importance to the ever increasing population of patients who have impaired immunity. Infection in these patients often results in excessive morbidity and mortality and antimicrobial therapy is often less effective than in the unimpaired host [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/1\">",
"     1",
"    </a>",
"    ]. Although immunization appears to be an obvious way to prevent infection, many patients with impaired immunity are unable to mount a protective immune response to active vaccination. Furthermore, immunization with live virus vaccines may result in unchecked proliferation of attenuated strains.",
"   </p>",
"   <p>",
"    The risk of acquiring infection and the inability to prevent infection by immunization are directly related to the patient's \"net state of immunosuppression\" or severity of disease. The greater the degree of immunosuppression, the less likely the patient is to respond to immunization. Although certain existing vaccines provide some benefit to the immunocompromised patient, a vaccine response cannot be assumed. Successful protection of the immunocompromised adult may require the use of vaccines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    passive immunization (ie, immune globulin) as well as adjunctive measures, such as antiviral drug prophylaxis during influenza A outbreaks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for immunizing patients who have undergone chemotherapy for treatment of hematologic malignancies and solid tumors, or who have other immunocompromising conditions, will be reviewed here. Issues related to immunizations in patients who have had hematopoietic cell transplants or solid organ transplants or who are infected with HIV, as well as in healthy children and adults, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer are at variable risk of morbidity and mortality from the infections that can usually be prevented by immunization, depending upon the underlying disease and the type of cancer chemotherapy and radiotherapy that is administered. Patients with hematologic malignancies tend to be more compromised than those with solid tumors. However, patients with solid tumors are also at risk of infection on the basis of debility, malnutrition, and, in some cases anatomic obstruction (eg, lung masses obstructing bronchial drainage).",
"   </p>",
"   <p>",
"    Treatment for many cancers has intensified greatly in recent years, resulting in improved patient outcomes, but few studies of immunity and vaccination have been published during this time period. Although there are no formal evidence-based guidelines for the prevention of vaccine preventable infections in oncology patients who do not undergo hematopoietic cell transplantation, immunization recommendations for immunocompromised patients in the United States have been developed by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC). The immunization schedule for adults with medical conditions is presented in the following Figure (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cancer patients should generally be vaccinated with inactivated vaccines, such as the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    , as indicated (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 1",
"    </a>",
"    ). Patients with cancer should generally",
"    <strong>",
"     not",
"    </strong>",
"    receive live virus vaccines, although the CDC states that patients with leukemia, lymphoma, or other malignancies whose disease is in remission and whose chemotherapy has been terminated for at least three months may receive live-virus vaccines such as the measles, mumps, and rubella vaccine, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    according to age-specific recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Live organism vaccines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All indicated vaccines should be given to cancer patients before initiation of chemotherapy, before therapy with other immunosuppressive drugs, and before radiation or splenectomy, when feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/2\">",
"     2",
"    </a>",
"    ]. If inactivated vaccines are given during chemotherapy, they should be readministered after the recovery of immune competence. Revaccination of individuals after chemotherapy or radiation is generally unnecessary if the prior vaccination occurred before chemotherapy, with the exception of hematopoietic cell transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INACTIVATED VACCINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tetanus toxoid, diphtheria toxoid, and pertussis vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many oncology patients receiving chemotherapy are not protected against tetanus, diphtheria and pertussis. In one report, for example, only 59 percent of patients being treated for acute leukemia were protected against tetanus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/3\">",
"     3",
"    </a>",
"    ]. Little is known about response to tetanus and diphtheria immunization in the heterogeneous population of cancer patients, although children on maintenance chemotherapy had an immune response similar to that observed in healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tetanus and diphtheria booster immunizations should be considered for all patients with cancer. In addition, adults who have not been vaccinated with the acellular pertussis vaccine should receive the vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap). Td or Tdap should ideally be given before starting treatment and preferably not during cycles of intensive chemotherapy. Pertussis vaccination in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link&amp;anchor=H10#H10\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Polio vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inactivated polio vaccine is the only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    recommended for immunodeficient individuals and their household contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/5\">",
"     5",
"    </a>",
"    ]. However, a protective immune response cannot be assured in patients who are immunodeficient at the time of vaccination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"     \"Poliovirus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pneumococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal vaccine should be administered to oncology patients prior to starting treatment and should be avoided during cycles of intense chemotherapy because a poor response can be anticipated. Pneumococcal infections are an important cause of morbidity and mortality in oncology patients. Responses to the 23-valent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23; Pneumovax) vary, but are better (even close to normal) if the vaccine is administered prior to the onset of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Serum IgG2 concentrations predict the ability to respond to the vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Response to PPSV23 is greatly diminished after chemotherapy. Vaccine responses are particularly poor after initiating cancer treatment in patients with leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/12\">",
"     12",
"    </a>",
"    ] and head and neck cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/10\">",
"     10",
"    </a>",
"    ]. Among patients with Hodgkin lymphoma, for example, vaccine responses remain impaired for as long as seven years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/7\">",
"     7",
"    </a>",
"    ]. At least in Hodgkin lymphoma, priming with the seven-valent pneumococcal conjugate vaccine (PCV7; Prevnar 7) appears to improve the response to the subsequent administration of PPSV23 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/13\">",
"     13",
"    </a>",
"    ]. Additional evidence supporting the use of pneumococcal conjugate vaccination in high-risk adults comes from a randomized trial of PCV7 in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1419557391\">",
"    <span class=\"h3\">",
"     Recommended formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPSV23 has been recommended for immunocompromised adults in the United States for many years, but in 2012, the United States Advisory Committee on Immunization Practices (ACIP) began also recommending the 13-valent pneumococcal conjugate vaccine (Prevnar 13; PCV13) for individuals aged 19 or older with certain high-risk conditions, including cancer (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"UTD.htm?11/48/12046\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In accordance with the ACIP, we recommend that adults with cancer receive PCV13 in addition to PPSV23 as follows (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"UTD.htm?11/48/12046\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have not previously received either PCV13 or PPSV23, a single dose of PCV13 should be given, followed by a dose of PPSV23 at least eight weeks later.",
"     </li>",
"     <li>",
"      For patients who have previously received one or more doses of PPSV23, a single dose of PCV13 should be given one or more years after the last PPSV23 dose was received.",
"     </li>",
"     <li>",
"      For patients who require additional doses of PPSV23, the first such dose should be given no sooner than eight weeks after PCV13 and at least five years after the most recent dose of PPSV23.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pneumococcal vaccination in adults is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with cancer should also receive both the pneumococcal conjugate vaccine and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    . Specific recommendations for the use of pneumococcal vaccines in immunocompromised children are presented separately; the following Tables summarize the recommendations (",
"    <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79553 \" href=\"UTD.htm?23/60/24523\">",
"     table 3",
"    </a>",
"    ). In 2010, PCV13 was approved by the FDA for use in children up to age 71 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/17\">",
"     17",
"    </a>",
"    ]. Even though PCV13 has not been FDA-approved in older children, the ACIP states that children aged 6 to 18 years who are at increased risk of invasive pneumococcal disease may receive a single dose of PCV13 regardless of whether they have previously received PCV7 or PPSV23. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumococcal conjugate vaccines that contain a different number of serotypes (eg, PCV10) are used in some countries in Europe and elsewhere. Patients should be vaccinated against pneumococcus according to their national guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H3#H3\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Conjugate vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Haemophilus influenzae vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with leukemia and other malignancies are at increased risk of developing Haemophilus influenzae type b (Hib) disease compared to normal children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/18\">",
"     18",
"    </a>",
"    ]. In comparison, adult oncology patients do not appear to be at such great risk, unless they undergo hematopoietic cell transplantation (HCT).",
"   </p>",
"   <p>",
"    The Hib conjugate vaccine is indicated for children with cancer as early as possible in the course of their disease, but poor vaccine response is observed and booster doses are ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Hib immunization is not routinely recommended for adult oncology patients unless they undergo HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link&amp;anchor=H11#H11\">",
"     \"Immunizations after hematopoietic cell transplantation\", section on 'Haemophilus influenzae'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Immunization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meningococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal vaccination is recommended for individuals at increased risk for meningococcal infection, such as children between 11 and 18 years of age and certain other groups (college freshmen living in dormitories, individuals traveling to countries where N. meningitidis is hyperendemic or epidemic, patients with terminal complement component deficiencies or anatomic or functional asplenia, and others).",
"   </p>",
"   <p>",
"    There are no specific recommendations for patients with cancer, but any cancer patient &gt;9 months of age who has another indication for meningococcal vaccination should be vaccinated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Vaccine response may be suboptimal in cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/25\">",
"     25",
"    </a>",
"    ]. The appropriate formulation and vaccine schedule depends upon the individual's age and underlying illness (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 4",
"    </a>",
"    ). This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute leukemia undergoing induction chemotherapy are at greatest risk of morbidity and mortality associated with influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/26\">",
"     26",
"    </a>",
"    ]. Most infections in such patients are acquired nosocomially [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/26\">",
"     26",
"    </a>",
"    ]. Reported seroconversion rates to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    in patients with cancer have ranged between 24 and 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]; a two-dose regimen does not appear to improve the response [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In a 2012 meta-analysis, seroconversion and seroprotection rates following influenza vaccination in patients with cancer were approximately one-third of those observed in immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/32\">",
"     32",
"    </a>",
"    ]. The likelihood of response is affected by the intensity and type of chemotherapy and the timing of vaccine administration in the chemotherapy cycle.",
"   </p>",
"   <p>",
"    The anti-CD20 monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , has become a standard part of the treatment of CD20-positive B cell lymphomas. Since this agent depletes normal B cells, there is concern that it will attenuate the response to vaccines. In a study of lymphoma patients who had received a rituximab-containing treatment regimen within the previous six months, none of 67 patients developed seroprotective titers following administration of an adjuvanted inactivated pandemic H1N1 influenza A vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, 42 of 51 healthy controls (82 percent) developed seroprotective titers following vaccination.",
"   </p>",
"   <p>",
"    In a 2012 meta-analysis that evaluated two small studies, influenza vaccination was associated with a significant reduction in influenza-like illness in children with cancer in remission (odds ratio 0.26, 95% CI 0.15-0.46) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although an intranasally administered live-attenuated influenza vaccine (LAIV) exists, it is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in immunocompromised individuals or in household members or healthcare professionals with close contact to such individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H32#H32\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Contraindications and precautions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H775053590#H775053590\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Choice of vaccine formulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Annual administration of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    is indicated for all oncology patients. Antiviral prophylaxis should be considered for those undergoing the most intense chemotherapy under certain circumstances, such as following an exposure. Immunization of family members and hospital staff is also strongly recommended. The current recommendations do not support administration of a second dose of the influenza vaccine within the same season [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H413651#H413651\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H14#H14\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Human papilloma virus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients with an indication for human papillomavirus (HPV) vaccination should be immunized, unless they have a known hypersensitivity to any part of the vaccine or to yeast. However, cancer patients may have a suboptimal antibody response and lower vaccine efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with thrombocytopenia are at risk of developing a hematoma after the intramuscular injection of the vaccine. Indications for HPV vaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatitis B vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients who request the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    (regardless of whether or not they have a risk factor for developing hepatitis B) and all unvaccinated cancer patients who have any risk factor for hepatitis B should receive the hepatitis B vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/36\">",
"     36",
"    </a>",
"    ]. As with other vaccines, cancer and bone marrow transplant patients may have suboptimal response to the hepatitis B vaccine. Regimens that include doubling the standard antigen dose or administering additional doses, may increase response rates but given the limited data with these alternative regimens, this approach cannot be routinely recommended. Hepatitis B and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    may be co-administered to cancer patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hepatitis A vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients who have any risk factors for developing hepatitis A should receive the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    , probably in combination with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    since many of the risk factors for hepatitis A and B overlap. As above, vaccine efficacy may be compromised in cancer patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LIVE ORGANISM VACCINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Measles, mumps, and rubella vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients who are infected with measles have a high mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/37\">",
"     37",
"    </a>",
"    ]. Among children, the American Academy of Pediatrics states that this vaccine usually can be administered to at-risk patients three months after the cessation of cancer chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/38\">",
"     38",
"    </a>",
"    ]. The safety of rubella immunization is not clear. A case report described a child with acute lymphoblastic leukemia in remission who developed persistent symptomatic rubella infection after immunization with the rubella vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, patients with cancer should",
"    <strong>",
"     not",
"    </strong>",
"    receive the MMR vaccine, although the CDC indicates that those with leukemia, lymphoma, or other malignancies whose disease is in remission and whose chemotherapy has been terminated for at least three months may receive live-virus vaccines such as MMR [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link\">",
"     \"Measles-mumps-rubella vaccination in high risk adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Varicella vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary varicella is associated with high rates of morbidity and mortality in seronegative adults with cancer. One study evaluated the efficacy of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in children in remission after treatment for leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/40\">",
"     40",
"    </a>",
"    ]. The seroconversion rate was 88 and 98 percent after the first and second dose, respectively. There were few side effects, and breakthrough vaccine disease was effectively treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . Based upon this study, it is reasonable to immunize susceptible adult oncology patients with the varicella vaccine after completion of chemotherapy.",
"   </p>",
"   <p>",
"    As above, the CDC indicates that those with leukemia, lymphoma, or other malignancies whose disease is in remission and whose chemotherapy has been terminated for at least three months may receive live-virus vaccines, including varicella [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    may be administered to susceptible household and other close contacts of cancer patients because transmission of varicella vaccine is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/2\">",
"     2",
"    </a>",
"    ]. If the household contact develops a rash after vaccination, the household contact should avoid direct contact with the immunocompromised cancer patient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Zoster vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hematologic malignancies and solid tumors are at increased risk of developing herpes zoster (shingles) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/42\">",
"     42",
"    </a>",
"    ]. The incidence varies by type of cancer and treatment. Patients with Hodgkin's disease are at particularly high risk for developing zoster, with rates approaching 30 percent during illness or its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    , Zostavax, is contraindicated in cancer patients, although the CDC states that patients whose leukemia is in remission and who have not received chemotherapy or radiation for at least three months may receive zoster vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/37/30296/abstract/2\">",
"     2",
"    </a>",
"    ]. Age-based recommendations for zoster vaccination are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\", section on 'Recommendations for use of zoster vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1339714444\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of infection is of paramount importance to the ever increasing population of patients who have impaired immunity. Infection in these patients often results in excessive morbidity and mortality and antimicrobial therapy is often less effective than in the unimpaired host. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although immunization appears to be an obvious way to prevent infection, many patients with impaired immunity are unable to mount a protective immune response to active vaccination. Furthermore, immunization with live virus vaccines may result in unchecked proliferation of attenuated strains. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All indicated vaccines should be given to cancer patients before initiation of chemotherapy, before therapy with other immunosuppressive drugs, and before radiation or splenectomy, when feasible. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cancer patients should generally be vaccinated with inactivated vaccines. The immunization schedule for adults with medical conditions is presented in the following Figure (",
"      <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Inactivated vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cancer should generally",
"      <strong>",
"       not",
"      </strong>",
"      receive live virus vaccines, although the United States Centers for Disease Control and Prevention states that patients with leukemia, lymphoma, or other malignancies whose disease is in remission and whose chemotherapy has been terminated for at least three months may receive live virus vaccines such as the measles, mumps, and rubella vaccine, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      , and the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"       zoster vaccine",
"      </a>",
"      according to age-specific recommendations. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Live organism vaccines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/1\">",
"      Hibberd PL, Rubin RH. Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am 1990; 4:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/2\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/3\">",
"      Hamarstr&ouml;m V, Pauksen K, Svensson H, et al. Tetanus immunity in patients with hematological malignancies. Support Care Cancer 1998; 6:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/4\">",
"      van der Does-van den Berg A, Hermans J, Nagel J, van Steenis G. Immunity to diphtheria, pertussis, tetanus, and poliomyelitis in children with acute lymphocytic leukemia after cessation of chemotherapy. Pediatrics 1981; 67:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/5\">",
"      Task Force on Community Preventive Services. Strategies for reducing exposure to environmental tobacco smoke, increasing tobacco-use cessation, and reducing initiation in communities and health-care systems. A report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/6\">",
"      Addiego JE Jr, Ammann AJ, Schiffman G, et al. Response to pneumococcal polysaccharide vaccine in patients with untreated Hodgkin's disease. Children's Cancer Study Group Report. Lancet 1980; 2:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/7\">",
"      Frederiksen B, Specht L, Henrichsen J, et al. Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease. Eur J Haematol 1989; 43:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/8\">",
"      Donaldson SS, Vosti KL, Berberich FR, et al. Response to pneumococcal vaccine among children with Hodgkin's disease. Rev Infect Dis 1981; 3 Suppl:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/9\">",
"      Siber GR, Gorham C, Martin P, et al. Antibody response to pretreatment immunization and post-treatment boosting with bacterial polysaccharide vaccines in patients with Hodgkin's disease. Ann Intern Med 1986; 104:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/10\">",
"      Ammann AJ, Schiffman G, Addiego JE, et al. Immunization of immunosuppressed patients with pneumococcal polysaccharide vaccine. Rev Infect Dis 1981; 3 Suppl:S160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/11\">",
"      Siber GR, Schur PH, Aisenberg AC, et al. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 1980; 303:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/12\">",
"      Feldman S, Malone W, Wilbur R, Schiffman G. Pneumococcal vaccination in children with acute lymphocytic leukemia. Med Pediatr Oncol 1985; 13:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/13\">",
"      Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/14\">",
"      French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812.",
"     </a>",
"    </li>",
"    <li>",
"     Advisory Committee on Immunization Practices. Summary Report, February 22-23, 2012. file://www.cdc.gov/vaccines/recs/acip/downloads/min-feb12.pdf (Accessed on June 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/17\">",
"      Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/18\">",
"      Feldman S, Gigliotti F, Shenep JL, et al. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 1990; 161:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/19\">",
"      Ridgway D, Wolff LJ, Deforest A. Immunization response varies with intensity of acute lymphoblastic leukemia therapy. Am J Dis Child 1991; 145:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/20\">",
"      Shenep JL, Feldman S, Gigliotti F, et al. Response of immunocompromised children with solid tumors to a conjugate vaccine for Haemophilus influenzae type b. J Pediatr 1994; 125:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/21\">",
"      Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Notice to readers: Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2007; 56:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/25\">",
"      Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/26\">",
"      Elting LS, Whimbey E, Lo W, et al. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995; 3:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/27\">",
"      Gribabis DA, Panayiotidis P, Boussiotis VA, et al. Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol 1994; 91:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/28\">",
"      Anderson H, Petrie K, Berrisford C, et al. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999; 80:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/29\">",
"      Brydak LB, Ca��becka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk Lymphoma 1999; 32:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/30\">",
"      Lo W, Whimbey E, Elting L, et al. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993; 12:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/31\">",
"      Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005; 130:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/32\">",
"      Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 2012; 206:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/33\">",
"      Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011; 118:6769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/35\">",
"      Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/36\">",
"      Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/37\">",
"      Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA 1992; 267:1237.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Immunocompromised children. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.74.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/39\">",
"      Geiger R, Fink FM, S&ouml;lder B, et al. Persistent rubella infection after erroneous vaccination in an immunocompromised patient with acute lymphoblastic leukemia in remission. J Med Virol 1995; 47:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/40\">",
"      Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989; 320:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/41\">",
"      Grossberg R, Harpaz R, Rubtcova E, et al. Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr 2006; 148:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/42\">",
"      Rusthoven JJ, Ahlgren P, Elhakim T, et al. Varicella-zoster infection in adult cancer patients. A population study. Arch Intern Med 1988; 148:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/37/30296/abstract/43\">",
"      Wilson JF, Marsa GW, Johnson RE. Herpes zoster in Hodgkin's disease. Clinical, histologic, and immunologic correlations. Cancer 1972; 29:461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3899 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30296=[""].join("\n");
var outline_f29_37_30296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1339714444\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INACTIVATED VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tetanus toxoid, diphtheria toxoid, and pertussis vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Polio vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1419557391\">",
"      - Recommended formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Haemophilus influenzae vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meningococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Human papilloma virus vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatitis B vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hepatitis A vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LIVE ORGANISM VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Measles, mumps, and rubella vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Varicella vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Zoster vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1339714444\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3899|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42263\" title=\"figure 1\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3899|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/48/12046\" title=\"table 1\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/63/21501\" title=\"table 2\">",
"      PCV and PPSV23 in high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/60/24523\" title=\"table 3\">",
"      PPSV23 schedule for high-risk children older than two years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 4\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=related_link\">",
"      Measles-mumps-rubella vaccination in high risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_37_30297="Clarithromycin: Pediatric drug information";
var content_f29_37_30297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clarithromycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"    see \"Clarithromycin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/8/12421?source=see_link\">",
"    see \"Clarithromycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Biaxin&reg;;",
"     </li>",
"     <li>",
"      Biaxin&reg; XL",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clarithromycin&reg;;",
"     </li>",
"     <li>",
"      Ava-Clarithromycin;",
"     </li>",
"     <li>",
"      Biaxin&reg;;",
"     </li>",
"     <li>",
"      Biaxin&reg; XL;",
"     </li>",
"     <li>",
"      Dom-Clarithromycin;",
"     </li>",
"     <li>",
"      Mylan-Clarithromycin;",
"     </li>",
"     <li>",
"      PMS-Clarithromycin;",
"     </li>",
"     <li>",
"      RAN&trade;-Clarithromycin;",
"     </li>",
"     <li>",
"      ratio-Clarithromycin;",
"     </li>",
"     <li>",
"      Riva-Clarithromycin;",
"     </li>",
"     <li>",
"      Sandoz-Clarithromycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Macrolide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"      see \"Clarithromycin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     All pediatric dosing recommendations based on immediate release product formulations (tablet and oral suspension):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing, susceptible infection:",
"     </b>",
"     Oral: 15 mg/kg/day divided every 12 hours; maximum  dose: 500 mg; duration dependent on infection site and severity; usually 7-14 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute otitis media:",
"     </b>",
"     Oral: 15 mg/kg/day divided every 12 hours for 10 days;",
"     <b>",
"      Note:",
"     </b>",
"     Recommended as an alternative agent in penicillin allergic patients (AAP, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bartonellosis, treatment and prophylaxis for frequent or severe recurrence in HIV-exposed/-positive patients:",
"     </b>",
"     Oral: 15 mg/kg/day divided every 12 hours; maximum dose: 500 mg (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Endocarditis,  prophylaxis; dental procedures in patients allergic to penicillins:",
"     </b>",
"     Oral: 15 mg/kg; maximum dose: 500 mg; administer 30-60 minutes before procedure.",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, the American Heart Association guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur (Wilson, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Group A streptococcal infection; rheumatic fever, primary prevention and treatment of streptococcal tonsillopharyngitis:",
"     </b>",
"     Oral: 15 mg/kg/day divided every 12 hours for 10 days; maximum dose: 250 mg (Gerber, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Lyme disease:",
"     </b>",
"     Oral: 7.5 mg/kg twice daily for 14-21 days; maximum dose: 500 mg (Wormser, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Mycobacterium avium complex infection (MAC):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Prophylaxis:",
"     </i>",
"     Oral: 15 mg/kg/day divided every 12 hours; maximum dose: 500 mg; to prevent first episode begin therapy at the following CD4",
"     <sup>",
"      +",
"     </sup>",
"     T-lymphocyte counts (see below):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Infants &lt;12 months: &lt;750 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children 1-2 years: &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children 2-5 years: &lt;75 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children &ge;6 years: &lt;50 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Recurrence:",
"     </i>",
"     Oral: 15 mg/kg/day divided every 12 hours; maximum dose: 500 mg; use in combination with ethambutol with or without rifabutin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Treatment in HIV-exposed/-positive:",
"     </i>",
"     Oral: 15-30 mg/kg/day divided every 12 hours; maximum dose: 500 mg; use in combination with ethambutol and if severe infection, rifabutin; follow with chronic suppressive therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents:",
"     <i>",
"      Prophylaxis and treatment of HIV-exposed/-positive:",
"     </i>",
"     Oral: 500 mg twice daily in combination with other antimycobacterial agents (eg, ethambutol and rifabutin) (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Peptic ulcer disease, eradication of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      :",
"     </b>",
"     Oral: 15 mg/kg/day divided every 12 hours; maximum dose: 500 mg; initial duration of treatment: 7-14 days; as part of dual or triple combination regimens with bismuth subsalicylate, amoxicillin, metronidazole, an H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist, or proton pump inhibitor (Gold, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pertussis:",
"     </b>",
"     Oral: 15 mg/kg/day divided every 12 hours for 7 days; maximum dose: 500 mg (CDC, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumonia, community-acquired (CAP); presumed atypical pneumonia (",
"      <i>",
"       M. pneumoniae",
"      </i>",
"      ,",
"      <i>",
"       C. pneumoniae",
"      </i>",
"      ,",
"      <i>",
"       C. trachomatis",
"      </i>",
"      ); mild infection or step-down therapy:",
"     </b>",
"     Infants &gt;3 months, Children, and Adolescents: Oral: 15 mg/kg/day every 12 hours; maximum dose: 500 mg;",
"     <b>",
"      Note:",
"     </b>",
"     A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out (Bradley, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Presumed atypical pneumonia (",
"      <i>",
"       M. pneumoniae",
"      </i>",
"      ,",
"      <i>",
"       C. pneumoniae",
"      </i>",
"      ,",
"      <i>",
"       C. trachomatis",
"      </i>",
"      ); mild infection or step-down therapy:",
"     </b>",
"     Oral: 15 mg/kg/day every 12 hours; maximum dose: 500 mg;",
"     <b>",
"      Note:",
"     </b>",
"     A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out (Bradley, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing, susceptible infection:",
"     </b>",
"     Oral: 250-500 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute exacerbation of chronic bronchitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     and",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     : 250 mg every 12 hours for 7-14 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      H. influenzae:",
"     </i>",
"     500 mg every 12 hours for 7-14 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      H. parainfluenzae:",
"     </i>",
"     500 mg every 12 hours for 7 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute maxillary sinusitis:",
"     </b>",
"     Oral: 500 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Mycobacterial infection (prevention and treatment):",
"     </b>",
"     Oral: 500 mg twice daily (use with other antimycobacterial drugs (eg, ethambutol or rifampin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Peptic ulcer disease:",
"     </b>",
"     Eradication of",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     : Dual or triple combination regimens with bismuth subsalicylate, amoxicillin, an H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist, or proton pump inhibitor: 500 mg every 8-12 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pharyngitis, tonsillitis:",
"     </b>",
"     Oral: 250 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumonia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      C. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      M. pneumoniae",
"     </i>",
"     , and",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     : 250 mg every 12 hours for 7-14 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      H. influenzae",
"     </i>",
"     : 250 mg every 12 hours for 7 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      H. parainfluenzae",
"     </i>",
"     and",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     : 1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Skin and skin structure infection, uncomplicated:",
"     </b>",
"     Oral: 250 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal  impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on a dose 15 mg/kg/day divided twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR &ge;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR 10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 8 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR &lt; 10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 4 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis: Administer after HD session is completed: 4 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peritoneal dialysis: 4 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adult:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Decrease clarithromycin dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis: Administer after HD session is completed (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     In combination with atazanavir or ritonavir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: Decrease clarithromycin dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Decrease clarithromycin dose by 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adjustment not needed as long as renal function is normal",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, oral: 125 mg/5 mL (50 mL, 100 mL); 250 mg/5 mL (50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biaxin&reg;: 125 mg/5 mL (50 mL, 100 mL); 250 mg/5 mL (50 mL, 100 mL) [fruit-punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biaxin&reg;: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biaxin&reg; XL: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablets and oral suspension: May be administered with or without meals; give every 12 hours rather than twice daily to avoid peak and trough variation. Shake suspension well before each use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablets: Should be given with food. Do not crush or chew extended release tablet.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release 250 mg tablets and granules for oral suspension: Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Reconstituted oral suspension should not be refrigerated because it might gel; microencapsulated particles of clarithromycin in suspension are stable for 14 days when stored at room temperature. Protect tablets from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release 500 mg tablets and Biaxin&reg; XL: Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of upper and lower respiratory tract infections, community-acquired pneumonia, acute otitis media, and infections of the skin and skin structure due to susceptible strains of",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pyogenes",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     ,",
"     <i>",
"      Mycoplasma pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      C. trachomatis",
"     </i>",
"     , and",
"     <i>",
"      Legionella",
"     </i>",
"     species (FDA approved in ages &ge;6 months and adults); prophylaxis and treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex (MAC) disease in patients with advanced HIV infection (FDA approved in ages &ge;20 months and adults); treatment of",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     infection (FDA approved in adults); infective endocarditis prophylaxis for dental procedures in penicillin-allergic patients; postexposure prophylaxis and treatment of pertussis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Clarithromycin may be confused with Claritin&reg;, clindamycin, erythromycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F152425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abnormal taste, diarrhea, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Prothrombin time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening:  Alkaline phosphatase increased, ALT increased, anaphylaxis, anorexia, anxiety, AST increased, behavioral changes, bilirubin increased, cholestatic hepatitis,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     colitis, confusion, depersonalization, depression, disorientation, dizziness, drug rash with eosinophilia and systemic symptoms (DRESS),  GGT increased, glossitis, hallucinations, hearing loss (reversible), hemorrhage, Henoch-Sch&ouml;nlein purpura, hepatic dysfunction, hepatic failure, hepatitis, hypoglycemia, insomnia, interstitial nephritis, jaundice, leukopenia, LDH increased, manic behavior, myalgia, neutropenia, nightmares, oral moniliasis, pancreatitis, psychosis, QT prolongation, rhabdomyolysis, seizure, serum creatinine increased, smell loss, Stevens-Johnson syndrome, stomatitis, taste loss, thrombocytopenia, tinnitus, tongue discoloration, tooth discoloration (reversible with dental cleaning), torsade de pointes, toxic epidermal necrolysis, tremor, urticaria, ventricular tachycardia, ventricular arrhythmia, vertigo, white blood cell count decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clarithromycin, any component, erythromycin, or any macrolide antibiotic; use with ergot derivatives, pimozide, cisapride, astemizole, terfenadine, colchicine (if patient has concomitant renal or hepatic impairment), lovastatin, or simvastatin; history of cholestatic jaundice or hepatic dysfunction with prior clarithromycin use; history of QT prolongation or ventricular arrhythmia, including torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal impairment; reduce dosage or prolong dosing interval in patients with severe renal impairment with or without coexisting hepatic impairment. Elevated liver function tests and hepatitis (hepatocellular, cholestatic) have been reported; usually reversible after discontinuation of clarithromycin. May lead to hepatic failure or death (rarely), especially in the presence of pre-existing hepatic disease or concomitant use of hepatotoxic medications. Use caution in patients with myasthenia gravis; may exacerbate symptoms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When clarithromycin and colchicine are coadministered together, inhibition of CYP3A and p-glycoprotein may lead to increased exposure to colchicine (monitor for symptoms of colchicine toxicity); if coadministration is necessary, reduction of colchicine dose is recommended (concomitant use is contraindicated in patients with hepatic or renal impairment). In combination with high-dose rifabutin therapy, uveitis has been reported. Use with caution in patients with CAD; postmarketing safety trial suggests increased risk of cardiovascular mortality with short-term clarithromycin use (vs placebo) in patients with stable CAD; however, more smokers were randomized to the clarithromycin arm (Jespersen, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Children may experience some adverse effects not reported in adults, or more frequently than adults,  including rash, and vomiting. The extended release formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe acute hypersensitivity reactions have (rarely) been reported, including anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia, and systemic symptoms (DRESS), and Henoch-Schonlein purpura; discontinue therapy immediately and urgently initiate treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Macrolides have been associated with rare cardiac conduction alterations, and use is contraindicated in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and ventricular arrhythmias, including torsade de pointes; avoid use in patients with uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and patients receiving Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents. Use caution with any agents with substantial metabolism through the CYP3A4 pathway; high potential for drug interactions exists.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F152413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Macrolide Antibiotics may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Macrolide Antibiotics may decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Macrolide Antibiotics may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues.  Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Macrolide Antibiotics may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Macrolide Antibiotics may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.  Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Macrolide Antibiotics may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Macrolide Antibiotics may decrease the metabolism of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Macrolide Antibiotics may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Macrolide Antibiotics may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Clarithromycin may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin.  Management: In patients with an estimated creatinine clearance of 50 to 60 mL/min, the clarithromycin dose needs to be reduced by 50% when used together with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Macrolide Antibiotics may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Macrolide Antibiotics may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Clarithromycin may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Macrolide Antibiotics may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Macrolide Antibiotics may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Macrolide Antibiotics may enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Clarithromycin may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased. Management: For the treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex, consider changing to alternative agent, such as azithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlipiZIDE: Clarithromycin may increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlyBURIDE: Clarithromycin may increase the serum concentration of GlyBURIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Macrolide Antibiotics may decrease the metabolism of HMG-CoA Reductase Inhibitors.  Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed. Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Macrolide Antibiotics may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Macrolide Antibiotics may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifapentine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Clarithromycin may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Macrolide Antibiotics may decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE; PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Macrolide Antibiotics may decrease the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Clarithromycin may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Clarithromycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Macrolide Antibiotics may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Macrolide Antibiotics may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Clarithromycin may increase the serum concentration of Vardenafil.  Management: Recommendations regarding the concomitant use of vardenafil with clarithromycin vary between international labelings and between commercially available vardenafil brand name products (Levitra, Staxyn). Consult appropriate product labelings.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Clarithromycin may enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine.  Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zopiclone: Macrolide Antibiotics may increase the serum concentration of Zopiclone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1046413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release formulations: Food may delay the rate but not the extent of oral absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release formulations: Food increases AUC by 30% relative to fasting conditions",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse fetal effects have been documented in some animal reproduction studies. Clarithromycin crosses the placenta. The manufacturer recommends that clarithromycin not be used in a pregnant woman unless there are no alternative therapies. An increased risk of teratogenic events has not been observed following maternal use of clarithromycin.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, serum BUN and creatinine, liver function tests; serum concentration of drugs whose concentrations may be affected in patients receiving concomitant clarithromycin (ie, theophylline, carbamazepine, quinidine, digoxin, anticoagulants, triazolam); hearing (in patients receiving long-term treatment with clarithromycin); observe for changes in bowel frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial RNA-dependent protein synthesis by binding to the 50S ribosomal subunit; the 14-hydroxy metabolite of clarithromycin is twice as active as the parent compound",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid from the GI tract; food delays onset of absorption and formation of active metabolite, but does not affect the extent of tablet absorption; in pediatric patients, coadministration of the suspension with food did not significantly alter the extent of clarithromycin absorption or formation of the 14-OH metabolite (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed throughout the body with tissue concentrations higher than serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 65% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to active and inactive metabolites; undergoes extensive first-pass metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 50% to 68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Dose-dependent, prolonged with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarithromycin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     250 mg dose: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500 mg dose: 5-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-hydroxy metabolite:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     250 mg dose: 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500 mg dose: 7-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Immediate release formulations: 2-3 hours; Extended release: 5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: After a 250 mg tablet dose, 20% is excreted unchanged in urine, 10% to 15% is excreted as active metabolite 14-OH clarithromycin, and 4% is excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F15831766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/8/12421?source=see_link\">",
"      see \"Clarithromycin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets and suspension may be taken with or without meals or milk. Extended release formulation (XL) should be taken with meals; do not break or chew extended release tablets. Maintain adequate hydration, unless instructed to restrict fluid intake. May cause nausea, heartburn, abnormal taste, diarrhea, headaches, or abdominal pain. Report rapid heartbeat or palpitations, persistent fever or chills, easy bruising or bleeding, joint pain, severe persistent diarrhea, skin rash, sores in mouth, or foul-smelling urine.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, \"Diagnosis and Management of Acute Otitis Media,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 113(5):1451-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/15121972/pubmed\" id=\"15121972\" target=\"_blank\">",
"        15121972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aspin MM, Hoberman A, McCarty J, et al, &ldquo;Comparative Study of the Safety and Efficacy of Clarithromycin and Amoxicillin-Clavulanate in the Treatment of Acute Otitis Media in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(1):136-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/8021763/pubmed\" id=\"8021763\" target=\"_blank\">",
"        8021763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD, Wong BC, and Practice Parameters Committee of the American College of Gastroenterology, \"American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,\"",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007, 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al, \"Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute",
"      <i>",
"       Streptococcal pharyngitis",
"      </i>",
"      : A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(11):1541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/19246689/pubmed\" id=\"19246689\" target=\"_blank\">",
"        19246689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gold BD, Colletti RB, Abbott M, et al, \"",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection in Children: Recommendations for Diagnosis and Treatment,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2000, 31(5):490-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/11144432/pubmed\" id=\"11144432\" target=\"_blank\">",
"        11144432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR and Craft JC, &ldquo;Overview of the Pharmacology of Clarithromycin Suspension in Children and a Comparison With That in Adults,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1993, 12(12 Suppl 3):S106-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/8295810/pubmed\" id=\"8295810\" target=\"_blank\">",
"        8295810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Husson RN, Ross LA, Sandelli S, et al, &ldquo;Orally Administered Clarithromycin for the Treatment of Systemic",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex Infection in Children With Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 124(5 Pt 1):807-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/8176574/pubmed\" id=\"8176574\" target=\"_blank\">",
"        8176574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neu HC, &ldquo;The Development of Macrolides: Clarithromycin in Perspective,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1991, 27(Suppl A):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/1827094/pubmed\" id=\"1827094\" target=\"_blank\">",
"        1827094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, \"Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tiwari T, Murphy TV, and Moran J, \"Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-14):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/37/30297/abstract-text/16340941/pubmed\" id=\"16340941\" target=\"_blank\">",
"        16340941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, \"Prevention of Infective Endocarditis. Guidelines From the American Heart Association,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115:1-20.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13165 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-8A237B75EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30297=[""].join("\n");
var outline_f29_37_30297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152372\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152373\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046404\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046398\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152345\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152331\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046408\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046401\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046407\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152427\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152425\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046411\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046397\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046396\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152413\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152340\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046413\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152342\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152355\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046403\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046395\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046410\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15831766\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13165\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13165|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=related_link\">",
"      Clarithromycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/8/12421?source=related_link\">",
"      Clarithromycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_37_30298="Lichen simplex chronicus1";
var content_f29_37_30298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68426%7EOBGYN%2F81018%7EOBGYN%2F59195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68426%7EOBGYN%2F81018%7EOBGYN%2F59195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Vulvar lichen simplex chronicus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar lichen simplex chronicus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAV8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5bmlk85/3j/eP8R9aZ5sn/PR/zNE/+uk/3j/OmhScUAL5sn/PR/zNL5sn99/zNSR27OwUDk8VoR2iW+N6M8meV6fjRsNK5TRZgFLM43HjJNWVhuGGN8rO3GASTWla2Et3dYCluwUdAK7bQ/BGoXrsXxZW/AZj97A7Cs514w3ZShc4SO3mRSNzxjPK5yx9q67w9oOpXab7W0mEeQu9m2gfia9B0bwxo1g+62ha5mXA81uQfXnoP510Eu4IAskYHTZHyc+ma4KuMvpE6IUtTh7Twc6MEv7pcgh2WIlmX6eprpbLQLOyUBLYk9mlbd+OK17aArFtVfLOeSw+Yn+dStC6AlFd1xzuHUfjXFOtKW50RpJFHydqgAMRjAUfKP8AGmTuI0VYs5J/3QP8asXMnlwKXdPm5AwQfw45pFaFoUkhVtxOd2MY9gTWN2aqN2ZkqzyMfPeZI+oUMVJ/LkU3EHmKttDIrleTt27fxFacUL48xFTzW64y7qPx4pVjRkRULAgk/Mo49T60nM0ULGbFYxsdwvHhZupkG3+Y5qYWk2wRs0rZOchgAfyq7POhHzY8te+Tyfx6VQZkD7o45FJ6hBtX9etCbb1NFT0Ft7NVKmNMg9WUZP5k064Xhsl1iwRhx2oa4UNiT5iFxjdgA1G9wsiMDzx8w3HijrcdtClZmZbhZJvmyQJMt0A6Ef1rVnV/t8JV+RyCGzxiqTPJErsyJLCTgNG2eenerFnNANUQSlRGLfIBP3SG9PxFU79BaKxLeQGNd2AwmLMdxzjHP/16qaUz2lvDbTTnypEV0mYEsuf4TWlqTwm2IjJ3E4jC9yeOD6YoWWIxeRMy7EG0A4DdeM0ru3kNWLLF4w6jzMEHkDO76+lVo4meCGKMu1xIC+N3y5/z/KoLK9XfLbTSO0sOU2Rcg578e1XLWVYYdzW6gqNqjzD+Z/8A11CXS5TS3SH/ADRbRK+xV4YDufb3pbh3kCpGzQQr0lmJyfcKe/8AnFLHugZpthkuHG1Tgnbn0J6VKVmJCTFTJjGWA+X2A9feo06A4lRdNjkjMzyzADjdI2WY49Og/nVmKBbWIbNoJGSAckfX1onnKzKsriVIxkKnQ8etNhuhMzBIl+fkDHP6mjVhyjz5q2xk2z7f4s45qQTStEAoWNWHG4Zz9KgP7nJaMkDkKUySPzqVRbpGrRskgOS0UmU2/Q0tyGkPlwibYlkw/wDzzBAJ9x0IqN2EQ23atjqpiz/LqP1FSM8ZRRDKEjY9GcNj6Y5p5aCBfMLxSR9Cd/P69Kq76kcqZW2tLEDDIWXPBkAOPWq9zp0syfNJDIo4AIOV/HORW2ZLddps/LVyOSHBDf7w7/XrUEiRs7uke2RQS4zk49R6irjMylBHKXuixyo5u7YNKRiR412Pt+g4Yfka4/UvB9yoaS3ZbmAA7cNyR25/xr1rMcyg7CjLzjoyn1H+NUJ7KYOZLU5lJzwuN3rkdD9a6KeJlF7mEqOh4VdabcSM8MqyKy/eD5+T0xWLdWM8KFLoyFd2FdT90ete/wA1pa3kO24iMV0oKqwGPwz6Z7ViXvhRL23aSEFiud0RIJ+o9a7aeM7mLprqeFXVrNb7T5jMrcq2ThhVbfcROTHJKjA44YivUZfDL25ELhTZzN8kjH5R9D2NYmq+Dru3dk8p3jGTuPXn3rrhiYvcydLqjF0jxr4h0ghba/mKg5KsxNd1ovxx1uycfa4/NQnn2Fef3WiXEauVUuMc8YIFZcttIr4wSQfSuiMoy2M5QfU+rvD/AMadIvIY3NyY5SQGRgeK9A0nxnZakVMdxEwYZGG6ivgt4iDuUkHNaGj6vqOn3ita3Usec9yO1FjNxKhtWaZ8An5ieB71ftdLlZlDICD1wM16jpfgKSPLXZESlido5Y1tWvhiCFwkWdoOcnjH/wBeuOeMS2OhUzzXSfD8sjMIIdxX75IyFrrND8CNIxlvJAitg5HU/QemK763soIrcrGgVP5j3qTh2UMRjOMAcfn/AEriqYuTNlSKWm6bYWCqNLtUd1Xa0zjgfjV5rLzFXzmaUHOVxtU/hUoJUbozjZkEnjirit8gdF2s3GT2/CuOdW50wpWdyukTIg37FUDuOnsBU4WVcGMDZGOOwJqZEBPD5BwSSKmiRJHXPzpnjcSAayVRdzZQt0M5/tDNluud20Ckk8qM4lknyvJ+bP4CtSZBHIQFJbGSAP8APFVD5Mki794H3i33jn0Ao5i4xW9ir5JkBmkkOTjjHQehzUcizO7XSxNIyALschVYen1FSzujSyLErsBzngfn2FIp2qFmUEISSHJx9MDrRzamijoQwO75WGYhhy8YBDJ+dQySE5aO4ktw2f3hX5vT5cdfx/Wm327Zm6SNRu/douVK+mTVeSUoh81XljPG9F56+uORTjsJq4gjVGZkZmYj7zgEn/PtTkjLffzISMnL4A9TTmnjZDsIdFIz8pHPvxk1GLthwcEE8qxwMfSqaLStsI77FbaVZc4wByD+NUriUZj5IVj3659v8Kn8yNt3lldqHJ56f596r3KIuRv7ZGR0/HtVLQV2gNz5DjKko5DKxIHOf5+9Twzk6uJDCjlsRMCRnBB/kcVl3cQjVyjeYmc9MfpVe51WO1tVmaPE6jeSBkH8KuEW3czqSsrnTS3Fo98It6+XbDcWJOXcjgD0IH86zpLiA3MgYhwACMDbg+9YCXB8uFI1ccF3Kgkk5yW9sk1bSK4iJkjAkBIxkdc9c0TjZiT6mzb3UbXUgMbNGEVmELctyeeR1rRa7Eh8m2nUxHGDt6/WufthhwzSbixxliQMeg9Ku21z9mnLMzRxMdjhudhPfI9elRZSdkWttTohIEhDgBUAJLk5BPt79arS3TgNKAQuMAt396ia95WM4cRgldw4x649aoC73zKwXeUPLYyB9PzrKUbFotMzNht7FyeWDYFWYo4T87sWccYLc1UgZZZFDE46gjrnvVxNyRkfdjfkZ7j+lTcHYsiQFv8AURMAOMIcfjU9tJDjdKmwMOjdvoe1VoVDbkLAk9guVx26VPH5j7Y0ETKAcqV24/GjUHYuZDEMYxsAO1nwN3tkd6VXQNKFiyh/if5tp+vaorNBIrKrtFKpJCv90/WpmS4ieOSVkWXA2sBlXHoccGkrEbbkkcKRr5slrEyvwJE4A/8Ar0S26L99DuHMbx8MP6GoNr4YW8UibTllDgofwq0sgjdFeJ1BwcqQR+fpTvYlq5RmlXYIL2PEgOIpIx95vYHoT6U+I3W87mjjZQfkKlmwPxGatpJHPcusu2VQu3BA6Hr/ACFMSFo5SjjzYV5UlvnQjtnvTTvsZySW+xQuobjKsGhlUjDJKmMgdMe9QxRIkgkQtbyg4KYyr/8A162bj+HA/d7ukg5H0NQToykDAKt39P8AGrU+5MqaexSeITRyI8CS28n3lRQQ3qfY1Saz4SEcjkQSE5z7E+taYEkLsYEypHMIP6jPTih0juQzRAB8cqeMkdvY1qqtjmlT1Odk0i0uGkiuR5dxjBKrlT+VY2qeA7eeJjGwjduV+Xqa7GFVctHKSr7goYfyP+NSqZoGEU0QljHAJ5z9PQ1op21iyLtbniOr+Abu1SRlAkCjB28Yrm20G6iu1V0LMOBkEDp3r6TkiiPH3oCevVl//VUM/h60upIyyLnr5mcV0wxs4aPUnkjLdEE0kZMu0AHOMnqRUCSKfRnz3HQe1IsZwI1BL7z+9Y847DHpzTLqFrcp5iMDj06iuGc7nV7CxbCs8g2AAjJO84BqSFdq+ZGpDEkfKOaitWXYJPvgMGyW4H0rTgtk2vMmSPTOMZ4rKUjWNO2jRS8t2GLgFULBlAGc/X1/kKt3SokkYhUgbcuR1A9KtLbl7cGRXZh0weDUIlSfdFAo8xRlnP8AKsnc6IJbkFuk5kWRIwgJwqd8D1NXlf7PMzXCjPBwWBwTSLE9u44CsBycfd96JcRELI3mO/z/AEHbNDsO1xqTgo7OxIbhn2nOPQVEAjy/Mo8nsq+nuf6VZ5lCRBFUfxMTyR9aoSypC/3zuJxgdvamkOy7Ek8MMc0jyyCNFGcAfy/OqDyF0XYhBOSHbqR2+n86llzJJJK652ABVz3P9ary3qidFm8tMD1zxVp22KSYixgp5rMHkztw/Jx7U6WMYCsMsDhAcdev4CoGvoIwrNMFOd27YQAPXOKWJopVd2lAjOcOo37u+DjpRZvUdl0IriFZJcoEMgXJ5/kR0qiVHLOQQvIyMBT7ep960XigwhRVG44Ax09fpVSf9xIZAV8tmC4Zs7feq2GkVZJgGZkRGyx+fpz9O5qMuJQCFJYcnimXckczLE8j53FigUED0A96ljhluIVDKqxnHU9fp37Vpy9URLazMK+nJLAHy5I2+Vs8fj7e1c891Nd3kkCYKswZmHyghTwK6PXY18uOJoI5o5HKsnKkd8qQevHvXP2Kk3Mr253KX2qMDKgDOD6V20VaN0clV66nTaJZloJWkYxSdgvzAjHFXhOqrEj5EMfyAA5Lk+tYUd3MkKKJJHmkbJRedmOn8vyqO+lnaeIMMSs27d/d7c1kopvUv2iR1zW0YdPPUCNv4kHK+9Y+poyRSAH5kGBzjI9/WrNhqlwuJJEV4WQg87toHUilutslvkGNoegx/D/9aseTlndFqaaKbX5nSGZuHKAY7Zq7YRsVjx8xYn5c/wAq5jS2QXLW6yggMVYnkD16c11tuIxCg3jezbQFwSOO1OvFJ2RdN3RfttyxSN5e5QeCG5yauxSDdt2NjuDz7c+9V4FyoLNtf69/XPX8KtJ5r7tvKqRlumQO/wD9aua1jUkSOJYsgeXMR8pibnHvnrUtvLIHMLkSxZLBmBG72PoaYDBFErJv3HjGzAY+3NEKy5SO5VvLByFQZz9alPSxDRdS4tiY2G126Msvb3z1qyJoomZRIkcUh28PuUH6dRUFq0D71SNVH8LgZCk9v8irUEJcSBHVUIAw3IY/Xsam9hOPcW2lWN5d28rt++gP+HepDdQFVR1YA5xlTx+NVUhDtgO8BBIcDkD3weCPcVcEk63C74PM2jG+BcAge3XP50rsTSQwx2qKGZEkV+N6kb09Pr+NDw27DiEjPG5WOR/h9KmnitbuRvLIGepIxg+hHUGqcqzW5zvUqOHw3J/xpJ2d0So82jESSSOM+XOZAOBG/Jp0jhovMmtyP4TsYkfWpCFkjGCHCqeeA1NWPKKFLoWPAI6kU1K2jJlBFHJjlIhmIx/yzk5z9D1qRoTI3mITFKB83vjsf8akMDHk7QxyGz047e1M37GAQ8g4OT0FXzO5m6d2iCaMXQ7s68cDBHsakMyhQpWQEdQRn8zVgqqt5kY+fHJzgUiEiUFuh+YZ7mrTMZRfQhhCyFijgED5lx96rEGUfKH5m6j1pk4gmchginHDKaZbrIsgCyb4u4xkitFK71MXHsYtoR9sCfKGDg5J5OfrV2/RHmgKAtJJ1ORg8dKzkjU3pCKHfdkgjgY/pitObJhVFYFV+Yso5J6fyz0rOSd7o9WKuhNORo7iMYOMbdpAxzWvFarG0gQEx5xuP8X4Vlwt5syRJtCJlvMJPrkKa6a2CXkUBfBKrglR39/yqeW7aRMtNTKuzO2I1wYx8pOcD2qG3sktAJAcynBZic1t3EIVAAincowSB1Byaiuo5FjDRqvldAM4pSiVGXYgu4/uiNSEONxHc1Fc+SLc5ODnLMe/oPekuUItFZ5MAnhQP8/nUZVBIhlQ4RcsTz+VSNLsUb7akhcAkJ7/AOepqlFcTeRK4shtyQHaTHJPPQVZ1AzTxsIY8GYcM3OB2wv5dfSqL/NbsZneViBgMeAx68dM1di4xbFknQAPK0abV3Y3ZBYdiT0H51mSai3lyGK2Lq7E5gVjkf8AfOMVpmFAPNDM5ThQxAAP+zQi5VEQ5P3exG3/AOvzVqVtBcpSt7km3Dyo0DNhvLkQsQPqOKR2gmcTAolxIwJ2kLgY4H/66sbPKYvvZVAOwAAlR/8ArpVtshfMGZMld7tnA64FJNGiiVvLIZkw0oI6xcHGOvp+RqjKI2hJI2r3XdyvqSPU1rG2hmkJMbuoXaQScnHpVKawVgRFDGyg4ORkZGO/atOZEuL6szLcRvIvmRKGyckEhmI7g4qeG9aIKkkLyMc8JIPfHXFWvssTEtchdzE7YyOfpnsKtRWkMEHlwouSDv45OBVJp7ozkmcXrFxK87FoPKjQF18xMPk8YwDwKz7ZWtod5kiQu5JGzJY4Hy9Og963vELyWywzwnLyyeUO/B9fWoVjD3cNosWyODDZPzF3I5J/Cu2LtCyOOcbzJLO0CW4yhSeUgp5alee/6VqQaM6xsSmSTn5iPmrX0Yu2puhfKJjC84Bx/wDXrVjhIs4pHYD7xDYxgdqxkmbQppnC3lq2mFhGCbeYnk8bG6D/AOvWTf3LC1dULRSopwc/e57V02uur27wON248E9+OvNc/Mhn0yOcqu0oZFwBweh/lmnT1SbJqQ5NER+HrLagkEe7edzH7r4z79a6hEikiIdQWVRsV+SvPaqOmW/lQQq7ckbi2ckf/XrZREMEW+PDZ5J4Y1hXlzSNqUfdQ9ZESKJhIpZcA7sAn2q4ka+WxY9wCdw4+nrVFI+XCkcDr05/HjNWrZoHKRyRooGcIBhj71hLc1s7Eqxut0cMSg+Qe2R+lW0EmY/JEnJO4A4z61SgjKsSZPl4Riw545AP+NaWFEIIVdqkHBY9Pb1qNOoNMZFbus2E+Tfnd33D1PfIrSTzFSVcJIAN24HHtwagWSTdGrFTIeUfoCD7+tSSw/KHWUeYe65x+NRK/QVixabcky7V7DJ5BqaNZlb5VyoH1H4mo7a5jkUu0IUouJBtyM/T+tOeae0LCE5ikHK5/h7c/wCNLoQ07kptVW5X7rscHI4bn39KryxRKXLqwZRkD+lWEiDO3nShepXI/LH50LEZY5JHcBkIIAPWkwStqQILcwsCpDZGP8KlkBEcSrIcqDzjO0+1W3ihijdQm5MA5HO361FIA4RcDB42g+n+etJ3RLszMmBKMSQZM5KdMk98VAluUaMvtw+Tgdh3+vetG5JMoG5iU77ecduaz5EkkLyFSAP4j0HHNXdA72sIrxI5G4qByPQ/4VX34LOcA7RjHrnpisy/v4hOYNxwmBnlVJ7c96rSySCQgO6soyw38D8xVpNnNLXY2jJuG47gVHHGBj3/ABpYbxbeVJGXerZ4Q8geprmY3kn/AHZcSAEYY/L+dSwAho3V9qOM7e+PWtYxSaIcWzVjjM2oPcOnloimMdORjue3QVauH220EAChpyT5gGSOeo9MVNCiNpp3H947kjAzwOufYDNQzKPOEke0YwQpPCg8Y/QU+ZtXZ3JC21m0UoUl5IlwrAnIB69f611dmpjVHZmKkcbR1HQn9ayNN3SlmMmVQ/wkEN/nNbsWAkW7du9QcgcdQPxpLfQmeujAQBLRI2Zcs2DzwT/9aor+NTCsYz/eOf0rVeACG3ZTuVMHOMg543frWbqcYO5N27BznNKSaREJczM27XdbB8BmbgZ4AHb+VV2tWuLTEjEvJ8x4PQdB9KsTovk8kEDge/0qrIJhOkasy7hx6gensKhamy2KAci43HAwdpJ56VnTyKDdIVUktuXPByeKvPHD9odWYOpYjk5NZN2I5XnK4AB2A9ckHv8A57U7G0dSfGy2TA3spxjGevHNPWNTGquWXoSfTHaoImUSRoXLBehzwcD1+tRiX94SrB3PzYJxnPv9Kq19RNlhSrNvG4HIAyQflqDIMhDMNxIUjrjPepWAiTB5LYAk3evJGKhkRlVVReCCPlHQUnHXQ0TvuLLKocpuKqgLZ7ZHf6VSlkd1O4AgHJboMHpj/GrDLtffwyHgdOQP5VHPsePzHf8AdkABM9vQf1qo3YpWE8p/MCx5lyeVc57dmqdkVFEW5lkzggA/LnrkVBaoyeZ5TorcEq549ePTirMgUyKsjYcgvlW6Htg1cUYyMbxOq2lhbyBgVSYqMcAnGazvDuzc1zcrLNMzlwi9wen+fepPF8yXC2VkilpTJ5mwDBwOM8dRnrT9MP2aRIvMP2lQOM/KPfjOa7oRXKkcsHdts6rR4AB5kjfvHwzL6VfllQWChm2OqkAZ684496xbe/mFssVv5AfJ3uMscj8qyjqN1amWScIZFJAdgSQT0xV8sZR8y1L3ivr73M1q8iRBEVsAlsEkenauetrpBAiTo1vvysWGzvOfu+mfbvXcahYi809Z7QgxBQDjp9K5GW3mjubeKSNDEJ1kIYcq/QEc1ELL3WXWWl0dRaMkdtE+S8rEjAPQY547VfEcYcMGG4gHnr9KghSMKmB8pVvbB/z7VOdrSKIkYEL1BJAPvXBPVmkNh8pAdNyZDcNnjd74p6Im/EkZJZTgdSp9BVR5FMjnafNwQwjUsD/hU1pcAyMSGVlGVBbk8YPT86h6K6NFcswR+UxEXztkfu3749DU7OAQHC7gcBRwPp9aVGLozJGd0bksQcgHsfalEiyud3Koc7W5xnoeOagGurLAlPlDIYhTgqw6EHtVmJlkR96/eAKMh5x6YqhvhR2Esgjbrjd945wRj/ParcMLCB2VvmjfG8dAD/SpfkGiL+ngxjzQxyvy7hwcehFTCYMcug2kFSAOM+oqlAwid0Qgqy9Dxnj0/pVi1uAqybCvmucHHYgdvr6VPkZSWtx8m51WQgYBxjrjirNgizK8qlQUb5vTP0qmkqG3zIMOhIc+31rTiKB2VDsQgZ4/WlZXFK+w2OB59gQjGzOOnQdqsLGuFYIFDIQBjJzT7fKRxDAKA7w2cnGaeUGUlIYRDIXt68mmo6GbZlFHCSz8AZ2gk8tmubZjMk9xIziEK2wHuB7e9b+qhksTGAEaRiAR6Vz+puIdJuZljbdIQhHZab02K3Vjn98k8k8y7QkKBMD3qW5t7ePTjcwfvWnwu4nbtOMkAD+fvUUqCGGVEKsGwWJOC3pkfWi4QM1pb/IjbfvEE4zn9a2tYhx6osGF49Li5UySEwxqPvc9Sc85wTUNsqNOFOePlDH0x7VY1UmG4srbK/uoi52HqT2NQQv5MqOGUkAllJxyeKpLUm1lc6KyMZsh5hYROxEnfK56AdhT7FBJqCxbAI1/eKHzn6E/lVmO3VLNGmkCts3cAnJ7Z+vX8ahgkVW84rlx19Wzxj86Xqbp3ZbsIHWQKnyhlDFM4AB9/T1rppFjDR+V8knAO4dQR2rG06HypFacRofLyqg52eoNbgHn+S0eeCrZI6Yo29TGbuya5b/Q404YgB3wOevSs68f98U27QBtJYcDNXxCCC7M2w56HqcciqN5EquEBLEYAOe/rmreqIhZaGLIgguMbS/y/eb/AD7VDdFWeZlJIRcZBxz1q4kYaeTJLqy8AY6+vPbisu7mCsY34ViNxA5NQ1Y6Y6lKULDiWReCNxAOBx1qhceW1wCoCKBv9+RWlqx4hYqdrBgEJ9q5+WVTIpDDO0KcjpzRy9DaOiuMjzNMxjUk7MgEY284yadpdqqKZfPaReT83TPTANTLs+1ESsGRuDtO0YGM/QVJ+6M/7lg7FflVDkA55HH+eKtOyaRNrsa4KyRpJnK8uM9ck4/pUEkhaRFjc7QMMz/xNnt7Yq3cSBmYABnZiiZB4OOAKqkEToWPzIAu0/xZHQfrUpX0NkmI8oV0ZdxDjBbdnBz2pLlvKUyr5ZIHzn72R60khYwGNQcMxQE9iPTHc012MivGxCvsUR543egq7Gc9NR0DiWAKwUgkAPg7iD3q2FkSR02naMbcHBIHc1S00sFe2mOZIX2nHTA9/wAM1qSbYpRKjAhvlI9KaWplUVk7nGXplvPEU6xS4UOis+Pu7eev4mrWpE2+6K2YJcTc7+pVeMt/n61T0uUPqF4UCCK4curE/qfT6VT1e9U6uREGkmUKAN2QR3/CvSSf3HFdJ6nQaaERPJQ7QFwMfMQe559//r1YQxSWzA5kUnDPt5/njiuRR7x5GYOIycMRgMB2A561LC0swlaWWTzUJYlH2bfoOhPap5Uy1NJ7HZ6A8Nobu3u5CsUgBgYNkI5OCMY54PqPx4rOv4N2pQlyNwlw2OM4zkY9qzrLV30PUdLudRVWt4LiOYSHJxhgTvGPTPFdb49hu7TxI9zqRj/fuZUlWPZHKh+4w5PVQD1PXHXNW6XNHmWtjT2ybcX1IGRkIxKu4jIAHHB4H+NRxxtJGkpXIGcqSBznt70yGeJUlkLDc3zLhScHr6dKl+0qUBlyGbg4jOT7CvIludULWJoQ4XfDtYE4OeM89P8AChlHlhmeNXVvlJXJB9Mjv0qsLqPY5QOXZsOOgC+o/n+FT+ZJiJndApHBC8E+/wDjSs0Xa+xdijRoHZG/cnqMgkjpn1/Cp418uBTGFUrgMqjHBqhE0kU6napQZf8AdnkA8EYOKvRlpPMTqpw6np1xkH/Pespa6DsWpVV4d7lWKcEcY7Z/pUMMYhcspwrMUIB4IwSMeh/Sn5IidTzx91eTgHriorl+0ZYknKgHjd6flQKz2NGKZHEEq8Kw6g4ww9qczlJsIFZSfT7o7DP51CrlVP7r/VKG29Md80sALrKyko4If0H0Oe1IytbUvWIYSyxhSzdSvBq9CCzRhsmIkjGMY/x6VUi3xSRurKucZA9+2fyrQAkjVlbnuAP6U0kRMsB/llQgKu7licAD/Gn3rrGUgUBoy4JVfSooY/mf5QFUZJbqSac0TGWB2JLKAcdOD/kVVr7GeiZn+IirMI1zhV4579Olc7rDr9oUKo8pgcrnAG0cE/kT0rb10/6WyKQAX249RyawdSUvos0/y5PycnLHPGabjrqOKVkc64eSAF8KeMlvpnNSbWk1GeJnEjRcbiOW57VHI8jWkqkLgYZSewHHNNs0AQXCurM/VfStOg2ibUTGdXuNvzKqrGCDnBA5NVklQXAZ97cYwBjnqfwps0gWe5kI5J59MnvS58540KhdpJOW6nv/AEqkjM70hDEEZj5S7lYg5JOOBVKND5SqcKWbBVfTGf0xSRl0kkjfZlsnGOxrUjWFLhYlR/MCAM/Ynris9LXNL8pZkWL7IhVWyRlmxwcHnn8q2Le4WNcDoVxwvTsP8aqTRZtV2s2N4TZu5HetWwjQoVVhuRcDOOtCV2Yyl7pnFGMzZY7FUkYPHJwTUN2+JG2qVkyFPPQdK0ZUPmkFVG0F2JHbp/OsTUC4i89A7Bs4ZSAqkcjGecVqopotO+5TJMUruRvCDBznB5qjdQlrxyQfNcBjuPTirUknmb0XzSW2474J71TuHaO7cOBvQEbW/P8AHv8AnUySaNola4cCRAxJKkru5444xWLdNAF+eVUZwBlu2P5Vr6jMiTbFQFZE+XbjO7r+XTmsGdXcSea3mByTjgD0/wARSW5qlpcRp1+yK5I3IR8ucEZPBFX44onKPBJ5UhU4kTncQPukenvWa+nqtvttygMi58tl3dB6/wBKuROVCeZFlgck4zkemR7+1D2uVbSw1Lp3KK6qjx9FByHOeoPGamulK3KB3UIdwQbuVPr/AJ9KrXk1ssMULxhoi2VfBG31HPWnkgLiIPOrLllOSyDHTJ6fjmgfNYrRy7YCmSrIdvyn7v8AtZ/r71WjlxqEcMg/1alkbu3pVNWkY3MausaZywbrjt0q4ixXUDqHH2hSHUjkg+4rXlsiZtPQuRI0MiypGd4wzsRkn+netO7Dyhg0hZ9pZQOOMY/yapWxkuLclowGACtzjLAfnT5ZtscbMocsAhYn7oPTmnTSvYxq35Th9KljgEh25mdwQxyCOecjHU/0qjr81uviB5IWLqNm9lbILYwRg1RTUHi8RPCSskYkaJA4IQZ7+3PNaF0kepzLOgIYKEUMw565H5/jXrRi09Tzr326FmwuTHEB5O9GPlyBDkrkf41sWlzZ/bI0ubERRumFXcGPoCfTPpXIaJFdSXM8eFglZsFQCdvoRXQWX2Uakgk8yXaQEAOCp75P1zTdJJGtOSkrs2NRtLf7fGigOkikMrHcqgZ9unSsiFJPs1tpD+WLZJWlilbd5iqRzGpztKZGemQScGtq5l8kXN3K2WkUrGqkYUDms/w6kkmoAMxYLG0i4HIdj3z0HWspKUU7aDlBLU31KxwKrkqCAv3ahn5lCu/lgKWWNRyfTHYVcAUM20FmYYMj9fy/lTBDCpRI1YORlmbjn/PevKaOuNymtmjREzmZXZc4ZmOCDx0rQZys4+zMTCy7uSAQR3psp8uMNkhgCF7qD1FQrGUzcA4V181TjAB6EY9OnbvUs2XmaESTt9pdgCi/KSAM89P5Cp47goI5LlMgpngZHTkH0FQA+XInkqAGG5h17cUlu7MQCWUcEMW6Zx/9asnHXQtaotsfuujhiMup9uT/APWpykyWx3Ltzhhj+VVWtWPzKSk+Tk5O3aT0Pvn+VWLS5HkrHL8kifMy4684yD3qbaWFr0L7u/lFkwFbr6/SmaRfxTvPbwSrMY5GRwQeCOe/XgE063LM0WQoBdicHjPpSloUndl/dyFvnZV6kZAz/nvQk7XIa6I1rQhoN4Kk4wnHB5zg1dlkL43j0BCjsKoxsZLJBnkdWAxuPtVsOuyESfKwI3YBwaq3Qxe9y8n+rlLFwy5BZjx0/wAasn55E2qNgUH6cc1VeRjbbmyQwLY7lakUNbWKZ+ZQchSeeOn+FVZrUxlaxzevyBNSzICYX++V/h64rLLLc+H5vL3mCOUMzfwk9gP6n6VpeKz5U7SEMVYblGOSfSqd7cRjQP3ICptXIB5zk5J/Wp6miV0jnPMBjmRUAbCkNjnjH6d6r2yeXCihdiseT2yD1q5OsUZAJ4eHcM+4qhKGNtEjk45/Ada1QNsjuJGZm3AHa+GyMk4PB/lU8W2Ty3baWkZm3Htx0o3mRNoADAlumM85x+WKW2UbkOPkIJBPHPf+dUr3M2k0dqEjnuISB90/vGx1/CtO2InuYwRsQZ4xz0qlYbjAWKIZHG3qefX9MmrNoXMspYgbOVJ7A84FZNFtXLs5aObK7nGdm7GccD9a1dOjYpKrjkrgMOBVCELOBKCY1jwcjn6j2q3pJEjBULALnGfarSszCTaVh91brEI/Nb5SwUyYyfx9c1y3iS7uVtvI02LfLKTGjY4QA9T+tdhqO1rRGY7ixwMjPHSse+tj5kbQgsXIAGMe1WlZWQ6cusjAjV4MC5fzJ0ChggwGOMk/nVacK8KykjaZMccknnr7Vr3CJ/aGwNsRV+bjNY2ppGT5UYUszKykdxmlbc6YvUz5SBGxRciMEHIwWH9M1mXkiiNQQ2xVIfZ2GBnnpWjJtF28cm5BI4bj+6e1VJo18i4ZULRqCF7YJOBUvQ6FsVDcp9kRGYrKh3KhT5mx2/KrCXH3BgbVIDDByB15pJY0c/6UflKhRFnG4jrk1QSONLl3RQ0EvC98D1Pt9aWrGzT1U7tPeQICsTDJx09vyqO3KIy7NxJj3hh/Ee/9auQrBKrjairIpGMZJ6f/AF6xoptmlMRgNHkE5w2Acf8A1qtaqxl1sZ+pIr7VjVV82Qsyn7wPHT/CrOmxtDdyLENyM2zKnaRjv+dOvYZJ7dZYdvmg5AA+ZQO+PoOtO06VZYoZSOUcgnGMbv8A64rRv3SlqbFrxbMXUxsGPOzHI689+Ko3UqhHKsVjVCCD3I71qxJIiso5Q/KobOKwdRuA2i3M7vtaCBwFYngAEf4VeGjeSMa8uWLaPNrLTDNdeZJM0iu25uMEc9q6fR9NIcyws7x52xrJyuB1II/Km+HdMaSSJrpgFMa70RvlGRkgt6juOnWujnLWyTukimEKscYTA47jH5V3ylJuxyU6S3Rzlxo73viK2jty/mu4JBbapGOx+tb8mlS2rCGZ44kVc4aTbu755+van6BG88V883mmaH5kxIPkHX5frnNWdRV5bJpI7QM+NoduSR3bJzxWnMkrNlU027o5rULjzJ/ItvKjG3D4J2qOm4+mad4daN5ppRFJIo/d73OVDZ5xg+2c06G3SKxuVuGSK6kCGML8wlJOCuf4SBzTvD1o9pFJE2P3cuMA9SfT8O9ZV5Wgyrc0jfDzSXBjUpGSNqsicdOuc1YwUBSW5eVDgAOoAx3xgcGo7MDzpo2O192WK+n+HtTLoiWRlYkIAVZsksOv4GvNa0OmKHXctsJJo1uXBxhlWPcFGPb3pkF0ktrFscsU+VSwwByOx7dPzpZY4Y3w42RBcq5GCR0PvmobpAzRmJmCnO4OM7ew59CayeuhujQjuijtCyPv3ZVOhU+3r0/WnD96oVXwXwfmOevp6HPH5VmK8rJHK8G4BgrLERwc4PXsassxWO4CljErgliuCgA4/wA+1S0yrdGaMXmRTIZGD4DBmBO4Y6jnqfpTokDEqAThiqgdf88VJbYkEzGRASdwLZ+6Oc+/WpIo2ADkMJY3Y9MjHJ/kRWb1G/dLFtOxLYXleU+X1p1xAZLlQOTwzYOcdM0y3cKtw4XCPGrD0HFXLRyshlUhxjkY5H/1s0dDN6M01QLJJGWIiKklc9+nH6VZt1EhhYnPGG9j2H0qERBY45eqOCpDN71e05d9u6OQCwDDI5I9D6mtTlk7K5XZz5bmNpAseSCOmc8jPpV3V5N0KAdGxghenHtVcRBTMpbfHJ86oOQSOMEVPqrMsWHZzkAg9we4qb3TbJb1RgeLopJrW1k2oCCyjBIPbPFYd7Kk2ms0ikSExlgvIPPcdjXS+JSU0+FmUZUfd/CuYErRRBiEZSQWLepU4H+fWptqXB3imZxwzvltoRW+Vl68Zx+PrVMxb7JH2g4OBnngjtV1Gb98mAkp3YfPGMdM9qqzB/sKSOSCRjaeo+lbJaCGTMjRKFjXjv26UsLERpuY4UcEDpz0p0hDLbooCny8Ng/5xSwgFnEYbLEEewAqutiGtLnXxvIhiDttkwWXBGAM8fj9faryjdKFAKJtC9c9R396ybSNjfITl2yNwI5IHJyfwxW5PEPtSHJ5Ct8vbP8An9aze5d7bmhAypCsbYEeBuB647YFSxEqq+WmBk7huwAOvWmXUcccEQi3ByRz3PPFT29q0sSxEFmPOcdfU/WmtXYyb0uIrtcuoQjaDgMO3sKZcsHmCSj/AFHRVPcetS7mgD7B8i8ntz0/Gs+682K5d2U73ib5gwBJH9MGrWjJirmXdjETybiC2Sc/xEVm6yokaBYgBG478fN/nitG7LMDCFIl+8oHOc/4Gs7UbgfZ4XjDO6NjP8ONvP1NG6OlX6GNel3klcKNyqoHzfkaqyFnkaKJMIIiZD2J9AfWrV8jFN0YDLIp3ADn60Quss0cigEKu3jAz3NTLc6IPQrJBCyIrrvkZCBu6k46mo7NY2gQyfKxGBjjJHt6ZqRHJeZSmFz8rHjoeB+NV4YJprny8gEDBbHTPQn+VFtdS97kum3bPGsUknlQohK8Z2nOO3+eazHaPaYnVt8qtuLcZKmrYljjZ3RCICBkeo/i/DPOKq6+r4WaOMOiOBuHZSO9aRXQyS1LoXEKld7Iqqy46rg4OD3pmkQiQXAYqPPUn5OFzk8/yq1Cxx5QcszxliAcAg8Y6fWqvh8OsMUbAnZIxIUD7p9/rSeiKSexvW7MtuJLgsuPkwByhx29elcH4x3QaXewQu+WYFiBwq59/WvQwBHc8x7kmII56HsfrXC/E2wZ44riF3LSSJHIc4Az0yvc+n1rbC/ErnPiI80XYp2l3GLNcfIgj6nqW/D2rT0rzbswTlZAysUjhBAX3LZH41naIIo7QbZx5RUAfJ8xOc4Iz+taqxSTTPuJt7ZiJImzjb0yR6E4rv5uV2MuVvQWzRY9TvNrfKDuKRjsOo/EY/WtyVXMYnliAiyE2gbggPPHofaudEYsfEbFpSwmUxOWkAUnOFI7jrzkVrPO0zGS3mmkiVVTLLkl1+nbPSoqRsOg+lirqsUXmCWVPKXzF27Ow9PTNVtG3PFPII1y8jbQcnb75/CptbjT+zbiIv8AMJeZCcnOAfpxVfREI05DLlnbDu2cZOf89Kyn/D+ZpNe9oatpH9mhDE/PMPmDN9wH69qllVrWIRQuOWBVTzknpz+HrTogrRuXhDSOSAR0YeuarSSSK5/1oEOAImAD84zn29K4XqzaEewPEPNKSgFiQPNAxsBODj2z3PvSS+cLsxW5PnDDPHj5fT/Dr6Uk7SQwLFL90uSFzjK5+ZT6dvzqG2xLdyS7t3z7GBOMDPUn64oirbmiVyyMvAw8s+cnEiE8En0Pp/UVokIiLcYDowPmEHoCBx/j7iqeFaaWMRhniG4tk5YEA4IPUZ7dsirqyLOru7ho2YEMMgMMYI/+v14qZR6IaelyL7G8McZgXachDAeFB5IOT0z+XFX0lM6KyK6h/kdSOkgByf8APY1AkjLbg7kDTYXDNnaVP3s+3FQqs0d2cOxIKK7ZwDxw3Hf3rProhPU0YZViiO0hi0eCo4+bmrmlIGgy3O8nJHb/AOtWXafOjbBl9wIJPBJ71fs3MMC7VycsgIPIJPb1osr6mb2salvL5lqscQDJGSQT79jW2xSEKEj4VcgE7sjH881jaQV+zSCVB5nQfToP5VsJIksCuy4Ujy8McnI/rVW0MJ76li2ULAsm1RxsJf3B5/QUzVkfyozJyVUMSD0J9qWONZLeOP5WJ3MeSSB3PrSajvntUZsFI8Rtt5B9/wCVK2ljLZ3Of1uUNarHuGArEEDkg8D6dqwr+cyRxv5WT5a5UHgY4/z9a6KdSLRrgx70ilA24ySOnP51iXSItnOi7gUcOPUE8Hn05pdDWNkjFcJHcOjAqpO3/PtVSYk28iuWJjb0zz0qxdMEuY52y6b9uD3A4zUOoZSQlciOZeQOrHJz/Q1otBO5CjrI1t5JyzZQ88//AFqmt4994Wz9wEY7elVkwsq+VIdqrkN3Jx0xVm1Yeaj7cFyTtUnk1fUzaOrt5fLuQvzpIW5x9cfhW+1ttPmNKhZuqjtz1FZCiN7iKWEZCcO3UZx3q9Zs0sgJJwSCQR0FR0sXLXVGsu1Hj+QszPnef4QO2a0LIYgGwZwM4B5JxWWs/nzQrIGREUtnuT2/pV2O4VpSI+Y4+W/h4780J2djCUWKySSSyDaglJ+QNyF9fxNZ+qv5s1sMLtjRmbPY9Oa2o1QTSIqiIlcgenpWFeTRfbJ0lUqojHI75bn+VN36jhuZmtyy485gojIC/KPese+BFhKqqFCtlT0xW3rsamVlgJMez778Dtj8awrh3ZpPNIYSJgY7HHGapJ33OmGqRlKFEyxOxbgEcnBPao4gNof5RlyrYOOe2ffmmufNffFGzFQM598dfxoXy8bLgff6HPfPPPTNNxOiLGSyOLvzQwaPzNpAHBOMZ/z605IiZI2AYSFG34HGCcDJ69/85pnkiQGBk2uhJyBnPPX37Y+tOkkkiUXBwyqgViBkMc8H+lTb3h7LQy7Zz5UTOu4I2zHPT3FWoLQ3MV5ayDfLGCAxJ5B6Z+nAqO7ZofMGApMgkjbruOBn8qn0qVrycyorMjRZKJwcgn889afLZXFJ3d0UNEn8u7jSf5fLx97sQSMZ/WtaxgJ1SeNigyrHpjGe1Zmp2At5+IyJnBIGcfN1B9a0YZ1ugswQpNGuHU5zuxyKUrSVzVRbd0bSKssFvKfvPlSDkYx0/lWH4/hiuvDF0k0YWeMrLkDDNtIOCP8APWumCxXWlQyxcsiDOD3xzn0rB8Z4uPDU9zGwV1jOeecj+9+X8q2o6SuRUinDVHNeHYU/s1JZgBKE3YJAMefb0rZtJknjWSVwjIoG8j5Vxk9O/wCPeofDs1oNNtfMYBZVxuA5OV71oJ9lt5JIlLyC4Gx1jXIQdsD1/wAa7JNt2bOWMWk7FDTzFe61JJ9njICfMX+UEnPPP1q8sZsbWR7csYhLtb5vlZuwUdzVJGkt9baOAyJG0aptkAzxxjjqeP5Vs3Qe5N6BH5QQbS2ej9j7dOtKUm7JMVNNNs5/WJwIpmCPFJLHs/fDIDtgFhjjIUk+op2nArmFDtgB2tuHJ/n6D86yNfmR0sbYtm5dwEjbrvyM9eo6Cul0q3eSVlGfLh+Zmz3xzisq7tFeZcY3nd9C3LMIrJ2w5LjIVl+VMfy71GYWWKVpJ1wz5XvxjpSLbl7o+aXeBFLlXYBmPbd7D0rOnmZ5dsef7qqgK4btXFpe6OlQZFe75lWNwFfaVyv3iBnqD34FXIQvkQwRRJvePCyMCCwHUEd/X8KgslEkiXUkkYnjwDE3JXsSf/rVddV8iWVFRpA3zry2zscE44IqpO245bpEluw+1RmRNxlbI2nb5bYGeD/X8KkjiddzRtExgyIxnGR14Pr1GfwpktrctJlpF8sMCF+8UOBtJI5/mKe0k88M0xGI1bblRx8xBIPseSPTFQ1dE3HW7R/ZZGj3faCwYxlcYbvx2I/WkeRma5lQkc+Xt5B4GCMfjUcyEPCsUrLdzRBFmPRmzwGBHGQMd+xotWBnjuVidZy+JIj9OmPwqbNWQW1uy7Zw4YqqhI9igsODn0OevX+VXrSNhbgMw8qJmK8/eA4zVO0l8+2gICmJG9MHbzj69cVbj2/YgG3q5cjBznB/ocijfVENPqbtmnmaejKAGc5BZugJrStXlWAFGWTbIS3Gen8s1nxMxmdYmK/KFYgZGB6e/etWx/49ZlUY2FmIBHPHPPeqS1OaeiLmkwiSaSd1ADKcKPT61UcNFmJkcoWLDbglcd/5VYtHeW4VWVwIlPmFemDyPr/jToFDRzbyDtckDHb396lq5k7pswJnYaVN5igHeSv+0MjOa5ZGKyyNvCksFCkZ6j+ldBdMbaN4WxtkBGPU9ua56QiKCfA/eqxQrjIPI6Gi1jdLRmbqG9X2N1V9q9+Ov69abfjfHBG6lZAv3/XIzj/69TXZC4KqqqxABPPQc596dejfFG8hAdCFY7T0xkHP44rRImXQyhE8ci7htXcCOeRjtirNohadgoUnqNp7fQ/WomQOzs/KD5mbGadbDc5fblScAd6bV2TsrnXxxGPTnSMqskh3uQ3Cr7+/er+iTukICkh2OMY68jPPXpReRlFClEk3fLjBxkcZ7CrCBY3RSoikHGFPBJPf86lRVwcrx9TSWANE7McbsKAT7Z/z9at2eyG1w0asegB659/XtVfTT57jzZP3e8nZ2OPr+NW7wedPuQBEhwwwec+lPbU55O7sSwugaFCMum7LevpxXP6iXd7ltpCgqoZjwzZPA/TittmYqJY8AMGOWOCBjPI9aydQtxFp+9w7oDuPfBz1+tNlU2rmTfu81kWQglDhk9AKzvMWS4GViC55CAjYOmK1YVSV3jcEgcjJwcH/AD3rBmBjuVkBZskqw/i/H9KE+p2RV9DGkQQrcED92jFWy/UZwf55omj+SMqQwlJUHnHA6kjvV6/iC3RRstFOBIyg8Z5HNQ3UMaymGJVXbhkGcj7v3vzH60PTQ1j72pWuHj+1Wzlzh4ijZ45B757024iD2reXIiydAjAnJ6/QYPNTzSG5tIdhUYkDO/B2nnP0/lTLPE0onzncvTorYOMfXFHVMWyZn+aLvTMJhJ1JIJPRuc4/KnaPdCO6a3LFRlQzJ2z1xUO1bTWmjQk27kOMgrg9xilkUQak0jg7o8Bwxzzng8Vq46WNKfK5WOm1SxjuUjl2DOzarE52elY2nz+XfRq6IAww6+4OM/jW1ZTAxRmZyYVdX8txlGwc8juP8axtdjMN/JqEca+UxJkVBt2ntge3FYt2OulC/us6CwjfTZftNp82SQ0LnBdD1Ix06/jWZ4hst/2lLcrLaSrtIXleRnP06VtaFM1xZ4i2zbEB5XLEY7f/AF6gMf2OIxbgynCSRqM7cen59K2jsmZyvzNdTzfwmzx6XFJPI7RodpRBtxknH8q7vSylnaTXsQ2AYYRyKHzzxgn+lcl4bso7e9nhn3FIbhvkjOSFzwcevNazRxTaix0wkKoJCDJUAc4GeRx/Ku6euqOOnT05WNvJpm1u2vlSWSZWZy7/AMTDGTiteWIOz3EpyjLlnLAc4zjP9O9Z+uS29u2nX0TI/npiaFSQYmzznsc8fh1p1yyRNPC7jyWUSxkdCeuP1x+FZyUmJaM5mZzf6/bqUJeP5o1P3kBJHJ9evNd3p1nIYUPmRwkE7OSAc+vr61yejWv/ABU92cGR4VCEAY6nPX+ldhetPE4tbedPmTLMxGEHXkdmrCr7z9DohDt1MeeWeff5DlgxwQQA3HfJPU5qncs8SQpEgaZyUJzjnPXHrjg1uT/ZbOAyQmVpNoyjEDf9R3FZ6QGON2uN208gKctjrgdsZ/GuW9tDocdL20ECG2C+a7KxJ3FEB3DuT2I/wpjSNNNDK8p3SNiINwkidgSD39Paq8IaZJYo5G8tWOIweQw9u4q4cJGjKkOxgeWHykemD0Pt170uplKLXmJErBtx2qUXE0O8jDZyACeR7flQGkg3xJtRDwyyDIjXklT+J4+tMEpnZ5WjVolU7o3PzKB2zjpjn8OKZGDLbo7oypJnzCpGflzgeoq7WWhKWupoSpHGy+QzIIsOoYj5ecYP1yOlEkbSCGVJ8ljtLMuDyDtBPtkjNNdxJsePC7lCnK478Hj8P1oh4t2nkXMsibMKOeuc4/Gpl2RNupNu8p28qAALyCDwGIxjFaUDg3kEUSugjYMfNOCcdv8A9VZ9qrROwYEYB355PA+8fetPTJSC87Yb91wSOmOvWktdCXpqa9lOwnYBl2sMZPrVu2Zgk0UT7kSXIyuAQev1rJ09XZ4o2D7GDSZHPPbBrTsS7rMqHy1XazgnqfSi1znmrGvpl0IJLgTSlm4yCvTPQg1JFOTcMmAys2VOeMH1qO2t1+3kuWJkQnIxnt6dqfKojnICIFKeUCM9Qf50Wsc8uW+hzOsgQ3BbYuwPtIJP8J6Vh625+0M8bDbOVcBT/nkYrpNUSNLeKd33HzSWXPof6gVzmuxxPcyzRcxSKrgKcbecc/zoXc1i7mffKiusUbbyr4wPusfYVBKCttMhbkDdtPU4NPvIhHcxxOXO/DBt2Nv4/SopYzL9pcNgMMIT1/P8K0aE9iLYqSlFbdhcAqflpiBRMyDLLu6nuMVYdQbpcKpGRlV4/IVEy4maMMQpOc4GQcUX7E77noM8kM+pIY8yKp4AHJP41oQ2UKj55Ms7Dn720j/9dVrK3KzKJgAc/eTnk9OehxnpWpDaqkMkspIAU4yc4PH6cfrS7mMuyY2CNopd0cf3eFx/FgccfjVky+XZvGuWLAB2/wBojJ/lU1oWKsWAyp24+9/nvUF5Igtn8vBDPwD1J9cetSStXZkFyqvabY8h8fMFHAHY1n6vvSzeGcsWY7I+wHvn9avl5BHlfmjQDkdCM9jVTXXeaRIgnziQOwPPGODn86aWjbNY7+Rl6rFJbxJcIWDMAckcEHg8/rWZchZ7h1yFGBzjPOP5VfmkZIyihSCTESTxg+g7isMmd7mfagMnUxsMbgDjiqX5m8EVbtHaaDkFfmjJXnkcjiq7MrSxuzMrE43EZ56c1NeSSNZJcsNwWTOYyRjP9cU+RfN/fRR7kCAFs5OeTn+dJvQ6YO25nxuY7m7WUqGUjcifd2sOcfpzTFUWskKxPjawyNoG5cfe/PFOvnCPbNIhCvld3bZUWqSLFHbvgutu3lkE5yG649ancpFTxIiqLW5gYsVb5mzkrnsfap0ALvIq4Y7duRkEd/w61dhgW/sJ08glHyfkUEkegHU1iRhrWYWVwzAIQYpOh2+3r9K3g20OCN/SJlWUQyEgRHK5OSAewz9Ota0qxTy5kKsuw5XqoJH69qwQpVvtD3K7V+Ul885PUHtj0NbmmyeY0+9l8oElfmIGfUepxScbnY19pGRaqdK1YR5kFvJ8w5xx3FbmoYkkVZGG4rvWWNsjGOMkdD7VFNaxapaxNcRyK0RIyDjAz1//AF1JBHLHbNaJImyM+bhmy5I/jAx9OOadPZwZFSadpdVucNcJNBrt1/pKRrIqsHY4LDGMfXiuj022iOnMigRXA2MoGMjPrj2/nWJrKiXxLZznY04jYSbhz9R71oSCNJbmaykMaIFOCvLc8kjtXTKzin2OJpuQmoW0smnXi3FmIZYHDBlbcp68fQ5zTHt1On29zNcBxHFtUE4KnJ4qTxDd3MsFsYZA1s+NwUAHaeMn37UzU4orLTSkT5+UMUZRljjHGOfX8K0jFyjqZtvm1I/DS+TPM78SNISuPpx/jXRyeZezvEZCS5BuZ5BlsdACfTpWH4ZA+zb0jKqRgbWClSedw+ldVZQxWCEvIJ1WETXbkjCAnGMnqT6fgK5px5rpf1/X5HZTdkrblDU3giILyibZxGQpwcfxcisW8un1DKxlY41UqJWOO/p3q/q0326WR4VeG3wTGrdCAOTjtn0qvpw3lUwwUDofug47CuO6TZ3RhaN3uJaWjQ28aI7SSEkKSACO5II7j09KrXEkyzTidMhhnkZ5B4IPoa15RF9mUNsBz86Efe+hrDvZJCqiIhpslQD2UdPxxmnozJwb1LOlT7pWDKGSZyERQAM+hJ/IUy1jH2eO5RiyLKSVJA8xVyMEdQcHr/hTYIwsVtHEOXXI3Lw7DoOPXBqWFQJWSZBGXZUVWBxGWJ6nHzKatJtWOKWkrjyyMVaJcBAx24IJXsPrnP5e9WLkyT2cBhO1fNMYcpj0P6EmqLbg/lbVViqRmQDlfmwc1owFSJnYLG2UyFbAXgjJpOO6E2tx0jmaQu8ZHmxHZzz6Z/pWpGp8qSP+NUA3HkMe9Z+noJ4zK2TGD5ajHXBzn8cVcs5RFaq7LuMp3EKeMcjH4VD1Jk3sjei2LcxCPYyKhAzz/Xr7U/TjGssrzyKBK5AB9Rxg/lVOznlgaKVo+Y8qTt5OQc5+lWrKBbi0gkkxmadmJIwBuznj8atHPLrc1bRppLlJwxHB4z1Bq3aq8sU0gbLCTcA3QYPOKitFW1vnR3DbI9qjI9RU+nyvMLg4/iO0YByOeKlLozmqPsYuvlHuSRyjvuySe/H4c1ztym+K43jaRhflHGc85H9a09cSWaYLbuqmMbiDwD9Pes1tpSRHYYkAyhOST3x+NFrmy2VmYs6OTEwOFHJXOcD/ADmq83mR3MkSMPL++DnPBq7tQ28aBSzCQqYz2Xt/M1SvIXjEZTGQWA28HAIq7sWiK8I2un3mAGCQOCR/OrGMu0a/dznp04pqSESRdDsPAHcU+IhJHBBIzgkHP60l2B9z0myVpJQuEZmONo7fl0PNXZ87olQ5XdtIbGMiq+lFIVllmcd+B2H0Hep7W6Q3jPIECqCQFBwDSlojBavQ0LtYoY0BfczAZ9ST6fWsq6KOYWcZfOSoHIA6Cr7JHJDNLhiVQKoY5xjkn8zWIwMl1/E6ghQoPTtxSchwibPmq8csJZUfGNo7fhWVZ7xM6PIJCp5JGMDPFWobeOa2klZS29thb+LHpz0xVOCJmmMiSEAADJ9BxjFWlezEmldGZdxKwBiJwCWKYxgjI5rGeUSys8WPmByi8bfzrYlgxdSgEZ3nB7jPP+NZsyO14WZ28xPmRlP3gex9xRayudMTPhR3Vo1Q+Q4yADjp1/r+dUtOwziIMDFksJN2OF9a1LJwJpCVGTk4HUVR3RRXzRzI/lxlnJAzhT6/mKmyeh0X3K2rxtLOI8xjEORxtDDqO/XmqEs4l0+MBkdDgOCMlfRh+PFa+HNtC0oV5lbb5bHnAHTj14NZNuIpLS6SOQorybRxzjOQOfXmk9NTaLNfTSWVWkVVcpjcHxtPbkGs/wAUWD3EQljYO0bfu2xwDjOM+lWx52n3iI3MfAO4cmrN2ALZmZX2SDGO6nHBx6VrDR2NVFXUjB02YX0EYkCKG4YtyCRWlp7ss6hg7Rs4HAxkZ7Vg2z/YdSeBwEVmzGcbee4rchjbcHWQqSMrkZUinNvQ6FpddDoJoHs7x0kugLaVwQI33Av0A/D16fkKr39t9rmaSUFbmM7maMbFJ+g6UlvZT2c/mxTW8pcEDz0AByOfp7VE/mGFxdO5uoyCCDlWXHQ+9HMpGfJ1TOQ1i9kTW7K6P+vjZopA3VgefxrqLuFNR0xru12FWURyxfxcfxD0rl/EdvDPrFpdyx8bGXKtjDYwM/hXVRbLWwWyt4mHm44H/LTrzn0/rXTdcqkcTT52YcFtEulGdZCRC6omX7cnBWmeKrtvKingjaEyR73mccSL0wq9sY61oXqW15qlrpMahUJC3Dq4Clu/ze2cZ+tZfim5jurCGzgCiOIFfO/i2ZwM+/8AjW1PmauzGeszT0hGg01HKMzOuCQAce9bljYI0Et1dSJGnH3gcM3pj6f55rntPkM2wIfkTCrk9wOtbd0t09sILibyrRBnccDe3+z2Iz3rkkrvXoenTVkrO1zPuJGuZCjxOka8s2MYH+FacaRW9qsqK0sYXPmqc4yfvY9PrUOnaakyySrI0gVN+OTn1H4VO8sPk7baBxcfMCFjwjA9On51zxj1aNqktVGPQz9Tu43jAjOVC7SRnB75wehrN0VI3D3jOxkRuEPHFJqs2dqpGFmfgAc/Wte0tRAkCuxR3x8xHyn2JpPV3sW2o07LqVrqNUMf2Z2I84Op27fLfH3eenf61X1FQ0uUDMzRnjJbB+9kfka0bxFmWaIbhKq78sOpU5H1qoysl1FcsNzBS5XjG4DOR6g88fUVUVZnnVlbUgCxiUpJ88ruGSTdwR6n6mrVt55QyyeSDI2epYliT83oOMiotNhA1IStnBiLleNoOATgHv8A/rqaGTfcW0KtgKxdRjAAxx/SpkRFl7SWDCGFV/1LszZxyDwox7da0rWOFbOckHYDsIVs5A6n69qg0iFlQhyGm5LsOV9hToXRbQpGBlWMZA6ht2en9aV9DOWrsjUTdDpilmZXcFz824HPer/MdpYyxMq4IJ9x0P44JrKvsDSiwRkdMIR2JI6j2NbTbBpEayoyyhQ4GM5GByKrrbyOaT2fmTXvyqJIiRhirEHG3pj61pWkPkoDnDbjkjg89c1jXCCVJWjV97FWIY8g8HHtWrHI0VxliCj4bnse9Tez1Mpaoy9YihdpA2wHtgcnnn9K5+URnT0MaDdHKxznoMdvyFbeou7zsQHTJIHYY57VmNFE/lwG3EMqcbwxOc88jp/+urtctaLUxNyq8xU4wQWOO3+Tis65yI1eQtg5OR61cdkEEufvFiATwfSq1zDNLB5KqdytnOPbmpTsP1IrVvMlVLgFo1UsuOOoFKshLlCAo3Ejt+dMVttyGUE+qoOPzqSVU+3StggNyu0VVxNWR6jCga0kKcsQST05/wABV6CJDboARul4LEdh3H8qoXyyqqRxEtEV4UDP+e1WrYmGOMMdq45IHpS2OV7XK8qSiaZCz+WB5m1QMgds+1URblfLEbbtxBwT95j/AC4rQvZI/MmKc7kGTnsDVJ2MeGkyy53nv/nis2rmsZOxNHFKtm0YYKGJ+72z2/lTIHEM4h2hVOQpPOee30qe1uGFqDMQEeT5fYd8U+6jiMaFVAHIAb17GtI6Kxk5Nto569JGpyyyKAdwUYHbHXHWs25bbejaTmMZwCR156Vr3shN+vmAyOQuWUnJ7VlakojZ54PnQEZx12+maL2TOyDvYzEjDC7KAx3EOX25+ZvY+tVyzlzcRBd5iAA6gnqB9cfrWhDHC91NJLI3Q4bH3uMY+n9KpWS7beST5trOIzH0GD0OPYii6tdG6vcqsY/KhkJDGWbDIByCB/PBqnYwRR6vcW8iiRdwddozt9R9a0L+HBe1nykM8hZJB/A+OMnrzismyuv39rcLtEjZVyDk7uuffOO9HKuU2Wpe1mOdZEkUt5K4UhjvwfUn1rWsZBc2hMqyTIBtcLwFHQE0lxBut2mjYOroQ8OAoyfTPeqOjTPLDLHB8nXdn+RAp2s79zpg+an6GN4osBlLlPMcIwOe2fxqXTJJJoUYu5UpxntzXTXg/tET20cDMohEjjy8uCOCVA7dM1yelNNZyvbGVlQqSrbeSM9M/lVOy9DWE3KNnujr9Ouoki8m5JYE58th37YqtfRiDMc6kShsN6IahWLY2IZFlm4JTGeTzwfbNXpbn7XZ5uLYxyQ8NKzfp7mqavvuZp21XU4TxjvSNGwCS4YbfXPOfwrpvDjSf2U97cSCKdEU2iN8xZs/dGOhwc/lWJ4ggaa1EanALqARyM56Vuafcz6boG6SGC4DOyxHkPC4wdynvwR+VdNNcyT7HNU0k13M/QbW4i1C4SYxvcsC0bkcpnOeP73Ws7WbPyEv49+JVIKHIwwzkEe9aWjXL3fiKAoZGu50JiZWKGN8n7x7nvj3pvi9UgtYWaJ4jNCrKNp9fvAenWto3TVzCWraJtKjzaboCgCoAytxnPXB9aluLhJ7pIltWjSJQDEHLL9QffrVO3LSxhYJ9gm2hgD1FdJ4b02S/M6QPmaOMusj/LwP5/SuOcW/cW56MJxjHmZBbWZETTRKy5yUTJB9KLqeWCwhRAwwDJlgBz0Jz36D0prS6h9mEy3G+CSYQbuOx6YPOOnSsfUzeRvJ5jq4TABIPA75rHSC6myXO/eaE09GuNRWeSbYduAD2Gen41tStLbqXjkMsOMCKQZx9PSsjSra4MfmeWChIY5OCfwrodRjMU6SyO+14vlB7e/v7GlDUKrXNYz72aKd1mQuzBAwXuvYj+VZlzd7bmNHb93uUoQvIHf/AD71Ys43a8lDO65jfyyoBy+M7fxxWdK4M0Eag7hIGVDyc9+vY1puubY5q8bKxaIBSFYn4cYQgDAP3SCfQjvWlEIvtowVyVaL5l5+UdvT61m2DrbajDuVJYstGBIMhD1IA9enJrQ06QG6aVWJjtw0r4ADHJ6Z7YqLXON6Iv2CwRJu8zczDzZGU8KeeMfQVZ0pEkEDzjCzOWckH5SeAf0qnaErp0jtGQ8mWG5MYBx/nFWmCR20CSSSYRSp3f3m6DjpyaSWq7ESe6J55HaeS2/gEoIKnOPb8a6CR57iK3R1RWRsbweuB1rBsYi+pxqOZBknbycn+YrqrxkhggJby2wU567gPTpTXW5z1ZapLcW3J+2bE3ABPmPXOR3/AC/WpdLk82DcCSVYoPzqrpx+0yMZIyvC4YHqevJ9TWjZQYWcRs4j3nA3cLnrx+NLfUxcklYxb5VS3nwxWXht5wMYPb88msfVyJ7zMcTKzDaBuJBOOua6XXVjLtHDGGYkcFuAfwrnr+5BvYCRs24Uoy4+vT3pS00NISuuYwvsxMUjeYm5XwCRntniqhkZzLIzDI4bn71ak0Wye6CsSGIcDOCQev0rMjjZZGTJ2ffycYXHp61Nmi009SAKouJcKrK6jGB/Knyt/qpJAAD8vSpMB7eRk4ZG5CntntSxpJJEA2Qv3g3cU0N7np9rDsbzZpSFXsecnrTVDSRA/wAUmWyRjIzwBTYLmSSABz+4TBeR+Cozjb9aZITJMqorBWbCFhjAPfP51Enocau3qEzQjd5Shoip3MemccfyqvNFHHpqhsB2PBAPP+cCpru3SB/LYblDKQCcDrWfqFwn2pgCAsOGAwTvzxxjsMfrRsaRV9i/pyB9yqN8h+7zkKo9fTmpdUkM0cYiDPMmPlweMHnP4VU024EBMx8sSDIICfMRxwfy/SraRzoVncDZIRhV6AHNWndEctncy7yyfezlzGSPl2H6jGaz44vs8bwFco5Kg4xjPXitjUXkkkjxnKkhhng/hWbet8sI25dnOCOcEDp+OKpaM6IttK5hToLR0lteBtVj83JxwRj3qKXyor5ZQCNgVZArfeJ5B/Dird9sxIEDblO4DqF9R7dap377Wt2ABLfI+W65GQMfhSfkdMW+omuq4sJvth2mNwY3A5dTxn2I965TUD9m1Q7VCL8pVgv3vf2z3rrbho7i52PtIliGVBzuXkYHoa5XXonMDC5SQNC/lrKTnAH3c/T+VXDVmkHY6XTbzfE3mIrBl6npVK2ZrLWZYvLEW47tvXA9Pejw+7tLCYZjFNhcNtBFT67as0zy3FwFmA4cJt57D2o5W43W6OqDSlbuaWs2strNFcm4kt/4Vlib76kYIGO3r+VYmqQNKsUtoCzsCzBVwF47GtDR5kltJUlTcWUL5hPAH/6zVIM2nahLbtKRajopO4c9qNte44cydnuvxJdKaXY0i7TIg43cZq/cyxXT7bXzfmwTuUjHoeTz+NMs7aVZt1uylCPmkWMsB7DOPWrOt3tnbrLHByzYg8xI2TPQnAYZGOnUfl16KdO8NQnJOV4/16nIa45t7eQEBgpB+Y4III/zxW9fWTS6HYXsBiVTnzU3g7zk84znoMH6e9ctr0zf2dcGNQzAZCn611XhS4Eml2kU0EciNcb1JIJj4AJKn+E/lx6it6C5o+Zy4huLuYljcLe63NeTRJEbfaxiXCjYpAwO/THuav8AjVmljnnDCRShWGFBjy4jyv5Zx+Bqk32VvEl2mTHbltq4y23rgjPJGMdag8Ri4kE4eHymjChwnICheO/er+J6mS02E0bM8IcBdseF29C1bs1zGVEUW+KU5VtuQAvYGsjSLdBZQhWACL1zyPwrStHhJDSOWYdJNu7n0I9K4qrbZ6FNpfI0vkisprVuJ3YPE6kMCR0HXA7da5y7lfUbsKu1JGOXIGAO2P510OtXc8EK2txDaQsoDpLboB5gI4JYdaxLCxmkmN5HueXdkqP4h/SoqaNRRtSejnI6i1iisdOEkk6j5MFMgk++O1c7dTyyyxi1y6LlWyfu57Ve8QzQXMcE8O5GZCr8/dYdqrlktre2ijURrIBJuI5DHPH0xjn3pOHRbIUNFzdWJZeT9lvFe6/fRurxRkbcsRgkGsyyjEmpvkjMaMAWOCcjj6gfnWsojgkEs8UhmUEIxOAAf/rZ4qGCSOMyxsDjaXD9NhBHP0xkfjVSeiRzVW2m11ILdnaMpG6ktKDI+QOG5GB68dRV2CNo4AjFRNckK7g8kAnII/DrWdp6Qm7ldnVHM4aB1HfHOAOoFaVlIJ7tpS2G83yhxwwP3s1k2czvZmrOg8ja6gQYCgoM9uTT41F5gqCkYYNgr6ccev8A9aoZWZnaINtG3KqTjH8R9s5xUul7IrCJmJUyZHz8bV5498/0qopt6GEtFc2NImEN0kwT/R1UorA8bj39T/SrjHfLbCSLzERnZgTnPHr61gabK32YxKSSzAjIOPoPetx7j/Q2TgTAk7SOVGfWnfQwmrSNHw+xMkryZ5G1f8KtJdLHcyqEXhypck8jtWXZTzKsUccZZtrFlUZOAM9K0LaIedMqSbWlPAI6AipiZtRu2yO/3borlTg5+fqCB6flWBdqJ74OyEIx3DccZ+n1xiukvZAumyxhT5kfynjJz6571y1yJpxC5ilVA5QScfeA5GPT/GhqxVLqZt8Y2uJhuO0kbc9+Oh9ufxrPRJCwijCgRruIAxkeua0dSjle3IbO/dsIHTI6ZqHdLFfqrgnauHVTg/Ws+tzdLSyKgImSQgjB564/Cm6cwDMQjSFmOBnjv1qMIqRyBVD7Tk5PX8qtWJZTC0ZUy8nBOcdaE9inpc7cILi78klWQPvk2nqeeMdOTVyVJAWlDF2VuGxwPw/z0qOSLyw0i/KrEso9/X6+1Sxz+ZCkEXzKgJYk9/Y1m9XY5XqtCOWJ5zM7uGijGwY6H1OPWo0miuHlkkU7mCqhjABPpVm+DR22ziO3C9e5+tZ+k24nukZiBHsICg4IHQH8c0RepK+FsdDLtuZM4DEHc4Of8itqR1mtvs8cW7aoJIHB9s1htG0MpIG0sRt45ABx06Vp2bSxSPDCSyKCzZOST6elaQd9CanczL2U25h+4yIBkquDnPWqN1IrQyRtndyybudp9cfh0rQuIo52Xcu1TyUJ6Z71S1CDybxtrbiFAUlQd34j61ojam1oYF7C0sXnW1wWI+VyiqFIzjjjr6Gqro4guYWucSoAeVUhcdOR1+taVxapZQTplSXU+Wcna/PII/Ss+0NrPIJEYs/KlSMEn0571Njsi1byKq5lSNrwr8ykLKh+6w6MR261mXYF5ZTfaWAmxiVtv3x0DAcf5NbkMDLa3Vvb7muI2HlsCBn2x3796yryNfIjuolfcg3SLzyM84/qKS6Gq1VkYvhu4ZZEs5txMXRicEqTwc11rzbreY6jaGbHyGZTnHUD8K5TVbSWC5ivbaNti9QvAK4zj69eK7LQtTtZrCN3uYphMmHUAgx+xBA/MVvK72NIy0TtcyVd9MaKSBnZGx1+6M/1p986Xdux85POzuAwBkk1rX9szRb4YUlt3TcT1D467fQjpWHZ+RFdyPGVDKRgSLxgjoam9tGdCldcy3RY0PU9iNa3E0yRty/lsBuAP61Y1Zrcbvs8iyLK2/fyWA54Oenf60mo6ErTJJKsUPmp5iMhwv19vpVcvLASk8xntsgjachvr6V0Rk0uVozcoSfNE5zXIvNsJ41kfYUPAOD7VvaBfxWmjQOZJfOt3ZUKSBSFdR079jWdrELYmZgFkkUkL04x6fjUHh+QHS5YmEYAUS+Zj97gAjaPrnJ+ldNB2ic81zu7LMBil1OVYjsgcjfkAlRn1PcfhVqeSOPT5kl2LPEksbyZwsi4zyfXOMDFULHzv7Z8yEpPbiMNIjE/d7g49q2m2nSb9VOTNbbnyAcBT1z26AeprR76GMnbfyMnTmxZoNivI6jr3rpdIiVbe4Nv5O6JTlJlO2QY6Aj+L0rltAxtgbJxsBz610YfyZPsd+gjid9wkIKk8/eHqOv/AOuuJr3r9jt3VkZNxctczJHdMTGihQCc8eg9q3J5WsYo1gWG4t2RX2xMWx/vf4Gp9MjsftepQxQtdoqFoPLbC5AzkjGW79Kp38yWMU9tb3CPbSFdyxgEK+ASQe4zn8qy5Gryb1NHNTaikYuo+Xcw7gQNpIGBjGTnn/8AVVzTrWe/Ejb1jeNd6lwfm7DFZyq32xgsZkTJYr0bHHat+8uIpmtrt7cwQhBGCrHHB5P19vehRumXUly2jEzpZXkh8u62Bk46nHoacgSC32osUjZZEbd1Q9jx0603UPIkxtcs4YhexYGqepzJDp6w28KBivL98ng/59ai2l2Zzs0kuozRjJLcPI0JZbYbRtIbIzyfyromkhmuGs0jO0uXk2DouBjmqmnk2lvGiQZKMAzj5Qoxzu74zjBqdYTbwy+aAZ5MuysTwTxgH2Paoepy3TZJFJ50krbgY3OJN2SUwOB+nvxUEkbeXHDksxcFkGct6Y9qdAmyGfe3EYLkHgE/T1GRS6fBJNOLrDIuMoB/CD2z9KqN7XZjUstmdJ4fiRLOZptu1B5mwHgc9P8A69XrwqEzEQUkAAj7ccCoLOAsjkoy7l2kHue3404RzTeUgQgRLtz7GlJ2VjlSTle5racAPMZDxzjPptqeWVk1CN1xyF+bOQPUkfh1qpZlo4tqJlJOcnsc9qvXVmfM/eDO4bB8vPr+fJpwd0YzsnqQ61FhptshDkfKFYcHt+veuYt1EluZVbdLltwHODXR3kM0qrGjEsBnJHYf07VzFpdAPHDjaMsd2OOTjGf89qKi1LpN2Ktwn+h3Ehc5R+B1578flVVLlop/NKnEke3ls8jH9KmmEgimkVvkDAMMZ69elV7aOHbN8vzgAr6fhWNtNDoW2pACrPsVcmT644qzYohLMTHuA2qf51EYXuGDAABRk4pbcBhuj3b9xyDgn/8AV3xQim76HoF6yPH5UYjfyyA+9OFJ96hsYkluI2UDf0xtwfc+/pSSSNJK8anChi7jtjNPLtCBdcBG4jA/nWN+5z8rSsifU2Z0wCcltgweBziqsDZkebzECxR/KfUetSsztDG7MDuJODjIPvVfUbREiiQSMTsGBnAb2/Oi9ncIRS0K8M7OwZicspKljnHvzWpFcK1myFGZ2UKcH29fXqaghWHcHdQSRgrjAUZ7/lTJmM0AVcpCWO4qSNw/pVQlZ6imlLYuptuIPMj2l1JKkYHQj/CsTVg8l7BIc7nGNx+79f1rTtZsbEYhd2RgHsR3+tUvEVuQHESFUVRlt3G70rWTfLcVLSVmZsimaFoZRsbI2OOQvODkVzaReXqE8UkhQsQ8PGcN7ev+c10y/vWtZGjQMBgc5Bz6j1rI1uBTHI8EoM0QYYPIwfvEehq7p6nXDR2I7aYTyTbx5VyD1U4AOOD14BxVKZXeC5ltXxIp3PCFPTHPPoQasaaybbeeEh4ifLkBGSe+cd6il3TtcG1ZorlBt2YPPrg9ulJabnTFFaOdLrRUSaNiUIjRVxtA5yT/ALWP0FctayvZX0iEgQSE7C3Y966KyZp2kCqrhn3iM9N3Q8e5qp4l0wypI0NvJGd2QCQwQ/X1rohdo1soSOh8PzSzSwxJJ5uV2+TI5VJM9ehHtxVXXdMkW7uZoQoEMpQgcAkdQD3rA0S5hkiWJ8lwdrDJBGPp+FdPPHLDpm+xvy8R+/HvBdD3+XOQPc0pRutUVrGd0yjp0sZhy5kyPuwrGScg9+eKc4uRMy3KpFE6bo0cYB9gPf39KtLttWjulE88VyDEQBgM5Xrx3DYOO9Z95cPPETcRkhW5boc89q1jHa5LfNe2xn3TAqzKp643k9PWsnQruGOzuS6kFQ0a74mwfm6g9q0r52UESBVz1XGMDtx2rJ8Psy6fP5u7/WN245Y9T2rqop2ZhP4kXdGkki1WWSJEdTHsw43A5BGR+fHuK1tXEaCaCAARx2pDhs8MQMgdcHPp1qj4cUPOREdzgg8jO7j0/pVuVESWa7ldEUNuWNFBDHk9D2/xFWleSMajerKmiAR2caMWdtoIGOenWtu3WW72xzTyC2JAJYnap6ZNYehowhTBZm6kj09K2GKC3VbecjOAYznr/KuKa3fQ7KT0sty9p8DRySXEF1bQorbN0mUVh0+oyDWbfQko9ykQjKHbhehBrThtbe3skmuJiwOf3anhiOi469c8+1U7ZJNSvWtjKiIFJBZsZ9B/9c1Dg9EaKerkugabDPBI988DSttEsY27lYZwQ359qu3OoQ3BUfZ4I1IJMbNhSSMZIqbTNXEOmvZTBhIq/Kdx2yLngMB19qw5C0tydgidIxnZ0GD3/M076JJmduaTcl/ww2ErasjvIjSoSVYgMm0jH51BY6b9uVpjhSWLE/7I7enPvTLqd9UvBFakRJxvIXgew963ljFrEtjahGQqpmkb5lQ5zgEfhWU1aNuhSbk7rdi3KzW975FoofCDO4dB/EPfHSorqXyZVjlRyC287Bu3AdAMHtz+daUxvG1GVpVCRNHgRtyWUH1/AVWhQ7biaKTbcZCjaeAuOT/u4OKhLU52+UqK4ubiRWil+zbcENH0brjJ9K7K3tYlTdMF3BQCMjggd/0rAuRDbsUWVmZiMuWyQSPm4rf0u1FxAqeYcjJZiOx6k1V2tOpyVJaXexIw/dbUYupyRjrk9P5U+2h8hhJImWZTj0FMitXMphjkC+U20sCMsBUkjMAoBy0Zx9ef51i3rchdia0laSWCNhn5T1PTPXFatxPuTG4qrYIOD69M1nW0kaxJt3nYw4JzjPWrRZbxM5cLCMgAfe55q4+6jGpqzOnu8ajueQBmUDJ+63rXOwS/Z9UkLxoyjI3FuAe36Vva0qw73RAzghgD3zjt6Vz96rC9tpMR75V3sB0znrTqN3NKaTWnUZdMYrxoRKPKkb7qg45HXFV0Pm3zGRlVdu0lRxgdsYqxeKBdQPzvAw30z+tFtHu1AtOw2OCQcckemKyZtHbcggVi7hVICqQSO4z3BpbNGZGKglQ2CR1z/nFTWBMMzlRvZl5XjBx/OrGj58tkOPLY5KHjb/8AXoiipPc3Z2Y7pEDb2JG49FAPb8zT1LTiK2DL5YO0HHGO5qY2jTN5Kq6Alsue4zyRS2UKwu4QKw5UA9SM9cVy6p3IbVrFqaNlg3SeWFYFQ5GCMdKzdk7zbpPuooK89DWzPBLcx7XI2hs4xgAe5rNeXypjFgEnG0k8Aepq2jKDetgWVJCjMgYDazhuSfYirxeF7KRD0kw/PArGthJMkgVfvMPmIxt9aszLtt0ViAqAnBOMjNOLW4SinoQXpJDyQDameGxycVdsbeGeCMTYA5GTz+P1pLONLi1G9gFYbCxHQDpUMh8uIiJ/ucAg5zirTtqw3VjH1BDbyqIGbZKGXaegI6gfzrPe4ltLiQ3SH7JIu37ucH/A1q30pkHlq4BXLIw6+2aozyre20cUqjeo3bTwGz/WnF2e51wV1qY5j/s+6WWJv9HkyysBtx7HH55p88wjnify3ZX4PmLhG46hvcdDUQnd7G50y7wuw+YBnhSpP6YJGPpUyedJpkgVYmU4jRXYblJGeF6n1B9q67aXR2ONlqYMipFe7xnyZn3Kcf0/CtuExvEbad4oVnBYmV/kBGcDjv8Al0qpqFsX0iJIDI4ThHYD5QO3riodH1BoXaOLyg5O1kmGR9aqDVyJ6x8zm9QguNI1M3IQx7sblxzweK6zQtTsrqylhuLdXVwWSVBiRW7D6ZqHV9EuL3T7i5jfzHRyZoVQARDJOcZ6cfhWDpRGXRwqSqDnsD7it0mnew+ZTjvsdJdxS2Sk29zExuE3SRgkjr056EECqTXDTRN5ilegdgc9eMk0CZ45VUyJt56kHBp9zFIyb4xsfbvH09T7UrdEDel5GTqkKnzHHUnv3qhpjKdNmHlssi3DfN2xjgY/WtDUoynmfvt6B/b5hVLSIfMg1EbzlXV9hUnPbOe3/wBeu2it7HPUelyx4SaWHVHnUZhVgCTxyP6Yq5qEroLqeICOJEZODuzkYGM9ai0BVkxCreWHlCs5OBHk8nPpUfiKRhYyx6e7vAshUyEEKRuwMZ6joeaajeWpnNjtPUiCIk7RjaWX6VuabDEziCecCDOGmUAMvqcHAP51i2aRyABXKNjI3DjPpWrEIEaMXhcRHJeOL75PTAz71ySir6nRB6aCXLDymDgeYg+8GBBHrVi3sI5rJJ7edTITuKs3JIHAPoDWdHbouoNFy0YIYA8lSexHTNbM5m0aGdJUtRFLlYnGHO3gkgdV+uKx5b3clodEpOySepFNdyX1nEu2FJItygINpAP8J9RjNYOrXCRjdC6uRwSBjcf/ANdXZJY4tju7KpAyw6nArLtrZrq/jRIdx8ws56jd2ApX0u9yZJR06Gv4WtbhbWVoARMnzyMw4APU4rWsoxDFIkEKSpj5nLEK5B9e4/WlG77fJZ+Uu9cjcDk7gOR+f5Urzyw6RMuAxb5QVABBz34yOP1rOX5XHG7XrYS/nkBMKCIGUbnIPzLkc/SnRtbLaNIY0EaIEGGzk55bn+X+FQWNmTKkuokM7YYL0G3Hf6YH50l1ILu/hjUM9pHgOAAdo+nf15rO/wBpmM49F0NDTtNe+ljYswZSWYgjAB5x/jXSWyMj3G3AVeAV+X+H0qtoLxWRMEoVVK/IgOSQehz/AJFMkuZZb+5FvjYOJB79M/pTT5Vc8+opSlboPy0BiIjXewCnaeT3zVtI2k2zXGDg7WDDofU+9RWtuJ2A3DagHsR9KuQM21IlJZlJ+X1GKwuKRNOtujurcB2Uk+wqa3SLc2wsocHIHAA7ZHfvUUsTQARl/ukE57jFSX0mHxF+7+XHA+mP1rWPc55PoYmsRAkiJgcAbT6e1Z1zD5dnDOsimZicoMHAznn/AA7VpTxOk8Zf5kztJXv6Cs6aIwXfkt/qywI389e1TJ9Toi9lco3jtJ5TqAODzuyDzQ4SRLQxIDzl+g+tPuIWFqqsNrLIY12ntj/61Ry48qMQH5lUEgjkHPJrPc6EtNCRZdl95sWMP2HvxiptPQxSsqHEbjILnrTII1+yJuTayk498+9W7SNpbZAGHyORnHYimr3Jex2uyRZnjT5i527j0HrxVXAgvDC43ybsJg4FS/v47p5AVJY4Jz9wetVkWX7UTKI5C2cj0+prCVraGSV9y5G0os3Ckkt1wMDJP8qpGLyp1VtgfkOQMEfj3qw+baw+U4G4YbnBHrVOTBhEsysuDkZO4Y/nTd0lchRGiSNYEZMkqTnPBJ7Gp4rRpISsrZOzHTkDPT9aYqxrGoxl3XcCg6Z9M/lTPNlWKXJwzEbcnpj/ADzT8yt9ijqmbaUxoxOTjC9D7U2wnEwCueRhAx4yKkvLWaV43kHCjDEnr6VXSAJckxn5CCUHqRzx+tCutUbLl5bMTVCpkLRpln+dQB7foOtZlpK6rsAYICVc5AIHbn1rZnt5p3EqSlD5eVx6H73PpWKUa2vjBuwjjKKeVZj0Hv1rRSs7mtK1rIpXtvDJARtdijZWQgccdKzNLmW3vWgZvmQEAgZJGen/ANet+4YrIUIHyjIHZvUHuKwdVsZJZvMtMJOAZMKeVA7E/SuuLS6HSnZcrZfZIzEQhkWO4cgRsx2/TPY/41zF9aFWaeCI748hwW5x0zWvp9zFeyR2dwrGQ8qysFwR3b1wcVJPFeyxAXCySC3YhJIxnOSThh3U5PNbKKuiOZxeu5S0/UbiKSSzmkCswwA2CMEeo6VU8S6c2nXSO7K7qA2+M7lOe1ZkrLHciZTs2tt2uxOfpWt9ohlhMIWUqTuCTYz0HGRzVx2sK6jJNbDEJkiLCVSAd2dvH5evvUnlvFEAWBZwGLKfXnDD1rLltXin2xDZCwxznC1b8qSLKHGV5yx2hvpWvLcOa1tRtxEzQliVCg7Qg68c5NUra6aw1JlBwt3GysM8nGCR+X8q0GLSvhsLu568CsDWyd0LR4VlzsPcf/rrelpKyMq/w3Z0egqoa6WRhHASzMSSMnGQOh5ziq2pPcGzH7wiCKVdikfK5J5/SneFb55jJczjeJH6SdiByT75p2uTefPHtZZPnJJxg/lVpWuzK/Nb5FlERkEkWBL0IPQj2HrVq1gVTC8qgy4f5i54wM9hVaxkWSJRv8tyCi8DBNWpIzFI9rdQOLpGGSDgAd/wPrXLLV8250xVtCWCGWGG4g3oJztkcEbi/cYPtnvVPUXdI0k8uA5H3Y15OTnk0FWmhLwTxkrvJUyDIAP0rMnmEssNvbv8xGS5BAHqPf8A+tWTsvQ0i9QmE+rXEtvEohjjOWXOcewrpNGVrVZPNijDImcnO32xjv0GPes3Tkis79VHmMUUZYA53dT/APrrUljngnlhhkDQSIJFDckg8j8RzWE273K5ebToELLtG4ukp+bC8YPfB7elWriGKW7QNfvLEwDIypgYHUEdQe3SrENpINpknCxqBIoOFDj61XlkEjF4AsSP96Q9APQeppcrsNSu7oj1bUFk1BUQs6Rxlcgn94w6fT6VFpRNkr3MnzyEAAKOCfT3qpYxySybVB+ckbj0P0pL13y0AKeSjkr6sw6n/wCtU6v3mdEKcWuTodJpE0l1eu20TDYV2MuQAehHTHfirWnMYbYxohAdjuweayPDbyC4IVPvnDrjlRitTTnEbIRtKgHIIxnnt/jXO31PPxFLlkzSjWWHCr1XAznkg9MfnVwJJDLGWZipXACt+WaqtchyzOpxkKvGNvWrVvvLozEquCOvP+ealtI4pXe5YZg94GIbB5IPoR/9apLhlMcX7sFsGNgxzg8Ut6HjQDePMGMO2KrQBXkMmWXJxmtIuxzON1coXeN7RE7WY5Qgnt1/Hisi63PqEUsu0hcI2O5BNdFDHF9qmWUBliDMD12n/wDXWFdy79XZdpfIDbV456ke9KpsbUbp28hs6kXaIBtUkMF9M/WqkePOnDxv9oJ4wQAo7mtC8fdcJcIqmMAKM/w8dKoSASXF46uMBQ5yc9R2/Gs4pXOhXtqWYW+ZTNkgHkAcEVa08lopFZlzvOemcdqpQ5aGDzfm3DaQvr3FWbWLyrx0JYL2Uc+9XETZ3FtJ5IlMgy+edpyPYY/GqiQoJCihmZx8jjqPUHPartyqR3DK3yoMnpyT2FOu8mGNLdCrKuGI7H3rBKxhfsQL++WOGRcRIBnb39qg1GB44tm7kDoODj6/nSW9xCsZ3Fi2RlgvH0p9yjuwMyh12sFw3Aov0CziyhDCnnGcSJvKHPPGB7dqZGCUYllZVITIJ9ck1TaG4EiLH8m47cBx2PH9a04lWNOUBSMAE56n+ppXNWkilPenyZUUeYzSBSqjAH+eaoXHnW6gxsgZuVI5Kj8aWado7uVlAVMcZHPP9abcXTusMaxgnBXcwzgev5UXT3Nox2shtzeTIsShgGKABlAGD7+lIbcTWXmSDzM/ebk7W9abJCwLC2iRdgJbHPH94/pU9m6R2txACWV8NHnOG/vfl1rSmrs10toZk372ABnYzQuTuGMD3HvWXc3YMrLMruzEEOBnkeo4xV/bi7aOZsxMRjjIzjjgd+1Muw8kJQlxKMBUCgbgM/lXVBNm1rOxyusMdO1N5oY3TJ3EqMYz39BnPIq99oWa3MSyTC4ZOGQnaqdyR3Hp71PNA01s4WLdGhyQOOT3OayLFBZ3EqJcMm/+ILu49B9PauunqtdiZJNeaJtSt7ae32xqnlgbdoXBB/x9TWRh7QRk7pYScgMCdu0/qK6bVLZ4nEr/AGdyx+Z43zu9CKyLho5JZvlEYc52qfu+grRKzM7XjZEVvJFNatFC8nmSMS7OwK7ewHemwCYui74GcDaDyQnOPwPHeq6wz28wddpAOMAYPT8qkiuViifbE6QOcFmJxkDFbW7guhpSwqkSorp5w/iVcHFczrQ8mVIsjfuLBvwNdL9pdrQmKA7Qu0qW+XtyB61zerqHWKRmOC2GODj6VUVaasRUXuNF7wqyQaYftC8MJBnbk5JOP51PqiBYrX5cyZwGCYz14J707QTFd2RjaUQk52sRxwehwKh1qOOG5tFEjvK2WYZ4AxWrVk2ZRtdI1II2uLGNI7eT7UnUqQAw+nrQZtgLRvkDCh9uCD16mnabOLdklB3MeFViADnjvUUscpvPMljjiWX5ljHCn8OgFczOiOmgnmsYzbmRQi/M528H0AAot7BzeWimQSXDsWZPQAcYNQ3SzC5xJbxosL7WVD3xyMilvA9hfsFlS4VkRlePJK5H3f6EVjLzKWvuo2WlBvZ3t2xA4CkNztPQgN3Hoauw2tzaFXS3VY24yTt5zwCT9KxInSYq1oTGf+WgkGVB+laTX09skQfa054SNXBORkZI7fp7VCgm22aXdkkaF/LFdySXE0+I124TaBubuq44wPWqepXS6i0NvGzRhRgKVAUAc8fmaXTLMLbvc36Hai/K5X5Vc9MD3pBdKkzyoiR7iSSTk57fl/Ws535by0uNWT93psLcgRxGOMDKAbnU9P8Adx0IHFZ95DFHcqkWZImOFd8/nz05/nVlpI5FLDfu3Bfr3/z9adZWjSThVORzggZxzx+GRXPUlpY2pvkV2zU023mSMFuX3AbgwAx071svZ+VaqHYMGbjB7DnH61nxOI0SJoywCk5H97/IrQhDvEshT92mBtBzj1rFu+hwV5uTuWLePDxLtLKRnBOAB05/CpZt8LM6HAU/KKRsSFUiZ1jjHYdKeZdsoyAY3BQk8kn/ABqG7HM1d3JvNkumJRW5IJyMjHfrTIomjwMnbkryQKn3CMSeWNpReeevfvUc2ZkLR7wM8DsfUVV7GVuglshN9dNFg/L9085z1rnrljaaoXChvKIXjqK6lTHFaeZggbdrAVyV5IzGaQxltrZz03e1U2uVWLpxbk+w9yoV4ZABG2SCTyDVdof9KIzhmTeSem4dqnuUWe5A8sorKDjHTin2io8zM47bdpHQCoS1NlohmnREW25lDksQCeueoP51Zt2+0FnOcocfWnQjhoXyFbkHvx3qayXZlXCKh6k+oq466Ck92dxwd6sAGkyAxPKn1NOwkUSqATuXaPWnzRl1GWOc5yOaihZEupIbh13gAhR0welS9zjvoUijMRGpGP4AVGRgio7u2VSRvIA7MOOeprRRfmMZIEnBz6nvVK9UxyzvdByoGN6nv6VFtNSlLUyJP3Fu0pdWkIOFbooJoUq0jM5LGMccdScZxUheCUqSRtRvqPao7pnldmRhGqrn5UByT6VPQ2XmZ2tXCs6IFVPLGW3Lng+lItyNssmAFyFUsOvHpSNp63U5YzSkn7w8zaGP4Vn3NmsYZHzKV5AMjHaaLtanTGzXKPspUNyxkGfmxk/x49fwxx7VNKY/9ogsRktxt6de3NRpaWQtWGzPz9mwP1PWoGWKUrjIwNq4Y8nP6YFbU7m6ipMg8xWnkiCngYHA49/5d6LsvPbwS7AMlkkcLjDjPJ+oxWYCftbAF9zNg7vmXH1qaNY3mK3a+UpBIcZPOMqB9en410029jWUFFjYMx+agQ5bGDI3BI/zx/8AXqjewQSZWZis6jejKNu057HuavyyiK2xKYygYPuAO7nsf6VQuCpuFBaTcwJXP97tg10RZiytZ3sLbor2GOZQwUyKuwqP73Xj8c1Q1l4UjchX8xWOCB2zx9adfhbW48y1bY5wrhjw2eox/d96tWNibryXlaNpCw2wj7oGP7vVufet7uSM7pao5+C7nRE84MsYJyUxuI7gVf8At4aBZCgEbghUxkKATwR2o8SE293JFC64jkKkhsjI7j+VZ2mXfkajC7p5kMnEkZ6N+XNXCevKw5NOZmj/AGs93EYUiA2Mfm2hc5wOT36Vj67cM8UUWQGVuCDwPXFdbJp9vMLnyzG8Yj8yJlyDgckYPp7+lcFfec2pGKRCPJO7IGQw7fnW8U3IynNcuiJ9JuTFb+Wzksh5zxk//qqRJXm1KOQq4t1BQO3GX/8A1VqaFoEGoX32y6kNvbQx+ZIw6hQcEgHq3PAp2oTrf3qQ2422lqNkStjOCc847nitHGNmZKUtrbbkk9ur2xkE8gdRnao4IHvn6VoWdzLcWhWdNoCHa7twvcDP9PeuduZ5Ipo44nD7zg7h90V0cAlk0uS1iCssf72RmGdo/wA965Zq0rHVBbNkQUbBJhCDz8z5xTEkeWbL4Y4ACA4Jx3xSwOqhY1SLBIYbuBx71IDLGvmCAyFcLgNwSeQD3x1rG19TeMUye4kgtoSsce24eQFPmOFGOff8alhQ293LLdXbzXEi5Z5Dli3pu9CO5qHS4oyA8is85PzbRk5z0qxezRPmytbcErISzSqNyj0z61X957Etq9l8y9fXLXvlKknmxKATgnYP9nHrk81HOSlsoH7sjlsjuDz+NVxCqxRrCxf5tu0Ng46n+Y/KqWr3ckcZZYWI4GAeR2rirzvudFClzySian2nzZEVsZYEKdg3fiK2NNjeCQzwujLGoIKnJJxyPzrA0l5pAPNhZSTkjGT9Bj27V21haoYWECnDNleMAjHPH4Vy3bYsW1TVitYxNJMJJAu3O41ozOYlmERzg7QDycetRXDnzXU7OxwhxkAc4qGNJAhlduSvO7g/T9az20R5r97VllVmhjeR8bXyMgn69KYssjEYUjBJBIz09B3pZZPPijTDhjghR2OauI8cMa7cJKCfvc80NXZOy8y6XZLFMooJyDxjOf51Gu5izrvJK/KBwOaqSNIttGjAkk52EdferKnybYIQFlH8O45+v15p+hny21GJFJco6pGQpBGSPWsSS3eS1uoAMuQSMLg8ela8DSIrFHV5JPu5/lUMCSvcs6ptVegHBzVRj0HfluY9uVjMKS/MVONxGRgirNq6+fL5iHBJIYd/8inaciS3UqzDBI2njGDn/Gk0w7LtmlJGOBnk0o7o0k9yYgshVVGegAPU4qaxiJgWJ8ZB3ZPU/jSurC58sIqo4JHPP0q5BCrRxvhQ+CD2DH2q0iHI6NJAZSsrPDMOxPDfQ9DTbmIMTu8t+m4uMEn2PartzCJ0dZFUqRgjtis8WciKq2twyBSNqyfvFI9PX9aJKxyppkNxM9modgzBuDk5KD0yO31qnPfRXgV7di8YBXeORu9DSz3N5CCJ7YuueWgbdn8DyPpUUkMUkZlsdtvetywCYyB2Ze/1rFpvY2StZspvFEL1RJsYj5i3rjrUtzPtjZbWLbGeCG5BPsazmuS96Y5UkWUZHy/OD9AQDirs9y7KAhSSNBhnQYYHvgetJNamzT0JYzbxwKJDjaRxnn8/es+5t98BIX94/OCQMfj9KslEMfmbkVlwxQrjn3NVp2M0ZBUoRn5h82cdvpTeug4eRl3NoGBCqjIXwCsn3SBycetUb0ttRASAW25GT1PPHWrlvCXkOJA+Pu8/XnFRzxyAZMimRVx+J/rVU/Q9CnKz3MS5DxY3MShY/Ix6kU4kStExlOOu1Rkj/wCuM5qxqEKSFTub5gF5ONp7/wD6/esyNvs8hQOCv8TE88dDn/Oa60u50StKN1uSSOschDASkNtGc8gd8H161WzbzSOkayPLzgHj68e1ChXlErzMR93bnkfUfhVWV/JPyiRvmO0qfb9etbxfdHLUgrbkYKLPICjBgv1PIx+P1rOFzLah13FXzlMDH4Vdd3hZJZEMeAO+W+v65/GqWorG0jE7ien3a2i7qxNP4iG4RiGVkdcYJyM496qzwmdI0UFPm+Ru4PtVyObERRi7TFsAnoB/jTwHkmj4IdWBGR3rSMY30KqyvEueG7zz7hReK+Uba5BAzjr7c1W1y1MV+plRowflb1UHkZ+lQI0trfyowCxlgwAOCG9uK1db230wbcWYqPm6ZwBWzdndHPy7DVL2en7gCRL8oBGeaq6TD5c+Xj3/ADjcvr7Us8l1PHAjEOIlCgjrj3Heryzx2wiiKuZsELsGct2z7VXNt2FLSOnUzbiGM35faGk6KgOecn8q2BEtnpcrTFvtD4CseARjp/hVWwWKziaW5AaZhjpzk9MfSp57ae7iN5P+7UDCKO/5VzynzSuOEb27FRLae4YM6xxxomSCeWA/z0qyXnl8uR3BSOPEayY+6OcZ+p70k10yYtYo4XlGCW6he4H1zTJYwzFXfzZGPyj+HPfAFKyimaybTJVupJ2D7wqkDKqxyfYntRa3cEMqosojZs4CDJH1quFUOBtAzyUHHHt+NaFlHDEQu1EJHG5OTXPVk3qONtia6iVIkZHCt/eHBBqnc3BmnVVlL71+ZM85z7//AF6vzJ5rgKjDC43cDn6dh0qGyso2ZAoUueCGHf2NcVV3Z3YdpR1N7SVEax7i4Yn5yFGPQfWtppfs91utAdpTlc4GQP8APFY9hA0jwIwZGJ4bcMcd/f0rWlXy7pCNzMuCTgfe96zbODEW5rIrhHM6eYGUnAyOD75rSu08iJ4Vdm5HPTHf+lUGZpp8ynJkb7qg8e9WJFlmQxsxjjPDYHftWVnY53uhYxLEyyLtZskNnoPSpd03nYlfa28tgLgEZp0iv5EIChFUE8Dg+wqYRlFidzvds5DHBA9KcYsiUia7k84qwiRm2BlB45zVhn817VcKHAwMc81BfI8sIkRMjjn2/wAipomMkUbKgEignKjAzmr3dmYu1kP2KEmREUuhyQB1zVNFlhkKld3mAY3EAA/5xVqFnS6lO7DHsecim3MYlaOKRjjcSoIp+gr9DImR7e+eIxDe/wA2Acbuant1WVnwhDZyVx29qZf4tr6CTlvm6kZx7VbXCXEjAYVz1z2NUlroU5aIjkdlaPbHlkwWLDoPXNTFsXB4DKfmHtkU3eqI8hfed3lEdTgU63YyOwAbKqAOwNOOoeZ2Mjbn4BB6ezGonRVbHzMWXPA6mpZIyxzEwXHG3HHXmkiDBi7n5jkKe34+lFnsct7Ir3MQFuNzYCDNUJ1huTsnO6Jf4SOfatQQHaRnbuxlf89Ko3E1vDcbbkgEZI3dOKTRcW+hg3Vr5bg2xbO/5SCfl/Oq4V5ZCk2wyqCCw+UkE8GrUs1xK8j2wZUQluGGDk9//wBdVjMioGuFMTqc/MOHB6qD/jWbStY6knbUq3IIuCoS42FhwfmGR360t3NCI0+zOFlUYORyB9OKllFvfywiJEZX5yOAPeqmpaYrSJDIkYjBwoPcf5xU67o1ildJso/YZWaSdriRZUGcqAuc8nPHNUhG7SbZ7iXzRyFGHD8/e6foav3GnLaWzGEyIe7KxUfTGazFcRdX3ThgELr0btnFNaWujqhK6bRFOrxs/wDq51Tllddmfr2/Cs6WYbmgmj8lQchWAIzj1Hr9a3jLHOrC6yh4yeOT0PJ71nyxKV8tYiImypD88ep9TXSnojZS01Ke7flthVP4SvHPeo7hkmldceZ8uO4Gev8ASpZ0a1/dI5eMYJRuSo9FPf6GomkjEamHMrMTnI6N7jsa6U+qMpy02Kk0eJnY48twcgdSMdOazJI3jTa0h2A8ADP61sX0TKTsIYkBSexz2HtWXqcjJtAk8xFx04J9vpWvQzhLomRQRZKeWFLA7s9xVy6jaSJpbVSrhg3PcioLG3KXC7my56c9RWhaXDveeXJlgx3Ko4bd0+n4VpBt7kzd3pqNktIrx9xHEy78qCfLP+etWLK0KxgScyqCpGM81ckhaIeZatuCnBGMEsPUdRx6VD53mJtW1keVhtCAHOR29/WtOaz1KV2rJmQiuLtmiTKgdWPAz0//AFVZEU4mMUGHuT8ryY/1Y9D6HrxV7T4pAHBjCF+S7DJH07D6mrAZVOLZS/zfM33gTn1PU561DlaN7mctZWRWXTorSEs773Jy0jj5j7AU7VdQmh0Y20k0sdkXDgHgg89up9ifwrUvGt7NnS6CmUrsUZyAwGQTxyP9kfjXKa9vutX2zgssYGR908dQ3qcn9Kai1FtFQkm05GfaFyodo1CZ3bmJ5HTp0q4qGR0+fbwSCOx7UgKyBYlfapztQ880+MPCVLygZGBxWb00HKpd3JrNTt8xpMdhkYGO9WoYzGUY/NGeVx2/+tzTYIVTOzd5jKTzz2q1bx8C2JLBuFA4/CuednoaReuo5/3O6RkGCvZ8498U+28y1vf3TCQtH1b7seeOamEcJMot4icfeLHKggc9BS6ZbRu/mZ3ueAFOOTxk1yz0NvbWjsX7B3kkxGW3uSAQ2zH4/lWlbR2trfN9vkLsylmy5I+nWqOn2cccnmA7WBOFYZ5zx9a3IrZbi4DEquAQAo6HtWK3OGo7tlB47aYzvaxysCBymQM/XjvUluuoQ2oaGHzo0ypV3+bP1x/OpkYpchTI+PMBAyctx0rSjMzRbHUBDzk4BPtmluzN6Ir28k15bId8TbcZyGyCexqSZpLcygxOT9792wIB984qxLbRukZt2Mc4wokU9vRux/GmKlyZ4xdmMbTt3LyD9RVWtojJ2ZIL8eRGuSHxwGXB6flVi0VxFJ5y4BBxk/d46VFDNmMRyFWOTkkYx+FS24UW4QZyeScce/NUu7Ia7IqW4mM53MhRuFI4wf8ACrToxuR5ihn2Zw3GfcGrL24RFdFG44bkevan3MKNb7sEgDbjPT6URTQpTuzL1tIhDEy5DD5t+M/UUyNlkki3/MCBvI7e1Wmyoijf5hnG7AHbv61EscVtdEhT5S9yOcGra6kxdlZkdpCLd5I1X5XYgHPLc981YihG0Dbtk5BHU4ptqHcO7BQiNuUHghc9frV9sSPujUsPT+9RFFSkzeYDaVUDnp6fWmKXBy+CD1z6VKeANp6HpUT24kb58HBzj0qmYKxBC7JL5JPI5VyeSPQ+4qvcQSXHmLKu2JuoPc1ZlikIwjrnqNx5z7H/ABqm92zhUdDHMjfNGw598etQ9rMtPsUmsIIoHMH7jIGVUZU/hVQTSShoHgyGAQ4xhvp71cumbYztl14OFwe/SoptSigXEimPf8ql0wD69eM80Wt5Gqba7mJcWEcFyPLjkVnX7wAIDdyR7/zrPmjAbMoKzE4TZn5vcY/lW3NFL5JdZmcSdyf1yO1Zl3Hd23/H3GXBb5SV3A+hyOR+VZyjfodMJeZn3Au3DASMyqNoEuOfUg//AK6ZJPIwVRaoSw+YhwQfXr06Cp4bxpbkpqEG5TnDxsDkDsenNUfMjvJ5Y7EGZupJ+Vc/U/0pR0N0yC6VSkkjuUj6/MCV7d+/NVrSPAUszlSfkzzxjnPv0/CrRUtuVnSWdWySPuA4xgD1FRzsII1TGGVsbs5PTmrhZbmqb6kBhMgZwQ+P4TyPpWbNlUkuIWCSLkBiePofWtFWEu8I+wq2CmOn+PJ/CqFzGGaRHMaKo25J4z611xXu6Ck73KipIWRJAfMABB3fL70y7CAFk6qvJHPJ/rU77LiNyBt8sA/KT+dU34iAZy54AGME1vDQ55D9PLyPlyoyABx+ufWr2oRNBHDKqFJEfg5657A/Ssy3jUXchVchDyuenvW9pEkLzPFcIshdcbnbOz69cVtFN6Cbs+YtSq/mw7yjzEr+8TKyR5GRns2agEk0k8kiFJZo2JbD+W3TuD/SpFjuPImso5g6I/mAPzsBxzu6gY4zyKp6jBNbTqsZSQDB8zeME47EUS7lx6iT2Ek4WeSRYg2T94AdemO/fpVi0eSBVdEkjIwDKXKBM9NoHzH1z+oqAPCt2ZZ2lZegESlvnPpVJr57i4nSd5ZpJP8AVRIwP03n2FHKrjUW15Gndm3bfLDO8jxgobl2IQEjPyk9WHTv9a5fznnmY2gZk6Bm7+vPv1rV1WRpo4FZo/L252RnCqc9MVkEk+WU3AE7evGPYVU9NjEulUjKx/6otyR1/WpYYidjbSygDknvTAudxc7vlyOeo96fGGRcoXZcfOg4yMcVjNmlPQuQxiZMBcFcYz3JHpV23hdplilJVuCMnofrVKzg320ckb4G4gMDzn6Vqw2s7hwCSoHUkZGea46jv6m97Ij2tbTPDA5Ee8hX6D6n1q9CVjkE0hj3O3bjPqarxyYRwSAwGMn86lMkksYYKhRTkMRgZz6Vz2T1KirrU2tNdH8zc4ZGyAcY2/jVyz852ZowShIx0yMVjQwt5ckkr53t127QM/h0rQsrAKI5UeZfm4xISPbr3qLO5zTSVy9FbPhsFTtbOMc1p3EMc0St5abVUA5GeR2+tYqtIbk+U5kKtg7QDg+54Ga1Dc3uI0S3iRdufmc9QfTFEWtmYTTumi3tVI4/LJUqeQQMUCMli7tuYvnHAqCCO52MZnTrwqJjt15z6Vp2MIIDcnAIAPYmrWrMpe6MnVZY8eUr9Qfao5FR40jbqDt5HP405lAJjC/j2NPeJXlBUujqOcRnj3p9Cb2HNbogXknAAAz1pt4JktiI8t1Oxuv4GnM6LBu+fg7QepJ7AChYpJgDNK0YYYCR8kfU/wCFUkQ2VraWK5HXaQDu9QT2qsCJroDaST8pLjn6jtVhdPK3BkEknm7flbdkj60pj3uI5h5cn+9gEj0NUnpZiuk9CulpFFMUw0gIxkscmrjWwhmRVkZQM4wx71XmjCyB5ZMrx0buKnMpkaEYJTHDL1z6UR7FN31R0ajduZCQR1qMRKzlnjUFjncvBpxb5s+2CfWmrEu1dmMLxx7UmYkGyWMkxS+YOPllHI/EVmX8g89nuIChGAOeP++uxHvitSdZTITG5OOx/l+tU7mRGZ1TcdowxxwfamXG5mG4RVR5AXhY53gYI+uOv1FWZwwiC4ie36rj+L09qznkEMzPaIiLnJt5BtVz6jPANNW9hVy1lcmGXOWtZsqrf4H6cUr6GrTKl40XnLHawXMU/YJhVP5/Kf50ye61F9kdykMaADM0fzuv/AeB/OtaK5S6tJD5ZJB2uknVR3GPx61nX8yWsO84aJOSh6j3U/0/Kp2V7mkG3pYzL7S7W6SSTzGuXPSZ3xt+gHA/GslJJpmxdrG6qSqhBgsP73/1hVy7eKUO/mSRbz82DgnHPzDv+PNVZnlntVRYwGXpMW2N74HrWbS3R1wulZkO+BYRltxHPlngk+gPXtWYHkeQSyxEIvOF5wD/AJxU2ptGsgZnklk2/wCsB5+hxwKz7lrpbVk8zZC5wWHJyOwq4R6Gyemg/wA0rDuQbFYA444AOOR9aqzyRMJi7iRyvIxn3P40pVI2UzOzBV+XamAOOlZc7R/vpYy+wnapIwP8966qau7XIuki0WQJH8ylioLHP6Ut2GeQPkBcdR3FURL5cmYyzBfl5U8/p0psd7HJuRtw2DhcHPJ4x610wj0RjN9y9YxKxZJo/nz8rYI3VdZGs5SrMYmT5kccHPv/APXrMt7hVnwCykHc28Y5qbMD2PnrI5ZmKMrMWHXng/zrRK1/IzcuqOgsbqISLLFIHzCdzqy+Ypzgg4+tOm2M5jWJQrkEHzBtXP0HFc9ZWsi3hW3WSWSQYUR8Fse30rReXe22SORWj4aNsL+f+eavVq9inJJ6Mp6vKq7ku74sykqY4nzz7n0+lOto1a2icOsEOCxkIyf8/Wkv5ysrLbpGkLfKzQoFwPXPWobqaKysURZCquNiovG/PHQdB9auCaeo5TtHRlI3C3C/ZbV8Wqtl5SD8xBpINyl/NkDoTjgc/wD1qJmBKQRqq4GVX/E1MqRxxAKwL8ckE49vpWU3cyTu9CZZQrkjGGOAB1NXYopJGCwxsWbgKeWJ/wAKzYkj+8zN5o+7x1GK19PeWGQT+WyOVwpY9iMVyzbubQ0JWjgihaSRH3hsZTjn2p9ot0r7lbLZ/jGBg9sj/CkuUfzUCOGAIOCR19T/ACoaRtyhyN8oO0H19655q+pvDVFoW1zJG85RCqtkYbqenAx0pRPcRhFMJ3qpxlxgk96tWg8u0KKXbcRz3J459PWmMY48s3zsny4+vX+lc7KjNpcrJ7S4uJf3IjJBG4/MMZ+lbUQuZ1Fuitgcvh9u0dsY71kWLuiNIsSqzn5VZuS3qfbitmzn8mP9xGbqRTkncFUEnnc3T+dD1fvHPUfYsWtsyRxJgiJfugHofzrYcNJteOL5QccN/PioNMjuPvXUkQDAlViXhfxP+FaMAYGSIkMoGTzyKLHLOWo9ADNsiBxjk+9WHZIomZQqsufl9R/SnxhYyN21SMAY5qBxmX9+iopUkg859M/hVswTuUnkeWWO5VT5ZOGGPmI9fQGlvL4l1GnJ9qdzjOcJ9SfSi6jTypVgRn2HBUcF8ngZ7VFGHtbWR4PLQMf3gI5z6L6fSkrs1VuhLZWklvI9xdyq74x8wwq59PSrVlNG8wO9A5OeDlT6YxVVZFuHZlTcF5PnnH4Be1W5Gt5HRG8rdnjZiqStoZ1L9S3Ky+YNmFJ5+tMnhjuImDjgkHAHP1qtNA8ZjEcrbcj5WIYD/CpzI6IQ6q0g/u8DFaepjbaxmXULwWrRRzb1JOFkAz+BqnYyzoESaMsrZPyMDitrUY0kj3beVGVBPfvVJLaNcnyyHPYHt6VDVnobwknGzOmYlzjPvyKC2RnaUIPOf6U1mEYywbOef896Qu8i5CqMn+LmrMdhBuDEkZXPUdqrXIzIfLUEEjeQRj61PIDkZZyCcAAdPeqbyxIjIjL6+4//AFUthrcq3yo6eWrFeoyOeKzrrR7dFaa1cRzqvG8/JJ9Qen4dKnluWMpZWEZwPvJk+5609YUkjBuh5h+98/T246UOzNdYpHI3c0kjI+nxGKYZD9TDLjqB/tZ7D0qYqQVeSWRi65V5CCp/3Tjj6Hmujn2qCrRAwTAK2eme2Kx5AbOKRZF821bknblouevuKz5e5vCSeyMhZgLkNNCAp6kjG78+DUWpXFu1wxQ+Yu7iJOccc1pXNjarbl4JCynnyyCyMPQen4Vied9lmAFuIUfgoeQR14PY+1FmjaOupSks2ulLOEgjQZCdSfr/AICq01tcJFGUjPkjO3PU47//AFqtXd9GZtlsuAx54P5eprOujIyCN53fHWMLt+lNWbsaqTSK9xcW6WRTbIXY7NwGCPX196zL1VcRovyFju47gdP1xV0uLmXZHHIfLwBxxx7+lUHkRZXWSUGUk89MY6Ae3WuynF2I5tblZImLSAg7kHfPOepFU5V2QMFwJCd2VOMd6tm4Z33KhIByxY4zn09qpyzxvDjbIskpOMnArrgjGpLU04khuo1kfzY2lGfLDl+McnnpUAifOyOQiJ24VVBKnpj3BrKsrndjZNLHPE5GOGG09vb861I03QRySOm9Sd23pgCtmr6mEWhmJYXjkWY4U/xHoK25Lgw4WYsXCbtwcYUY68g81ydzNEZDAwLhRndkc59aytQ1loYYbZQw52Fwdr7ee9VGCSJlWtodfBMpMssUZlSEbncksoJOBntk+lZzXc19JLeTtnYGUL/DkGsu3vWaxiszL5Vkj7mQH759Sau2s7OCi4WFB68EUSelhKd3c2UKeXHOwAbbkgdD/jnilWf5FiAj3Md7OcADPGD3xiufvdT8vbJBHLIF6YOFBzgcHrWpYx/u28yUvLJ8xZ2wB36VlLTU1jK70L9qyo5G8AZwCvOTW7AgnVMy4jj9x1x0FY1qEBYyAMRjCdBWxZLG+yKJGD9SA3H51wVFfY6YSuya1sx52WdQCc9eTxmpXixI8ilScjaGPPXpxSiFli3MMHlc461UaYJGqYJnOcAE4Hqa5pNo212L8lzk7HChT1kU5UE4IGfX3NW9MitntLmYgA+ZyXPfA5wfrUNtZxvFGzPHIhHUnIJz39vaqc3yTS2qBmQyDGCPm4Hy57fjWXW7M2zYiY3z+XbqVUJgA8HaT94nsCeg6n6Zrdgjit7eKNyX2D5cjgfQVh2d61vbiCNCZGbOY14Pbj2H96um0WCJ4ZHZg7PjBbk570eRjN21LtrDc3UUTM32ePpiPhm+p9K2XEcCbmA2jgBRnJ9PrVKOQ2bKso2sMcDlvrVxIGkl82dhhGyMdBVpHLP8Ck0Vws4mbJIBHlA4CDtg96JdRgS2EZ3xMOCsnynHc+9XrqfaisqfJnlmyB+FQizFzk3MatGw+WNsEfU0W6IFJaNmfDPOgaaCICInCI7ZI9T7k/pVmKMT4lKeXK3Rnbn8BT4NPiiG6yAfacEfwL7A/wD66sEJKqx3CmORiBtLd/b1pxVkOU09in/ZYMhknLefz8444/rVmGEY2YQ7f4lAGamdZIUD4ZozwFPLKPX3qEqjSq0Eh3A4O3pz147GrSVjNyctydtpURNyQORVoKFj3YKuOxqKOJvNywBwvNSyYKBlycdappoyuReWkgMbsDxt2k+tUJLcZGFAkX5cHqwrSKozLIAC6jHpVK9H+kMcZOPmwM4qLLZmsW7m1s5Ay2fXPSoZpHEgwvy5znH6U3eRvOOO4HUfnTDcSNKUVflAyccNVpdCLDJm2CSQtIAO1YOrMrsGXKOufmJ/zmta5uI1yzAoAuTu4x/jXKeItUihDCN9z5xwMnpxjNKWx1UKbnKxZtrmNSI5W3EdM/0rSVo5Wxwx5+X/AOtXmj6nM91AWLbHJG5V2k4PWuz0uWZZI/MUsxyFZf4h7+9YqTvZnXicM6aTLOsRK8bKcqqlWzkjOO3WqksEa48iaeNjzjzMgfUGr92ssoeNkEWcgHO8/wCAqhIdlv5rTP8ALH1O0c/lV8t2csXZGHLHexmRoVhkh5JVdwHuRzkH9KqG7NxIMowAByA2QPr0J/Kq2oeI2SQQ2TSPx91U38+mcD+dVjd381lu+z26SEZ3SHawAPUgE96Vr7HT70VqOvbdLMpPBOro2A6Z5X1x6YqjPIHkjaCYFGYHDDqPf/PNVLv7e7G4vYo3QKMOuRgdeQB/PNZsl/PD5brbSgM2PM25X2GByauK1FfTU1XuGSIjZGjEkE7c8fj61zrfv7xy53NjiLGce5/wqwWur+486TzNhHUDJ/LtUqqsJBaBg2PlBU9O+TXXSsnYl3tcpKyQn7OXchvuluST3zUV6YlVUlJkBzkbfufT8qffqzl5IovKYKHVcZDEf561mSu7SfvEkyBjJHqPX2rsirGE5dzIeErcSS2T4eIZKk8N2xzWrp126BkRnUD5tp7Z7j1FQyqVUyoB1KqgQ56VFc3CfarJoYpUUZMpkGD8w5H0zWsUcrbQmrsHklnjym0nJx1A/wAaxrSJtTkdpmDQowUYXAx/XmtzVIJJZCkKMWwd20Hbt9T9OKk8M6U8STyTruMn3Bgj5j/Sm/dIUbvQptaW0CIHkQIMHczD1/pzUkV7A0sxh/eBhhdv3dw/+tWvcw2tmz77dJSoIA5GCeOfbvWF9jm1KRhDFJBCrZURx4LfQ+nWo03G3rZEkG/UL9Dud0icKXP3SfQfSum012hjeOVg6EjAYAlBnsetVdGsjawyW8YISPHy7MEHGR1qyke5FCDc+Bnj73rjFRNXVzopq25qwlYj5bMBnn1IBPQ1rQAr5flMApOeB161k6fC7ruCnCkZdhnrW20DLs8osxB4YA4NefNHbF9ye4mKKkathsjJbufSoI7f98HYjL53sF4UA8fnzTQrgGaUFguQpA4Hqc1q2iRrao5DKep4PJ9K5qnZml7bDpo7a1sQE2vMwCoRzgnsDVVbWOOYQANLNKmWG7IOCefoOnuafcKodLmNCfLA2bRy0h/niqsaX0cpgsQsl7IAJpf+eeeQoPQED+eazsQtWahJtJ1t7RpLu4PMjYG8H/OMDjFbkcV7OgTz0lU9lGCPqfX24qDSIPsVrFGkSpK2Ms2fnb3ati2t7mQtJtjBAw8iMQT7dO1FnsYykWYEIkQ/aLlZcgfOu7cfqc8D61qW6TWuN0qtG4yr4PHsax4b+ayjgSe0nlUDIaIBj+X9a0GuYLuJVkmjaTAxBkgDPQkHk1S7mErt2LbzrJE4A8w5yioPb7xp8VmJI1acBgeQgPA+tQwN9igJk+eEdHxyPY1oRxmQ7nI2dQi9/r61SSkZyly7CSSbeIk3DGODhRQsKSORKC4bs44zUrAeSCTgAZPYCq6SGVR9nTIzw7ZCn6dzVmd9B3kCLKozKvoeQPbmoEQCRshfMPRkyCRUl1DPKsYExxuGdo6intETHtjB2nu3WizuF9NxI2lVuVEm3A9CQe9SOCwG5mAB6DjPtSxBlcpsO3bwaoT3UkrvDbguQTlx91D9e/4U7hGN3oaJSMxBkAAB53dKqpcxTSsqsDgZJXnvRBEPKxPukkJ4J5H4CiSDzHUpuGOu3pSSbLsluf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar lichen simplex chronicus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 304px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEwAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1xiQxIzjPrTnJx1Oaj3D5lxmlPK9815SPdsVyWBOTUyMSPWoH4bpk1YgI7DBFJbjaIsncQDTWkwB97INPmxvLL60wrzkfWkwCQkAnJ61DgnIzipyMkqT9OKglIXigCrdg7Fk+YFSQfb3qpETswWJ3e9aTcjHY8Gs5FILRkcr/ACppgYer24Ky55QjawPoeteP2kUWjXN2sgQDT2IjQrl5Gc8EepAwPxr3K+T72Rnj8xXjfxM057DxDp+qWtzHASfLJkGY8/wlqpa6BtqWL+xjttHa8169lTU5F8w4YhIu4XA4OMD8aXQoLy4gkuL25iitZiJGWOBhIy9lHzcD8e9ctNd3er3a3Gt3LT6daNsMaRFFZjjkKM5wMEk+vArvpNXik0ZmtrC7lIhC744cbBjGfWiQ4ks9jaG2kub9LpIMYjt0L7peP7hzuJ+p+tY93pMzWc0cUF9DciPesVu7BQno4Y/Kw74B3cV1em3pk0qWYXtveEgl0DAKmD0UHBxxz781T8WXttLbwmxJnaQFmaBhgLjjnoTzwKSY7HILotlPoc15FNFdX6xllaPIxGox9wDgjrk4JPB9Kd4RtDJA637NaSMUMbzwMRtXIKM6nKZ56rgEHNamjia1s7NoIpnhm8ry4UUYYK2S7qeQM4HcZrdl8P3TedOt09y8gaVllI2NLksSWAVgMk4wcjpyOK0v0M2rbHKano7adbz3MUxuFRsG3R1ljwTjI9yCOw6d6paRqUFtb3B1Ga9GmT4/eJlbm3YHjaehA4OMA/1drU0+mXEV1HY3Sbds0skMjXKAchQrjlR3wSOMZHarQki19PPMkN3cbRLIrqlvJAo6GJQRucHqSv0PrSuS7Mjh8VTLf6bJca4kulxPxdxoBIGyRh4+mMe2cdQTXVarfxXNgt6t5LeW8q+ZLG6+ZDszjdtVcrjk5BBXvjpXO3Okvf306LOjNNEhWRwIxcJ0OSBtJB4zwQawntJ4Nans7+3TTXKbo2ufljnUA4JZSEY8kDBH48gvRktWJ31a3F8LjUdWmJicJFCFLxlHO2Q7z3HXJA6EehNzxjDpz263cd1FsG0pbST8yRMwDNGAODu429MAkCsiy1JbezuLKR5kg8wbbdArhHAZSSoHC4PIHBHbjNav2T/iWaakVzBdaddJPavawnMlrwCBkDcSMYGSevpTt1D0OS1dPtN48dhcSbvLKxPJKDlUGSCRz0K4zg9qoWf29LqOxV2VBMkhgLt5ckg4JB6Zxke2DWh4eS3tr2OS/B+zRXWfNK/OM8Yb3IGfzxV7VIIbq++16e4S0nmm8mIMVIAUsygds5IA9TV81tDPkT1H6XKgvjFcboCIG2fagRGshJwgYA843D5sc/TNaya7e3Mc09k3kQ3WHuRPPjhVHBbqMknOP72Ko3lzJFZXOoXI8tdQVRiR/lIAKBsDrhlbtwT71iWs7WtrpkRtPOR3NwFlOHmG0n/vnOSPXHrU7l7G/B4me18JvZyXE0iJulaFlDjduzgtwdp9B0xzxwMme5vdYvoJp2WEynPlW8Zk81hjaNo46cfhzmpLrSU1Owa5t7iTYzAmyhLcDktyx6jj1zz0rQM1grRHQ4n+2KYSViAEYXOWJXOAeBnnnnIFGwWvuSaL4W8SzyLdaYjW5Zi6ByAzBcclcnHOMcVFrl1qluktjqV23nyspeSIqu4k9365zxtGPpitLXvGGqSW724tzb3s2xZLsMVO0HIxGvGB6+/euWh1i7s5j5U8l/JI5DJNCpUkk8gHJ3H+9970IoV3uDstEaUltqGjPpX27S5LaFklMcJcedMByXdcfKOg+bP5cVveH7i3jgSe/ksZwU5juLgsPmOdoAJPPUjr09a5ZYr+S6bUtR+3yEkAG5lJIVSOCzA7gMD0+ldTHYy+XbNMHtY9+Y40AuWz6ZY4BPOSamVhwuadzrk6xTPFFbzXJAjjgs9wjiTONoGCCTnqCSSce1Zl7b6leakljaWMmns+CXSUifA/iKggAcnjitXSNOubzVW1CfWfL2sVjRJUdY1GR97GAOewAz07VZj1a3gvpI9IJZ1BWS4aRmaZieSrYyfu8ngAe+Kzd1qaqxjw+BNXka6eC8njlSQ7ZJXUDOB6fMT+PfipLLX9d0GCO21W2gnVD5ckkTlX4PysTk5I9xk961bW2n1nUnvLm7ldoZC+0lgGbAwQqfdA6Z5J9eKg82SzM8yQC7tfMaOT7wx3PL9cE+/Q+ppKXQHE15dSg1qF7NLK/hvR829I2Cow6NkcNz61jRrrSX8t8GQzQkR3dlt/1u3/AJaAjgZ9Rnp7Uum65aW2qC01K/3RzAm3YxuTG3Zd46qe3U9qhn11NMubp4Wl1OCV8/ulZfJx/Eu4d/rSDyMvU74PpLwQlFWaXEZLbihDZw3pj37VD4CspZ7vULt2PzSCJAG4VV5IH4n9Kx/Ft/cG3mu5I/ImbPlO6bWwTk47E8dfc16D4J00adpFnC4/eLEGcjuzck/Wna0R6XOw0q3bzFQtgqBuwa3mTDoVZgAMYzWbpYw7M3H0rWY9G/iPOKllWJrMnYSSeTxzVtec8nJ4FVrRO/bHT0q0pAANK4W1JMbVwTxQ5YjqfXrUTNub0zU4yQAMfWlcLAoJILMc49aSbcCOTTggxu/DinycgbhzTsIqqz/xEgY9aiE+ZDhjxxU8p25HcjFQRw8kkYHekVbqTpnyicn602JWfkk9aewYJ8uMVJapwtAdCbaCDxg00ocnH5VPjk+lRuQp4pmaKroxII6ipUOCDSMfmx2pCaQxW28jGfSq/KltwzzU6n5CaYSCCOKBjUO5sD8KLiP5N2Dz+lNVWBytTO2UwDxSBmdOzCIbRwTgiq4b51bAyQQaszEI7AjgnIyKpSZWTamGGM+9MdhLobhuXIxwQDXF/EDSTqvhq5hGBNsJiPHDjkda7SWRShI5+TOPpWbfRo6suNyOM49RVJiaPCfC17AbG3jDXMdsj+bcN5R64wBu9+vPSusubmS3vUkil+wSsQ0KXRwmPUjsCecZ7dM1zFoljoPizUbG8IgG8yQspwADzjHTn/61aEGrz38l3Y2Er3MSgGR3h52DPDHgBRz7nA7Zpta3GnpY6Eahp17OYzDaw6iE5linVllY9CONrAck5HeuXSwu7mG5E+5oVQeVNGqxJjcQq7iBkcn7vODwakuPD8V3p8Qs7axV3ORJNM4Zx3deAAOnbvgU/SfDE8N3E91AGhicAwXUxdAwHy4cEYIBz7e+Kaa7it5GlpEd1BoREcVzbzKm2Q3G1lUjhcZyxXn7gHHvzWpHCs9u15q9xYJBFGN3lB5YnB6OMNuJz/DyPbvWIbPVYNXMkep2+nxn7kkMjXKICeEZW5/H1b3qv5Fxb6l5ksllcagXZgqOSjEDH3MYXJPQsOaZLR10esCH57fUUUyoYE+yWDvHGh+62Pr1APf2rhr5oPtm25WG3mTmG7EAUFgfn3OCAMgELnqeOKs6nqGo2l1Os1yNMUruWxtFGJSx/hjB+UnGCQSe/PNbmmRnUree71hLZULACwmi+ZcLx8yZJDdehB7k9KpbEPTUwdStZbC6XUNF1XUnEZMn2oQkRkN1w68YweeD259NO80C01G1hP8Abk0lxKYzLbSoU+VxjcCSNxPHUHPFZOvxxaLdtHBfSWlpdoz/AGSK3dooHP8ACUP8JJxkYI7jBrM8K+Lr+xtLezWBp7mxkCKr2xlAUnAjYqclM8jjIPSrSfQlyV9Sr4i0u80HWrezN157bRHsTACxtyBwemRkcg8CpoZTZSQNd2UJuo5U3sIjMl3EcqW2gg5GT0weOcGtKa9h1O+/tKzNlPcwhmdiu2MluPKwT0A+oOeetQrZpqEkz2+w3cBcyW9v/rdqlW3Ru3LNy3GQcDFV6k+hkixjkBuWtlvLeR9jpBuVpHBJVV3cg4GC3IA55PFUIbxPOge9eaSEAoIwBGLWQ524H93k+lXdYtzZ3D3FrOBJcKDHtx8204KkdVccZB/Ws25e2VYZLCWad40/fJImCF7EccgZwfpTWqJejLWpXNzd3AtP3eEBdEiTKKxHLD2O3JzwDmtrww1veQ2A1O4iVoJxKhP35SytgsTzwVxnOBgdKjbRCurxWtrm2Y2Qly7h1IIYFl5+6cZK5454IrAk1CW1NlJMmZLdwyrvwCh+8B+PB70rXVh3s7nTa1rsaJbQ2E8xitYPIVLcBg7nIZicDGWC4HUjNYGmQzzWs00u4mI4aTcSCxPCDHGfcn6Cnm3un0Q6oqAWcEsaKSAA8p9O5x1Pet+0js4YJrS3t2M0FsJJbi5maNFkPGQo+8ckHIyOKSVir31Y7Q/DNwb5L5liiVtgCveBWdWU5O4chTjpjpwTU50a+0svfRNaRMjtAkWwZUdXcD+FFIwWPYGluWktxBcavPcXd8sarY2vnJuAHWR8crxkgkj65PGfo13eWunTSQRRzLcS4eWT/VSMoJwzMcPg54yck9OaGmwTSOuTS4IBpk99PqFwzMJYYPKBeYY+aQLyFAyDg4OMd8Vnatqv2LUX0Xw+8VvDMClxcXLgCAN1U/hk4644rl7S81y7ke6gnvWvLxvLiWAmJpcHAAY9EzngentWrpWmCC7NpqrXnmxMZLy4ijUrC7DJUh+D06j2zU8ttR8zeiNiC20aRYoG1G41aRQCLexTDOSPXqBgDnoOlXZmvbCZ7bTtJSNZIQZIrm4R2SPnngcL0HLdvqalhtv7PggNjqVnFFKNy/2ha27Pt7Z2EEk+5/lWDe6lJDrEghu7O8vJQoZbMjai5JxlSM8nJA496lxuWnYnuNemdrqGC8ntJmCROyRbCEx/s8Fjkgfnmtix1QR3L2SvLGIgEWH7SJAwx8p+7wOOeT09a4e2sJ57m5uA85uJyDteJtsh/ukkDHbB6dPWtfTdQSJvO1CS9WJX8m4traMgoe2SQfyBOQeDxipaRRvXqWcdq4u3+1n/AFiwSA4DekeDxz0GazA+q6RbRPbXUckMq7XivHZtp65DZyBnI71dGueE1UzLLbKq4IjlJaViOhw3K/QVXutctDbteiC8hh4KPcMFST6DnP0NTZoq6ZzOp3S38tppUabfPulDqCXTG/JKn9K9WshiNug3MAAOwxxXkvhS4m1HxravcAIBE8qoE4zjGOfTJPHevZbCBUCscEPIQcegP/1qqStZCi7s3LGMoQuTgjkVoZySAwwF4qtbqA5zySvT8KshcnPTg1mzQu2a4gBPVualDZ5x0qFG+aJRwCtWCo8sjB+tSBH05OT6VahHyAt1NQY6AZqXHyZFCBk42gGglSpP5VVeXZEBu5zSxOX4p3Fyjwu/cKaqkEqBU8CkZA6HvUqxkOeaLA2V2UgYOOamtk6AdqJVUnJFWIcIoOPemhN6EY6nnvUcy8/L1p24E4zioyQHJpEoglDBgV69KWA7gQ1SKu8MW4qBhsUgdzSK3JI22koeQRTVYb+cEA1X3HzAT9KeyyB1MY+XvU3KsTOCrZToe1R7sx7e9TDAbJpgHznj5TVElW5G5RnvWd0ljJ9SK05wTESM/LzxWXlmyoIAzuGfWgpDpIsIRxlaz9uEaM8lchc9fXBrTkYkRHjLcGqd/Gyudo781SEeN/FTTFXWbG9EIdJlMD/NtAzkqSR6Guee/FpcBtQVXMiCGUxAMFwPvBRjLYB5J6nNem/ErSotT0eeAqDlN654wwORXnmg3tra3VlDp9o88KxjdJHEG3OCCBuxxgZ/OrTuiVudDZatcSL5dlbG0tvL2m4n8wyY9iUKqB9Me9WkjtIszvbzzaZt2uLifzY2A/jDg4GT6gDntVSfxG0a3EX9nXdtAq73lEbsQBzxjgfjXO6v4sRlmisTDeCVQJ4ponw+RwT1Gfekk2DaWp1Ni1hCsd3i2l08gl4ZohvtznBzkHdjj8hir1pp+i6wIbnTNNDO+SrwOI+mc5yNvXHBB6152mqzWdyTaSzRKYvLZXiYrGB0+bJ4IzyQCK6PR9avYJZ77RdW00yXLZuLFRgP6GMkEqx9xyarltuS5Xeh08xurWJrG/0izmEmZDJH+6baMHlVGS2ecjAbHBHSuf8AEOm2SW0U+mXaz3G7BaeMIsi54jfb8jdOOc+5JrTvfEaPBGLy21mO4LR7kkl5yCPuOigA544I61j3eqW7t5dk96s0kmF09I0lluJe5I+bYM9STk4zVK5LsMnv7K7ksbDQ9Lgs7m7KxTSlBMmNwAdV6k9Rgj+VVvEXgWDQNesV07VJ7XzEG0XMDDEg7EYxg++O/NV7bTTB9t+0pe2Wpo5VwJ4tpGBgEOcOBnsakTUtd0YWqXbRNDvWJCVSZXRsgZI5wMcAH2HvojORl60t1JBNaS6fplhPbuC1xaFojcbycMFPJAAO7pgde1ZVouqaLDFcWewWsjCRCjJMM+jHtn05roFsp7yEXN7qsSwtKP8AWBlSGTP3CeSnsTx9KjsdEvYlW1tbdPtiSFvJZ92JBw6qckAnGenI9Rg1bISuzH1i7S5sZ54Ilhifa6LI3mEEYBZT69R3x6DtNBG9xqcGlzultMyIROjDYAUDZOOgIYbvxFatnbtqketW0NxLBMSzSxTRqHdwuWR1PXBBOQe3euMJmhDQ3C+XPbkGJxxIDj7ue4oQnpqarGfTv7PgvodkI3Kk8Xy7lJ45HXHOAaz9SlDW8Vvsz5R3cg5IJ+8T+IH4Uya8E1ndljJIWIcAn/VkHg/jk/jUc8rzTRwsxeVYkiGTyxY9OPT/AOvVWIubenpcTX9jaxMzRpIgVCSCQxOSATjJx19sVb8V6ljxHcQ6Nd/uIkA3ZwqZXBVScAjk9sfWs97q3hu5pL+LzRCFijWP7hl5HPtjkgdz71Q1dDZPFFcyRzXPlBnXZjymJztP5/nU21uW5aWNRZ7i9sSjbILJGZmlfO6Z2A445JJ7nt3xmt+fUItDtoozdaXeXeww26pAJIYeoLDn75Pcj3BxVTQrO21HTPsy38ZuWxKQzKXQKMEAMQqLkjLseg6EA1XTRpfMWWGP5pZxGJRKsgAOeWkX5BkAkkdvxptO12CeuhY0I6gLoTaVDP5kcXl/aICoETMMZBPfAIyPc1rPqVxZm6gvzdxQW5yqR3DMpkY/fdwDlifoc+lZ91YyPdXUunOlxp1rIkcs0aMikk58uMZDHPop5BzkVfn0e2trGKbUfEIWCViyWqFlKpjogzncc7RlSec5rPRmi0DStHS5mR7e0neRVBmlkhBWDIzwGYk8Z+Y+vStZNT0mz0i/ttF+1+ZswJLW2JMpP8W7aCcHqSawp4ZbuN4otOS309Tn7IVd3AI+V3fP3j2Wrsmg69qKRzw2Vvp0MLCEJudWUdMZJ9OvHGDk56RKxaujqV161s9IMMdg0H2jAjZpfMmnz1LBQ3Pt2FcBq8GpNbRajBdWVkYlMQhecl22scDbjnHHByB7V1sdjf6Npki6pq9wskHCpBcohJP3UU7d5PYDPNLpmjsk1uNUhaSZRvlnnuPMaLdkgYcY656c8VOz0KXmcTJq2tXV6VuLQf2jLh/NBBicnnACghc47EVj6vb3z3AbU3t7DecBIxvX8gTz716fqemRW0oklvZZbB1KKnnKvkt14bjIPPB6Vx+pXOmLfWaW0T3Cq2JXndnRt3GN3IPWhT1ukDirbjvhdptwni24a7X95FbBVw+QoZh+XTpXtGNgQY+4cflXmfw1g8jWtXCIiozogCdAFycV6eQBJzkDr6Upu7Kpx5dDZRszptxtP61b+YuFHQ9qpwLtmXDY2jODVuHcbhpM5/GszUsoM3GSOFFWyW2DnINVYurFurd6sb8Hj0qRMAfmBOAKcSCeOlRqST6g1KF+lJAQzqGIUfWnWygc++KcyHdu709FGACcVQE6k7844x2qZRhcmqaS4OOvpUgZhn1NFwauPY5BAHTvUrtgqB1qtE+4kd6eGIk5oE0Nz8x70wE7zkVLEASx9KQoS+aQkNfGDioHKlMZ+bNTSjamRVFQVkw1JlIsFQV47U4MQuQOtIoIPqKeoJJOOKAGBcqSvJ702PI3E8jFPTuoPJqNTy6t1FADScoR6is6OP8AelW7c1fzhTnrVaZQsqEggNwTRcCvIpEZOOhzx6U29UOG3A/Mo7VK+RE4U8+mO1R3bg2mcEk45HWqQM5nW4S6GP8AhPG4V4zpsy6brtxZT3cNv9kndYwyliVOCPlzgk8V7jfLucDgF+n1ryDWLQ2/j6+kZR5NzbJIFwvzkDBAyD/d6iqXmTrc25Zf7TgiS/uy8RIAhEqfvT744AGc45P5VoXVnpt1bPb2VnpuYwV87bu2sSBgEYLH15xWJaR20sTsdLMU6qGaN1Dh+R1J4APTjBq4tkupzII9NjSxJKIIHALHGDuA7DJ4HBNIrlKmita2DT2cupWogkk2GW4aNrfeRkj5uSfbPB6miLw1ot7pzQw3ltuikdJbgN87fMcbdpIx06AenrXT3ktjYaM0KWapDDu81mswQAOT0BGSPwrEfTtJtrNLy2ie0ZV3Sx24CkDOduMEnHHuMcelUmS1cy7Pw5dy3F3bXeoObi3QNHv+QSoAQGKuB05HbnHrUtnM2gXm/Q5bUyOoNxAIm8y4APPJx799vv3qS7t9Kt1N1JqVpMGykfLuXJKuAr4ZlbHGUANR2epX9493aiyvTbyyDedQJEiJ2w4G8D3zz+daeZn5HWaZf2+t/abmS6hniUrKkdsoZ4WZcYMbc5+XB6/1qjey2CXWnXGoWUQjdHWewGGRQ3AdVYDJz1x26cjnkdblvormykW9t7c7mglvoJFLYONqkgYUAdTkjn8Kr6VbXId/sl5cRxvNsdxD58qFDu5baMj5QwIA6jiqS6kO5Z8RWVpp1xczWM7PYXaKqhpw0qlm+VWXJLLgdwTyOO9c59pvNKez1aKST7CZfImSNl+Vv7jL/CwH4emK6ibw/Fq4vtUutQW9vUL73lVRLwM/dUgHAzjbnpjArz3Wmnsr64tzNFIshUsytlZFxhWB69K1ijKbZ217d6Xe3lyx+0yWs0bILy4YhzLktHIfRgG2tjOV5rjJ54LzTcDf9sDO5bORs42n64yO1VC032JGWYJbjKBT/wAtWxj5e+OnPQUsk7D7YkaKxnIVWXsBzwPTNVy2I5rkuvWSWs3nQSb7SQ5K56P6H1wO/rVdrua71mG9lJWd5BIWGPv54wOwzioizC1kOMqSpXc2cE8Ee5OPwxRJZuouCFJjTGcfwA9Cfr0qiC7cS+XphSRGFwJyPZdoH69fzqmJZJJI5JAZC0ilpHBO0noCfzNLFIDK0kQVxCd+2YZHbAPrz2ouZZ5BtklMaq5Ypng5Ax8v0FKw27mxp1tNdStAk5ghmysjeYF8xAQQGP8AdyAcHuBV9vKPl28bC3jU+WkjkBNvBdzjknoAMdqwrW9lwZAXWV1MbMMEbTxxx6ZqVpRPCZHuHMm8b953My9OSfw4A55pNdyk+xuW+tWlrNE4SadYJGZIY5CIeeBuznJx789DnpVqyv5rjXPtKYvLkRAxPc7SlsOoUD7pCnuMZ6YA4rKgaAs1vDPttivzt9ny3J+6ijIUn1B6d66/T9HhjljlfT76Oz4Ecu9IGkJx13MQFHv+VQ2kaxTZpafcRW0ayXl09y8zsXmjmcySOevbKAY42p7ZArQj1rR1kiiuhfThVKLGszvEh6bCMk5bp8wB57CsK91H7Bfyppkvl+Wco/2oOM4z/rNgB6jp+YqnJY+ItevbfT5Ls+UR5pfaqlVI5JbknqeMZ/pk13Numho6nZzT3JupLe0heAqlpYoBIVPXLHI4GeueDnFZYvI7h/sptUn1AyFXdLti/PcFQcL2z7Vbl8CwafIIna6v55TlJo2JTd33j73A789ulahtJ9LMd5p4lu3jDMwvEG51xzg/e4x69ulQ2ikmYp8Kx3NvdRvazCYDzEkkYrGCOwUks3Tq2MjpisfVY0RBA9q8CQqEkaGYsAGzyoPbHNdzHfx31lKzpEJT86qW5247H0rkNORG067m1D955HCBzzt5K++DmpTZpZWNz4T28xF5MgleBCTLKFztGcKWxwM/1r1SMB7pgAcYGQ3bgV5t8NIzDpg8psRyp5jAHAOT6enPFemWcnmMZSv3vmz6inJkxNCKT94wIHIBFWrcYmcA9sdKpqGNwvHUDj1rQiXYDIeMGsyyZF6LnPapW4AxxzTFGdp/GrCKGwp5yM5qRDkUBuDketPnQEYU9R1zSIo+8PpTtuML3p9AG/dCr3xkn1pGGcqOtG3c+DxSldr5FFxgiBDk/lSlskn2ppBBIPTNRzSYT5W/Ci4ySIEP7ZqZyNy8ZOarW8hYcVYIAYZoQmtRR8sjCl3YHFQSPhznrmlR8uAaGxJEyHcjBuRVOWL5s9qtHgcHg0yQce5pNghIhzwRTmJA9KbEoUkNTnztYDvQgEAGCe9VhgStnvUillUgjn1qAgk5PFJsEhJASG7Go7gAome3FCuWV8nlaSdS0C44Yck0IZFKQSTnlx0FQL81uynoD1p6SHOT24BprnZGuO5INUDRi6kfKnt34wJOTj1FeZ+M7hLDxLpl3NxFh4XZQWKgHPbtzXp2sRlghU4JevIvixHHB/ZtxJkxvNmRd3cAg/yq4q7sTtqZmqak0kqzwja875jiBwZUzyz+g9uO1dNY6iot5Zb6a4TegLhU2R5HG1Txx04BP41w+jWsd9K1zHHshMuxeAu8DnGO3TP1rvdPdHjLSwW0SD/VzSJvYkHsD91vxqmrGqXMiF9UupUgVLa6i0xTvkDMC8gHICjrt6Eg8nH56+ppb6h9kuyLiSUZ8sospD+xVcAH3J/SrdiJbxglpOpmGG/eRgJt9DjBA9+aztNu7y2S/kXRyIw+1zFcqmAO3OCOvX0oSJlG2nUWC1ttN8+5sbYwwMcvJL5YlDkfdIYnaTz90ge3ep1gtJB9pntYZCE2pC05OV6Y2KMN9AffrWfdR6/NulNqbe3ZiI4ftgJdcZIeXbnB7AYzjrUNnDf2odVSDTMgyFgk8cgPrlOOPfPTpVpK+pnbQyb7TLO2k87RJJLZz96xLM6SAnqu4ZU9sEEf1x4b/ULPVJZrDWhY3ZUDy7xNjOAo+RuCPYE+naul1LTdTureF727lvBJHhZZ0kaMnt84w2emWIx9axTZwXEdza63O6Xlo21oppmBCgHGw4DEHOMAn6VrExqeRl6ow1q7kvbt/KuEk/fFX3vkD5gVwASBk8DkZrlZRDJsFzMXWCNkACY6HjJzyMk++K0ru0tTZPJHK/nrtkVGGSeSCccbgMdRj3rMuLiSPdBNbCFzD5ZAGOQckj6j61ojmn5laGVsyOZQzMoQgHt0xtx268U5GVzbbsDdmJ9vXHY+3/1qQhGmCxzmOCRQAZlIweCc7Qc85wfT0qEHaQY2DHqpHY1TM0WZmKWoiWVWiDBxz8xPIwfpUkGqzW89vLGRN5cLRGKRcoY2JLLj0OW/PNNW6gbTjD9nVXAUrJs/iBbPPuCB+A9KpAEJG+Am7JHv2NA2yaXYZDdwgRxByFjJyR1xz/F79+RTVkMefNUMsm1yD6c9D/ntQrvBKssDshjO9COox3psoYTMJSpYncxXjPfj65piLkCs80EUZACKcOxIByc7sf0rc0NYTNIQJrmQOojt4IS+dvJY81iW6briMSTCDzlLv5QOUX+EY+nQA85Ga1NMtfNtQUfyo0ByiyMpkz/CcHkkdgO9RI1hqbK3lyY43iRorZWXCoUDu54zjr69BXVaTYQyNOmrPcQQyqX23AZiF/uhRnr1JP0rP0C2uksPtcbrpkUbtg2sAaV8jGAzDjjI5JPNaeoaeLWSKbVpJLlHA8tJZW89jnoBnGPXGPwFZNnRFMmu7/Q4LTZDK0e0r5fmQeVGxB5YKo7cclTmq+ianpryXEv2iGS/3HLOqiMp/shyCenIAzn8KY95bRXCiJ5tOnmXbIbhGZjk87Tg4GDjA9ulaj+HtCuY4YYbm0+3qm5AInQs2fvbW+Y8981NjRDYL5jDJcWylyxEcXnSCMIR35YMMn146VSTW7qK4WU6fNcorZJifcCGHJGQM4INWNS0eBbsx2lpJbzGMNLJC4kUn0IkPTr71Vu4n02KKCezFhJJII/tFsgSKYHkbgSRn1Gfoaza1NTL8RahbFYy1vcxoNxRgu1o+DkblyMe36VyOo6gbeERrPHJuhEZ3cAgZwcflXoZ+yIs0LLGJ2+V9rdeo3D1HJrg/FkNpBZ+TGipcNIoIx2z1X0z7UU7N2JrXUW0ej+Dk8u1to0B8pI1DY79CVr0mBlYkAhie49K4PwtCUS0jAKkQgEHqSRnNdpYrhQMkjpn8ah7jRs7/LeMjHAPNXmbdaqCMepqiQocZAxjmrCszRAdx6+lSxlyI4iA4PpipgdoGOtVYGAQ46KOamDFlycioCxbSTggDrTpTuIwcetQ4IiXaOe9O3BlGc+9O/QBykqxJGaDIOOaTGXzn5aNvI9aEAbiTjueKhmBjGOOanYEY4qK5ywA44pPQpDLcEHNWASW5NNVAqKV59aWLLNyMAVSE9RXXc5I65phUh+nWphwSR60pO4jNDJQyNeDzQyk9OlOzjgimluCKl2GBJHTrS7sxkEc0dQM96YSUfA57UgAk9sEjtUQ25yw6VZ2hRkdT1qDoTjpmmxFdsLuIHHU0wnfETkelSSI27g4HcVVkJ2NxxmhDGFCsuwfWopAec84z0qTkzM3Q7Rk1C0myIpj5j82T1qgZn6iN2zk9c/TmvJ/jEka6VbiT7qXa4GcYBB/SvXNRXcjH+6m7FeX/FBIzpEvnYLRNFICTwSD0P51cN0S9UYemadHFZQzIcTMQM5I3E8AkfSrl/EdPkjlaTIdh5hLA4PbA6Z4x+NZvh3UVltEQ/K0YBO8Y49QPT/69a+q28F08aEhGABRWHyZzkYxyP8A9VO3c7aUtkjdsdYWeSUwOtvlchWwuWA4G7sCe+Kh0+9jS6lbVYwSGWQxRNuUOFGSw6n64xx61hx2s8rhrWG3jgT5GiTJlZupyxBGeeDjpitprf7Jp5FsNQsbucHE1vl5F6/IQeoOAScVolczqqzNiSV9RJ+z3dnewgbvKlkEMi85UZXrjGeQD05qrL4inRWWO8s3vYgFdZh8xPZeWwxOD8yk1QgtoVj84Xs82oEHzneZmZ/QRlRh+D07egrI1W11q8neO7vbp9Oi2sY3kE0aDsxU9AOCSG49KpWOaSHXfirS72AxWOYL0sSY5UCqDn5yd3y469MZ461a1vStLRtPimb7GlwfKku47hJVf5d4CkDC8j0ByawXgguXjuNSmn09AGhF1AwMc0owOQQNqsueehHBpV067EJt5L6bzTJ+5m3CaFuMrgEYByBz7itLpGSi2yS/MKaWNO1YRahaFmMdwIwZIAH+YK3GWAwdo7GvOtdhjjv5ra2maaCJmZHlUqSvbrz+lel2tnHFJcRTRz/2hP8AvrRXcO/nLj92zNjAJBGeCQcHtnhvEyG+DagsoaTzWgIbILdy31ycGqTMqsdDnmHmwglztyWwfzqIhfLHTOCcjPXtV1U/0WPccQy5IyM4xxx+tVY0LSCNXwG4DHgY5/rVo5miUK2MxspTaUP+zkZ5+v8ASgxg26OJCNvQe5xn+Yp8zpvVIgywvGoZGPXGMn8wfzq1pkqtexu7cIQpWNcLjjj+maAEltyIJG2NE4Cr5a/dyB3/AAGT2yc1FHZrdiVI7qMTLB5qKVOHwMmMH+9j88VpIFVmhmw8nK9Dljzxn8cVnzQGylt3H3925T0I/wD15FK43GyK9o6+exwxIjG0k9+n/wBeu28DRsn2kwxPLdphRIwDKikdhz6fU1y1/Ytp/wBj1CEr9nvY2ZFRgTG2SrD8CDg12Hhea6MMWkWqy+fLJuMTNtDM2ApbHLdDxzwDxSkaUdWdUymcQyatqLypAQws4f3Ch8/KAy5LNjB44yR1xmpY/sj3iJosjXV/cSMVmYEi3UegPMr9Tgk9cnFVLCWGUgwxW1rBHI1pBcFQSwHEk4Uj53bkA4wo+tWbS1t475YoYpl2AyJLAvlzyO27HzsRgYx0474rJpI7Yxub2jtfA3iW8KzW5+W4lniEjBgehO4AHnkAHAwMZ5qQJGUnsdRMFwXxLHHAhuGCgf3myevPIBXHXGKjKywvawQafY2bRoS8A3tuU9dzsQu7JySM5quI7m4vIraMyMY5A+baRSkIPViCuDjJ4J55wKTNFC6uS3NotvbtcHy3imGQu9swjGcgk8g49OD0rL1qaz1TTpLSaXzEmTACfezjIJB/+tV2KK6gupob17O4ghk8p3EYjl74f0IHAI4rB1s6c0qSWigPGTIzRcHb0YAj6njNZSQRRj2qyW6RLc4aVh5SbYw0mfQkjGOBzjuK47W7Z38QQxvMwaSUH5yWAA5z9OK6vXbuFbmKVJpYSIwiYY52g/r6/hXKW08V94i0tS++FVYHOTgEnIJrSmrO5hXenL6Hsfh25ik+xTbiFkjU5P48fyFdhZyLslUjAVsj3zXE+G7cQ6dFbkgtDkbx3AY4rs7dAtuCudvAH0rnlubRNeEsZUDcnGWBq3ApJ5ICgGqMLFijYz2z6VfjO1XyTnPIpMpD7I5lwOvcVajYGZ1zu9uwqvAp84lQAMA5qSBgZGLcE96gHqXi+FIGM4pyj91g8+9RRg8knOKc4O3IPHTilfqTYkU4AAPSkkc5BqEN8uBndnmnL8yYxTuOxZQB1OTxioplZh7DvU0ZAwDUUz4JHQUwW4R48ulBJYY6ZqMEKuD0NWFAUA0AQtu3HH3c1KoOabnkjpzT8EDPagQ2YhSKjY5GRSyqSM1HsKjnmle4FlQGjyelROcygA8daVgPJ4PFQ5KnPAHakwRbPI64qArzgc4Pek807FHen7iG5HbrQFiAn5zkfhVKUEKcHIJ5FWpyzbmGAPrVRy3kHg/Wmhoi3gseew/GqV8TuRV6kE59hVsbT5b5781TvyDenk4UYA9qpB1IiQ7kZO0pz9a8t+KLZ0C4bK/K0bHPf5wMfrXpd7J5eNwAA4615l8SkMmg3yIBmNVfcx44YH/H86uG6JlszD0i2V4YL1S7y+XyGPBHcY/Wta2l82SOP+FBtUOp+bHP/wBaue8OXkTWsIlt5I2jQBio3Kc9DxXbWV5aXWnO9vMB5LYLMcHrg+4p211OqlNJJlKe2ZL2GSJolcr5p2PyOemR1rf0e4k1CVDfPtaIM4jbglcZ2nPOM+lUbmRJbmKMv+5hGVcpwTjPP8qo6+s7XFgYWST+EIx4X/aB4Pfp7j61SdndFVajqWTNIadfx2ZkN3ZgkkT2cdqFWQ98FicH/axz39lU6Vp80rXep3F1JBjzreRiGic44ZQAB9fTmpbCwjspUuJbW4uZd3mTYl3NtHfYOMZ2jtgetaWh29nrtvPceelrK7EPJHKPMOTyGGeTjjp0/Ot4nDJmbrFlp8SyQQohEql4/s9wMB8cq2eoPykfT2rOlthpTFbmVYp4ojhVUCz1Hn51IH3ZAOoz1HccVf8AE2hzw6ZcxSmW5tbZRKsLTYlcLznHbHoePeqnhwX91oTIFTUrGEHyo7hmPlseSwboDyOvv1zSejGldGJ4l0u6s0fUrJJWsZtu0zNuTkDCkHJzg8c/yrmL6F7CyvXCRzQXYMKyFCT5isBkd1P1PI967G/E0OkvDqEEy2iMYTGsofyz1Q56Dk4ArmoWa9sY7As5WGTzWldjsLk4C47dc5+nrTW5lM5BxHE/2UsyL5xClwcAf05xVOBHgEkUobcMqqY4LZxWtryCSS4i3uf3m/zJV2sdowSQee2cn1rKCSPcBiWG4fNI2eM8jJPetUcc9y5odgL69eK4njtndltwZThVLA/OSf4QAc/pWomn2lvJcRaZK80AkQtO6bd6c/Mo644zzzzzWbDbSvCpbMiu5LsRnjkDn05/MVp+FbQXs81tMkzCJQxKybDgD0PUDJNJsuEdSVrMXDySqG2KFk8roWHTr9azr6S3uNRzF5gAIx52PlJIA+Ye3PPpVu9vDcXNy8carDsCxuCf3ar0Xj8KzoyhR41jY75EKDOcsOMH2welHUcloR6L9jE93BqLsqFTsCoxXfxyMfdPfoR2OOo6C1ubjT7+e5kd5CY5FieIEbpGJCHcOeCfb0qvb2bCBTbRQ75BLGjAZ56gnPfiui8P6S+oR3t40hWxtLeNtuTlmOTuHTjhufYUNhCNmdPoul6ZbJa299qTu0ECJOZWw0GclVTIOB6/XNXzcw2uoSyaWGkYWxVJ5E4kOWJ+Zye2BkAdPzveHNJj+wTxzRs3JlJndtn3cDcQQAwGPypdS0/y7+0MjwqjoTFJbjckbdQ0gzz6DAB/pk7tXO6FtmXLFLyeO2fVbiNZJl8yS3s1aNlOPvFskn3HHtTGjtXUhJ4LJQPlkhYCQ+pz0Az1JyfpWVcafcXMizX6mJ9wDBG2K4POXxymMZ2r6c5PIpaa80F81lZyxokqmOJSw2zAHBC8cE+ue/Q0maxhdNiavbXVl5t9PLLdWsmQVV+VP8LHJ5P045rAnKR7pLaWe4sygj2yv80LnkryOhHrXU65GbTT1tLO1NqdhCwkM20L1IPcgng15/KjxO7X6SlpcKyNJnzCcjJA4HIzioaEnocxrYdLsSEOXDsMtwQMdx05/oar+H1/4qRI4vmOzbwwAJOM/wBavaykSaU8jf6xmwpyeTnkY/Gs/wAGwl9bc/NkISSBnaD1J/Cto/Czz6n8RI9q0K7WUoLdAjSRltjjleOOPfmux09maycOMEqrY6/lXC+HzIQtnl2mQIkj4+6AME59wK7axyIWJ/u/Ko7D/OK45bncuhpWTfuSSPmUnP41cSYsFLYOOCKz7Nt0TgH7w/WrAb5SwPOR+NSaW1NCCUncP+A/hUpIVhjPFU7VjuYDhauwt5u84yAMH2qQehbUkKD6inkfL1GTUYwUAXnilgZ9vTnvSMyQBUUljmpIsGHpzVdgdvIPJpxJxhe3NGwy1t+Uep5psuQuT0FRK7Fh6U52JBU07hYaxXK+lSM+WQZyMiq5AwSM59KevDKPegGiwTyaTzAKheTDMOuDUSvlvrSbEkWwwIIqOT5VyTxmkTIPrTJ2x1oAk8xfLwKjcjarVHnK07I20bjtYdICVVuw7VIzZj5PNNX/AFeD07VBM2xc9jxS2FuG4GMnOBUfL2wP4mms22AgH73emk/u1wTjvTQ7FK4ypAA78YqC/TYNzMfMzk1dmBXYTgiql+2Yw/XdxxVIDJ1Agqpx15Oa89+Ik/2fTbmRXGSgMgwCCM4IweDwa9B1QeWwYgkFQRXm3xGQSaHfjlpFgLFcdCHH9MmtIL3jOb0bOYskeWCGaBY5ECK6ENu4A+YbR378+laMDJ5pWaNJpHfJUhfl4Bz7DmsDTCy2NnLaDYpjYSAZOSCRjHrV/Sp5JHTco3RIUbjllYggn35A/CrlE0pzeh1VskTTfu0khdIzvbdsG48fQ1dhNxZXssN7b/ammRPs8xzsVMc5PRTnPNMsFi+zFpVPnrg4C5JNbUN7M0kUQgCTbCrZfgrj24Gfxoigm2QxWsslvFJejyoesDtOVZ2zgZwMMQMcHIPFZ82kW1vMwSFbedlx5xjVbYvnjzR/CT0DDA56jOK1b3UbrT9R5i0xIY03CKV3DNxyFYcAZ7YNNm1u4WFDPa2jNIuGkjzOskWPu+XwRkEdcVsrGSuO0qxtFSKeLSLy9jmxujjIOQvLMgySQAD1456ZrK1DVLHTr11sd7WUmZjbxAojED5G55Dr3PcqM9aq6Za3bNKYodQeON/KUOPJEUZ+8NinOO525z371ev1tXgtJL6FbtkYx2yWmGC7VIyB1AyR9e/Sq1KuULu8m1jT9Pjb7OYJHZJXZ90jyKuGLDHynqfb8awfFFlbaVJLp1jcxOhjV2IGSxAIIBx7j8RW1f2UFrZtfBJRqwnaVUYECXPVSR169cg/WqN3pqSnT7i9uxEjRktGWLmFT257cH17VN9SJLQ5K9NvqHmXd9ex/aoEEUMakK9wwX5c9Qu0D7x+9gDrzWakLTKjeQtvEu2Fgmcs20tkgnj7wrc1vw8NOaydC2biP9+sij5WydxHtgjj61QtIp3ngadWE00+4KBn5SSoyPyx7Vqmcbg7kKmaz1drcllChdwALADcBwPpXYeDNJMsN+SGWJ1/fHdtJ4J25+hHArN1HRVsdUuInv0utXjVCRauJYUHUKZMncf9kDj1zXaeGopZJ2hubYq8sSuxIyDyCDn355qZbm9KJxfjHT/sE0pCFIwVZdo4bHy4P6Vz+l2VxvBmRVVHBwzYYZ9P1r1HxXYRXKLbb1Pk8yqxBGe2D9Cc1yETQzpHGmMmUSNnnOM9DjjHP50dCpxV7ly0gD6hY6dIPMb5plEQIO9hwAfY/wAq2/CGiyRapeQq7IgRRKkh3Fg3P3RnB/rVjR2RdTmupNymPYkcYUZb+I/gcfpXWaZZxL/ad6kSxpcTC3d26eW3JHHPv+PtRYWxa0/T7qa1iREWPT4lWQKzB2lOOOeeD6ewrdudP0p9PdobGBJI2850ePDyNjBzkcHrz71HbzW73VtaWPzOsCs6KzfIP7pbpuxzj86tXF9A01wss8cDJhsSDJ5457FT0xS0RtHUoyS2T3NulrKGZlV0Rn+bYPmCEfh9a5/xfZWl9ZxEQRSmyYSKZgVUJkbhx9QARyCParVnPE19fWySo5tgu0x4BU/NuBB5xyD69OcVm3kE94z3FzMzSQgl4YgcMuM7j+fI74NTfQ02Oftb37dukgNxPEG8spK7PNBjnaBg5UHnk5PviuV8TvNHdJNDbyRqF2RyHICSb8h8HnIrq9Qs7qytvMguARPGzx+Vz5bKN24r/ECeo/GuS1q6a4jMrXheJSI4wecE/efHvzU26kz00TOS1UmOEtv/AHjyNJu4wN3UAenJqr4TOL24ydzMuFUEgv6jPpjOag1QyPeeSMO5IUHOccfoevSr/gv9zqEwKMy+X5hKjPC/McnsMCt7Wgzzr3qo9U8LLMY3t4HKQJIBcMBgswA+76dcn9K7iwlV7aQZ+5z9a4/wSzR6cgnCruJmc/7Tc/yxXUWCkRkBf3TttCkc/WuCW56UTZ0/b5BLAgHABPrVoxtkwgggDiq1ip8vy2fKoeSauRsrzSCNsggc1JpcmtzGjgRI2QuG3evqKtQMwQ9g1UlUncwHKnHHpT1uAke3HHrUsLXL1vJ5cbgjjNTwtvQkGqikrGM5AYZ+tTxcRhQeRzmpE0So/BUn8KcrEgAZGepNIgGCTipYjubBPBpiFKhWGTnHTFOP3gSODSSKR2B96N3HPU9KBCMQCcfdpUwNp96Yo4bcDT4wWAz0zTEUZZNsjbjxmpbdlcZFRTxZlYkd6mgRQcDioL6FogjGOtR3OCoPenOCGBzxSON/HpTIIumMUdRQR82M9KXIAIpjHk4j+b8KZIMx4IyDSu27bkjjikzldo4FAiuE3Dy1GAOc0yJgY3U/eJ4NPlws2NxwRVeJtrsAcEdKCtyK5LZOAeMDNVtQdfIRc/Nxj86uSthV3Zzms7UW3oMDbsGcnnNWiTMviWeROmFJHtXnPxAbGj3gEmB5XzsB91WIz7nvXe3T7ZpjIeCoFedfEWTy/Dmp7SMNGiAkdTuGR/n0rSGskZ1NIs8+s3ntbf7NbSkuCwYIckLyMj3Pat21DW0ish3rIoyrdcAng+/P6Vy1rdNutm3qQCFIxz6/4/nW/Z+c7TmykJGc7MDgk8Accdc1vOOpnRmdZa6qtvdMsYjuA/3olY8Dpy3t/wDqrUttQiW2jazgW6RnGNsrbkym08kcHngk8Gua0S13MrbVkmTDOwf5QRn175JOK2WMU9zBbOwjiIBZl/hUcMeP+A8e9StDpequzattQnnube4u9Nhwn7q2lnxvb6EcKSe9dVHBDFbP9ps44HwZFlEoAyByqEEjr/MVjaT5K3NvZANLdBSy71AVF3c/Me3NdYpFnBDHbvHMIsMkQXCIg7r/AIVrHYza2Rz9+9tAIDZafeQp5Wy5mLY3qTkkAnG4dcnHXHQ1kWUd3rF1bTJIbe100u1vb3TKpk8w/M6gDJDDpySMda7HVGW4YQ6e0F5tJDxlcr07noDzTH063vUhubq1jeRVJTyn2YGcYUdDg8nNNpj0SMyFZEj82exDWaJ+7UDKhlPzFs8Zx79a5u00EXF3HbW6iZPPdrUfeURgc/OeTjI46V1U2m3SQyWcNv8AaVZQ8itcFWIz/db5SBx0waZpI8zVIjDIYYYgAFPyEP3ZAe3f0OPrRa+5nJ2TPL/HanUNVjWIeZMi+UwkO0bsHv8AxVLBYeclu3keZJcmJUcj5vk25PXj7pP/AAKt3xlpfleI5NIu0SOUEEvF8wYsu4Y7BiMde/FWrKBk06x2p9nMbfdDE5PQgjt3p6mKs9Uc3oVtYah8QdYtLqPaXjWWNemGHb+XFdlaWqxXdg7W4iLI8YO3GGBzg/4VyGl2Fxd+Mrq5iKw3aTgopGcKq8HNdJJqU76urruZbaEySoDgE55YA0PY0hvY1vEWnQalYTxSgw3cO6TaThXwM5Fed6bF5d5DHIrYywjRMEMw/h+mD+tejazeiTww893GsZKsFzyR/dA9+ea5XSNIWQpPcgi5KqLdVb7jKM44/ipM0lqaOigXOtlLxhK8zBpABtEewY2jj1OK7S33R6dNNbxoQrNNOxU7A4GNuB6fLXDiK4trxWA2B2Z+Bk7Tk49jnP513OnGy/4R1jAt07O+C7ODvYEE8fwjAx+dNMxkrWL2lvD9kjXyxHIg/wBTCnLEnlj6c5OPeql5dtFqENtc2KS5BkSQ/eyBxuA6AEg011tbglI7mVGmfewjfaNwJ6e2KdawKmp75oU80IyieM5LnIIBB/E/nSv0NYvuNvorNdNZrSXfqmXkTGDIzN1DDuvt2HfvXKx6nc210lvqMIsXOFMZO0PhsllPQrwePc+ldlqcoWyKgwNfW8RImtnwwbnIH+Fcn4v3avYxxOElCQZSfcAVkUAk4PA79DzUyLi/I47xHdLHa3bFi1vENqqx+8jfddfw6DpxXDa9cFtOikkLxTO6tjJ+Qen1x3rofEV1cSJDCtizXFsily+CrKMbQQTn/Irg9e1CW4KQyReUIS21Q24jPb8MdqIRuYV6lkZs07PIG4IVsj1bPqa6Lwmiq91cIkotC5RELAlvRSfp1NcyygsFUktjHy85PtXbeFkDaTaJEQHeYnpnnn+grSppE5KC5qh6JoMTRPaC6fKxrwAOFbbx9frXX20haQEE8HIyK5bToppCmy5cn7mFjA554Gc9q6G0OU27izqxJBwMVwM9RG3ajEjdg4q3CDHEW5I3c5qK3OJE8zjjI9qcsuY5Yz0bp7VJoTly0qfNtyMmpIwpd0xnPI9KrR5DIZBkj8yKnEuwgxgcipZRegKk+W53YGBVgOAQiEYx3rLXMbebzVmOYld5GQT+FTcTiaEWTxnPFOjJWUbxketVrdwQzKefSpoecsRz6UEtWJ2ky3TihgzdBUbNluelSo+2PoaESOUcBc808fKFBPeoYjgknmnli7Bc96q4rBKoZ2OBUYQBuBUrYDH61G+Q4Gc0mNCMTuwaVmKv7UjEhxzT3+VSWGc0gIiQfzpjEKCetNDhnI6VE7Ym25yD2oHYcGy4x3okldW2gc9ajkysyinSODIVySTQOxChYsznlhVdiVlGDyeakydzKM1UDuz8Dp0qkMkuHdlYkkgYBPoKoX0vA5wCMfhV1iruq9MDJA71QvAM4dgOMKAP0qyGYuqSYCjHyyZYH9K8++J0TN4au9qEKGALEehz+ea7zVEO+QDjagwa4/4kATeG/JLBN4O+QnAOSMFsenJzWlP4kY1NYs8YtwHhVgvAwHPp6VtwC3tb6zSXPlM2S+eQMY6/jWLaO0RljVgqSDGT0IHIq7HNG8Y8xdybASc/dPcj36V2SWpxQdkd7oRVZGgBK8P91QJMDGATjoQRyME11lpFG1tA8KqVgf51KcKh4fOepx/KvOfDcz/2xbFGDwlwpIOCygYH6mvQ4FElkUWSWNWd0ZYcbmHcnP4dPaskjui+aNzVtvJeNbe6hCfZAYw6ud6xyA7RxyegGP0ro/tVzZwwyeWs6QKBJNFxs9GZR09SelcyzPc6rpl1Ht+zxzKpfPMisDy3XgHHPvXTaQpn1K+jtpBYyI/lSFBlnIGcnPB/D2qlfcNSxdQBRE9hL50EuXlhRRmZj0ww6cenFP8ANkt7lpYrKK2lddh3ciMheSSMjOP5dKqy2iWlj9tsyIQyknzQYzuOQMAc/jxUtis50O28oqY0OZy2TIx7kZPPvmm9QeiJdQgluUigmUMGIYXIYMpbHAAzx+PFZmo2lvI8cd0I0RiN0b5CqAOCCORjnj1phsfNuwJi+1MwmFJPlwfcdWBI+lS6pHbLExhkna3jHlxp5o3KOhLnuc9aa1M5yMSUzX0X2BnxEhUQs8a+YgDDOSevGMew79olWOSFLWQOv2ZmGQSAxzwc+h61OEkhuRKX8y8yFjAkzlB/eJ6fXr9av6jbQT2sV5CGUxoC43fKemB2zg5o0IijgPtKaH4pQTFiGKujJ1ZeVY+prW8RN5V9dTKd5BiRSD99SB1P0P6VkapqFqvjyFrpN5S22ooXI5yT/wDW+tXjdNdXzKqMM7uDyF+XCg0+mhpFe8dL4nnlksY0YL5SorMDxjj1/wAmqOjtGplhlkUB2yWX7ysMdRUe6a+aKGFz9kk+WSJh1b0+netax0uGKKKNI1KxHftddxYY6n884pMrZWKd/K8U0q28YE8OQx/gQsCBz9c8e9bWjf6JYxCVQiTrsEStkuw4Hb9O1ZWphJWWKIrHdSureUFAxjHI9hj8yan0mOSTbcwhUYE4eMFwvrhfegg6zSoIyhDO8ksYJkWQLlmPQ5xkAdj0xSpHE00cl5ev5oODAJfkAHTJXrUEKPqFvAb1Hbyh8nkrtDEdQW6ipns4bu3URx+X5XAkOFfI5BPYj69aVuxafcqakrFYmt3tbb94zSR5yAmT1A7ng5rkfEskV1aSW5LRsvOWHyMAM8HHI6cYHWu0+1xQRz28lqZZ1EeSFCqST97nsO/XFctfy3bi5WO1M0j8RO8g2bVHOT+J/Ck1cObld0eV63L9jFzb4h+0SyCRQu1lOMDIb+7xn8a8/u2H2qQuMkk4APf/AArsPF+pR3l0RFCkEFumcKB69MY7ZIxXESbmmZnHLZPFXBWOLEzu7CRl0zIpKlTwQcEHt/KvRPBsLrZWAj++GJGBwmCDk/nXDJGvlskYRgqbmLH7zbsfL9Aen1r0nw8FghWXc6IqFCoXqvBOfelWeg8LH3rnZWUkquyxNtlLh1bGRnPWt23XNxIAA5PzEoOvqaxNBMkbLcyL5UU0YUZGSRnqfyreWEM8cihQwbjHBrhPRRqeb5xDsclMAeoq1Fh3znDA8Z6GqMCkSDI27jjJ6VYdiCEK9OgB6+9I0RbkLbkJB4qRWVZAOqvxiqySh3VTnpjmn5BGeAVzj3qGUiaZ22spPH1psT7FUEnb3FNDlk+VOF606PBUgL83XIqSlsaFvL8wA5U96vxEc7TketZcI5A5x1q9GwClcEH1zSIkiVwCRySKkVjj/ZqFXUjBqaOVSAgAoRDJYAQMt0NIoAk5PFKh3Agnp2pdgOM9aoQsi7yRTMcjNTj5WOPWopAN/ShoBrjnrTJySMZqWXBxnj3qCQUMCNFyC2OTTBCDKGPWpYyQDmnBeMnrUjInUq+SetVZQBNu9PerM7YbOciqU4ImznI9KY0RPMRIwQ8Hg1XTO/Ge+BinnBnyygU0KuWO4ADnNWhvQMCOXdIM44ArNuTvnAU4wSauMcRqzZODnFZt8rODIpBYt9wVSIZlzMpRi5YsWAHtz3Ncl45iN9o9ygAU+W2OepHOB/nvXX3SfKxbDbVGQeATXOa/5culHehRjuztPXIPT8xWkNzGWx4XaZktbnapdkQPjrwCMt+A/Q57VPYASpOXBJEZlzjgqDyB+ZqCxWT7WkUfyuTsxkgsehH496nmEFpqxa1dmsy5CFgRhWHQ+4zj8K72earrU6DSZFaZEhUsZYiQirhlxjnPQV2+nXL6rLG9xPBbENtbeDwSAvUY4zjgdjXBaRNc2d8IJFCvG4Db2IKA/ex6g+1d8iwx6U9xCC0pbMnljK8fdfHbkDrWEtGehRd0d2+2PT3e4tYsR22f3Q2upGOg9Dxwe1XNFt9lkwktZAxPBkB3IhORyPr1P9Kx7KOa9dXjhja2VhIQZSm844I+nvg1slmFkki3MlvcZx5cb+YFA7MvXHPWrLTaNWaWSaRrZEaJQQd8rAg98qevrx0qrdy4vGQRW09y8LKkcSne2FJPy5xz3PU1i3t9BJKZnlnee2YIkUSko7H7xyO/Qc4rTSeAws8UJLTDaIgQrE+pYdMYqU76A9iC1fUNUtFgRYNPiClmEsuTJjk4UDknk5J/Op5rW3+yxLJEn2dW3SgrktzyQPpTbS6SOOBJDFLkZaQpjGD0VjgH15q1c3sEkLtahGmjB3yFT5cZ98cnPf8ApVLXUxk9dDMiEaFJVinmCSnbuTJK9MMTzgU2aC4hhlgWOFYJSZA4bIGcZAB61ct7XFn9qlDyhgC0hOFkDHnaPQdMipdSge3hiU5WPbkAjlc9P/1UWGjyHxNZCfxJJeKXSWOBIlUHbznGfyNbulW6iKWwtvmXHmyyHr7/AOFYYkGo61fGfcCH2oc4KkdB/KtDR0uWmEqJKXLBHBHHA6j86nm0ubxikddElpBceYN0COF2Z4HGO/bmob7UIbeQRQMZ3MgdlPAbjGM9Mf4Vo3FqLqyt4VWJYWf58ruPAzjA7etYMUVpb3MlvcTII45Azg8E9cEdwOxAodyLodfwSOriM7bpmxCEPAzxhT16da19KuoLeCGKM3EMxUxhQnHtz+dYV3NJFLDf20QEAkBVAcO+eAB6evt3robeC/8AIDxPELlsTLFj+IccU73Je2pvxagYAkD2rNOoGNshzyOufw780l3cPBamaeXypZGHCpgbccoQOhPrVHSLu1klt4XiZZlY5ZWDOXycgH9cmpdceJUbzTKEZtzxlvmDDpn3PHShtlJFORZlje5muw2yJfL3LtLrn7p5+nNcdrmqxWtnLFMhEaLlGAOFycnn0wcf410HiPUVs3WSe4ZrlYhHKSAxY4Jx6dgOK8v8U6tJLGUBCDIBU4LPjJ2qvfnqaSWtiZS0uzifEN5HeX77Y/s8W7kAc4HqPWsySQHyQsYRAuAOp+pqREe7klmkkw7ZZVwWaViR8oA9j34/HApwt2aQrKDv6YU7jnHArZaI85tybY6yDPdMHIG47M49TzXqVjB9qsAElnF2x/cR8ALGo+Zjx1OcAexrhrOIyXkk2CJGYPHEDnBPck+nOK9GsIPsls80GWIQqgkBPyjBJB7dOgrCrI7MPGxuaTLGjMyoRAi5UdyT7fj+tdHaRkQoZVXA5O3+EHt71zmleVIiurnET7VC9Se+foK6W3dg4UYEbZB5zkZ4zXKzsLUbrnDdF7jv71LJJuTKEAg/e9Ka8fkkjbhhxnPBFPcBABhWDD1qDRD8Y2nI46N2pICCXDHjrTcN5BQ9eoxTfMA2HAU4wcfzpFouwPhiMnaeox1ojkZZf3YBBHNM3HPy9PX1pVjff8uc9cCoKL0MwdSo6+tTWu5g+W57CqUQVZBwferUYbIKtSE0XIMjdxTkjKsCp+uaVF8tRyOalDLyaZkyVRgDHU1IvUd6YpxFzTvlTaV5zQIVyfMPpTGbMme9OP3iSeKhlkG7jtTY0iWU/LTAuUyDzSO25Md6apKg4pCG57GnOcL9aRD8pyKr3TEAc/hQG7HMBtPc9ap3L7Rv4Bz0pZJCu3vnrUVwu8ggZPehDsQdyxOSaZt+TjOc807O9emADyajuJSh+UHHfmrGRXBAYIScVn3edp2n5jyvb8KvXJ6uCScdxVM8oMqMgdc+tUiXqZt8/kRDeFV92Sp5A9q5rxCudOkxubcpZWAx64P6Gur1W3W6VSpVHQbEwMlj1yfUVkanFJJa5ll2soGNo4yO349KuJjI8GvQ1jf3UTYQucElQ25TznkcH3FZkzLIH2OxGc4Ixn0rpfGVv9m1iR5EDdOeCADzjH41lXcds9qJYdgfcAev5n2rui+p58o7osaVc+ddW4uJXjEY5fGcDGOe/avUdP8AKubGLbG4dhs3LISkmf4Tnkd+DXkGm3P2S6BG3DfIwPIIr0jQ7gxmSESBbR1V2wpOCTgAHrnv+VTJam9GWljrtGa9SxV7Z9/2dy7xAgGYZwMH17Y7kCtqHWkETvepMgkbP71M+ac4BzgYPXiuQ03Vbe1GJJJppQ2dmw53ZJDEnjHHI+ldFp0Ueo3ZaZxAsDfJsOf3rc7SSOSPao2Oha7l1HBSGW20+RpFZgyx5SPLdgT/ABAY4ouZ3tYmlS22vEzxltvmNuIyMcnIPStsLdX8BhRBFsdgWk+cB92dwA6nB/CsF4/s08qymS61Ayf6M5k2YkQ/e29OOPy9aYXK2mrHuSPUrkzRyy4eCJTuQnJ+Y+w7V0dvc2KJiyQqqAxbXGUHYZPcn0/+vWLYqqrve2c3EjNIxX7gy2OxziuhtYZZA6tKtoQcRIyjy1AGcjcDk8Zqo7GUk5assQyy29rEt+ySSYwUQ/JENxIUD0GazPEb7LCW5W4BEalghPy4x1PfGauG0i8uSa5LztjIL8AehAx+tec/FKS9m8OSW0JZJriUHyYhjcByQT+PSm2CVtTnvDDvfpvjCl5GMjM3UFj/APrrqIZo7C+lN3OWFxHuwMs4IHQjtxiuR8OAi23w7xKyBQo4Ab1/DNdXZ6dtR50UNNEqSspP3lOB1PJOTzUOVtEb2utTQsp9U1d/NtiLSMjYgVOQo6nJz1NSS6WLSxeVmEkrHc5ZAcevXvXRWarb6aZLTqMEuRgKCM59sdKojUfPs1FvFLKWBik3/KMHq2ehNKze7Iv2JNFsbFdRtkuW2xrtMknLBFwSenftWncWskOntcW6nzYWZkxnoeSAOvSsfSSLO9jWRpIwrhkct8rAdAR3/rXRsxt4lmuZC8at8wTA2+h6ZFUtrCaszP0tlgs2uooBciRAiLEmGQkcknv16mqWt38cNkkl9C+5JAka43MMEbjnv0ArU8xrLUYmiaJ7eR8yxE5OMdQOntXm/wATPEot5jDGiKz5ZY4iSdoOAM9skdvTNFuwnKxj69qV9qupT/vTFbxTtJKvC5BPIBI4OABn2rzzxDei71eV7YFLWF2RRnYT1HPviotX1EXJYR5w+N+WJ3Y7D0Geap20e+E/IzEsFDdQPYDuauKscdSfM7Iu6daNLqEbzJLDCSMmIfMqdPl7E9qngj2yB4PLaV22YHJUdOPz9qksrGJI8MG+YAsCSK1FsriVAxMIkkUqNqBdir1wPpxnvUuRcaZNo9mst3H9maVjK7lJHULhF4Bx68V6Jb+SqWtvA7uY5NuXABx1Pt61y+mR+TcwxwCOQsmx3AIVD1GPp3+ldhsjXToJUVzNNhtjnJLegPpXPN3OyEbDtLY2TG3UGaYqWwq5zk/oa6HS1dUYT7TMTn5ew7D3rndKtp7eUXDx8XI+ZFb+Id8/56V0dixJcDhU7k8gGsjXqXs7mUqNwJ+761LhSPmGQDxjqKqxSpKJCp+5yMDG76VYjkSOGN8sGc4A71DNEOmlZJSTyg7iq+1t33MbuV96lKFm3TErnPHoaeoVw25uV6YqWWtCSKVllUEqrevarEG5p8A8etVAVZUwASPerMOd4BUk+1SMt5Utgkj+tOgGN2OQTTYySCHXn1qXyxsyG59KQiwmUyppVLFyuQVHem243FlbH41KqjAGOlBJLE/Kqx4qYJ+9HcZpixlQD1qSPKlT15qkQx7ISWFVnhOelaJByapylt2B0oa0BMik+UAYGaQHjFEiknmmqDv5pXGxRxVe4wXyO3WrEnHGOarnEaksfvUEorMQxJYfSoSxyQv51K5LNxjb61FIAie+aCyLILhRn3qG76ZPftUzMC+VU9Kq3Q3uOpA65qxiXCgoOB05qtKMqd/JYYyatXBLEBfu9cCoZv3iMGwMjPFNEtGfdKoGA3zZxkVnXgXYsSNxtOPbH+TWsYs23JB3EE1mXyKApYqEjyGGOST05rRGUjy/4hWaS2aTD5WyHYYzuAOP0Bz+dcjEn2i0jhjhLvD8xjDcMO5/HivUtS0w6pBeQRyJLOkbXCxgH7oU7lA7nGTx6V5VICT5ROVClSUYZDDpxxjjNdMHdHHUVpFC4CvHvUgyIQdpX68V2Xh3Vre4hhWdABjy2TGSxA+XnH+cCuZ1PTZbYK8oikKDLMj544Gai0m8EVyQMeWQdoIyP901o1dERlyS1PW7yOW2sl8iRZ5blwMMp3B+20n8AM1ZXUXstOhwklyzMHkt3QApJyM/TOeR64rl/DmrtPb2qXcF26lwqFJBsBGcDJxj1rodSsrm7tppry5nhUBpPsm48c9Sx6544qN9zov1R02h65tdZ2mvLeOV98iGN2Qqw5IY9u+Ca2XubRY53tIDPMr70ctu2knPzHp+XauB8Pae+lyXkM104jTc0iffQ/LkEk89zwD2rZtYp47IGxeWG1gdXIRSqS9STj8Rxnj3oSYSlc3tPgm+3XN7dRwqWHmKsY+RBnPQ9hkmt+KWKef7d5hnmYiNwSFG0ngAYwp74FZtvZRiaGWa3e5mRFITzNyrnkZ9frWhEbmSxnXbuiVjmTcAIz3xwMk+vaq1TsOK5tSrfFLeQGRX2Kc7WJfcPpXnniC7m1nV0SGMiG33MwOVJB7+o7V6DNcTwaVM0zlpmBMkrnIx7e2MVwHh0vJHf3Fy0isJ8OccqvUZHp0qU3zFtJXZhaPp5FvcvA0kcgZxjJxkHoa6tdQgbR9OvVDRShPK27fvlWwV+uf1FY2h6nFaXWrvcFCYrhpdmMZUgYOPSq+kwXMlzNPLGWinaRkT+CEOc/8AfRFNtJBu7HXaRJNdNeiZvLt1UBYlOPPJI3ZPO3Az064rds9NWOMpCjfNhmVjwoJ9DSaZaK1sYrfIIGU5wCR61bj1GGOORSzxXRUKyP0fHXk/h0pXvuVy9iVtPt7gpLJy0E5RlABXrgHPeq+oCSKwaOUJDExKSSMMkYGOueSahnnuUsWFv5LK42bElBIOemR1Ncn4h8Rx6TYK2oYkhUACIAlhIcgZz1wQfzpkPTqZniPW4NEsm+0m4aTYRHFGRzg8Bj2HJP4147ql9PeXUnmH5mJzk8nPbPpW94k1WXUpY725heK35FvEvAxnufrnnFcvNI12xdyioMgAHg9P0qoqxyVanNoRwxAg5yWPC4B5/wDrVo6dYTNONiMZWbykVepc9qtaPZ7Lgm5icAcKoHzMR2x1xnFbbg29lFcGOOJw287gdwcdAB2OP6USkKFMrR2ZNu2XHkxMybdwVmIIGTnryOg6cVs6dZtPqMMFxKGjMe79wNxcHBC57dTnHpUVravdss6lnkhTBjZPlQMRubGf65rqrCCUNHbi3NwxfzA4QIrY69T06VlJ9DpjE0ru3jb7KtlxHbrsRWwhZV5/PGaksbkSzqYYdqlNp8znyj3IA61VsbUSakBHDud2JJ6Dj09O9bmnwx3HzFBFO52rJ/dA7Cudm6Vitd+duVLZ3maPDeYikCP8PetWz+ypuaPczu3LPwxJ9aILBAhLShgM5UjH5kdTUtrboE2SR7sNnG3FRfuWl2L7IscY2SKZM8jHT15qwu0nJUZAxx3rOjjMbuyT7V67Zeh9qmhutpWKQBQT8pH3QaVzRIvyqPLz/Sq0Q8txwGBOee1WsHaFJyvqKiOfNAGMdKkqI4hRLkAYJyQKnRk3EgsoqNAOdwxg8VbVd2HGM9x61I2KkjMBlfxFPJyy54qIAlySNqemKSRgY+Dk5/KkI0YQBy+CG6EVZVVyOeKzVyseSeccCp4bgEKpHJoJcepfb5SNpyKRyS67enemqcDFOQ/OO3NUiS87ks3HFU5XIerDE7jVafGDnim2TFDHbec4xSRrnJ7imRAtn0qfaAhqdxsjfOOagm+dcAdKkdjnA61FhsHGBQJFaUiNQOBnrVeTBfJYdMCpNS3SKoVRweTSKAI8cZHSg06XK4VxuC5wvJqHG48/d9KsKT+8+Y81CnCk8n3NUgGsCkblfxx6UjAlkTCKcYyR0HvUx4jGDnJ6d6juVztO0+hNUhGcyyMzIgwpXG7/AArM1FfmeMK235Tluc461vsMM7sAu3oKz76JGmYJuI2ADPr3qzORzepwkOSmQsi53KPmHc4968517SYrmW5vbddw4lDAbQ4/Dpye9eq3CMsG+PczJlmUD06GvOb6V7W5mWN3CM7xbkOcK2fkORg1tTlY56kbo42QRTQxTSbp94ZXBXGzup465GazNStGtPKkiVSjkMo3dD1/ya67TrB7HUYsyeYmwTeWUwqt0Ix+v0NHia1zpodbYqGJZDs4UHJwB1AI5H0NaqVpWMXT5o3JvBd0l/ZLp7KPM83fG2cEd8/gV4+td893cX8QtZFjkkhffM6cfIOQBk9TxkYrxPQ7iS21AyoQksXzqT/EP/rV7B4Y1WNLe4v7uSKOKRlJKgMxyB2Pr6U5KzHTldElmo/4SlGvD5yTpueSP/VggZGV6cAjt3rstKliuLSOT7SoUk+bzwR/tfy/CuWGnvELWeFnTypA8pZcEgt8wx04yK6OwjSK4naVxOJEBEqgZUk9cduc/pTTsU0rialYS6bbrf2dwBawybjGWO4Kx+6AeDjr+PFb+mTWouRGFaYMMq5f92Ox46Cqu6JRN57+aJODnG2HA9cdx39a5K21lbPVLi3ZZTa3L74RzkHABOB0JwT3oVlqaptnU6xClwpR5SS7H90nIJ7En/Cucms5YdWupbKXym8hUmVhuWTnAyvfvzWvFdSvCGtrSdlXjzdhC5PfJrM1m4+y2E1w6bYUG95WPXHUD1qW7O40uY89h0x7/wAVXIkA+wI3y9QAwHIxnkD3r07R7eI6alqit0O/C559fw9a5HwlG8+nCZvmlmaSVs9izHC/gMV3el2pjiUF9hVdz7Tx+nSpu29BtJINLhkitSjsUBcoWPJ46KewB9afrOoLHDFEZDFfo4KCZM7eOeQMYxxnmnawXS3dzNGURDleVO36j6V51rl/HqF7F9luJ5LeKMu0md+18YHXjj1qkraEuV9TZ1rxZaWVzJb7rZ7gDIjhJZiT04AwCc8155qaajresQvdBIzICUySUQgEkfUDrjv3rrdI8OW8qxHTj9m3B1mkuAQ8gPQgEdMc5HfNY/i1xoluYozbrKyKI5OWkYYznPTBz+OaexnLVanBa0IfJWO3YvNI+ZVA+gFVra1MwYn5QWwV6DIxj6U+1iN1c3lyjNjorbcZYn09etb0enpDboYZSJ9hKQSDJ64I/Qd6blbQxjDm1ItPtnaRGS9mhKMPljG4564L8AfjXRaDp3nSrc3EqzTHIXdLv2Y6Egcf40zSbSGFbf7VeSLCrbJ4zuCM27jOOGHHStaCWDUL2JHx5UTMVlCmMFfcng9OnSs5M3jGxe0i3T7ekdyItsknzSAjhjyRz6ZFXr+ZW1VIbcOkawqu2POXOTnGfWo44Sj2jx+W0ilpGMQ2gEYA9fWq/wBof+3UmkiZnMeHO8bjjJyffOKxZsu5ehSJr6VYnYSowyFyNoxz+NbFu8bSGNEJjJILgfxVzypLJdyXMjGKaUZRwdo4659a2IRK0aERxxmTpIsmeQf88VDLsatom2J96OUGCcHJB+lXbed/LYsyxr0YsOfrUUKF5S8qyR3AG1yDxn+VaQitxEWbDNjndzmpsWnoQNBBGQxw7DksT1qSGIySBGQFW6A0HY+1Fh2xsOpFXIYdu0BskfpSZSGCzAVvKcow/h6iqh3R4LjLd8VrqrKykYOfvVHcIFcFlDKfapLiyvFl4fmA+Y/eNXIvkTGM46EVEkasPl4APSpHxDxwR2Oalh5AWLZ56U2BMkkDJ71K8YGHXGGHalVSp3IQT7UB0JmWMgYBwBTGjAZdp/GpEZuFkAGelTLtxgkc0idhYtxXLEE9qVUcuvPegDHTpUsQ+cZPBqrEltyctVOQ/Oc9KtOetUXyz0SFEkQgGnyZwOeKREwuTUTE55NInqROv7z+tG75W7U3czSEAcetE5CA9M+tA/IqzNuJB4FRYJ56c0n3pSSeM1OIyc+9BZE0KkNt/OoE4G1hwDnFWJH2dBntTFZnJAXoOBiqQEJYRsWXk9h6VHJlosjOVPIqYqVjboMnmm4XBQnAxzTQmVgqscgYLHBYnqajuc7lORhf6VIYFLbmOAORio5tsa88qOh9atES0Ma9jM3nlzjcMlV4GPSuP1S0b+0LZy24IQqr1XAG4Aj9ea724RggfaSpXgf3a5q9g8mVvOjwGcAYODk8cH2rSL1MZI4q7b7FqLNFELi2upiqlRlh6rnqOpwKk1K4sXtl8i4CgbYwAPmADEd+MDAJHbmi+hkQMDtcb/M8oLhyVJB/EgA//rpp06O5lvrecyo8TKcONrfNuLMCOuMEfhWr11M43TsefagjLfb4xGgWRgBGflGCcjB65zXXeEWt52gmMrNLG58yKU7VA9j2P14IpNe0NFuiDjLxhiGBG5wQCcnoe/41g6bLd6Bq3m2jb+0ik8kD/wCtjn3rS/MjPlcJXPVNRmubQXEEN7bSQPtZEkOMqeoyOmMVr6VqGnyiYtcwyRShdymQAhgvb1HT8eK5TTbrT9ZurcXUz2jjaqxEDeXx1DY2468/gTWnLo8dsYrxI7wIMGSbzAzYbGCAevoQKSdzVo7iJpNUltowjJbx4l3XCbUwOi46k8d653xNo0txILy0dYWUsFKk5Q45IP8AnvUtlrAtbZmutQVoshijIQ788fKelbEw+22sM0uVhJDFFPyohPOSe5/Sh6jTsctaa20MX2fUXdbqEgY3A7srwwGOlZGp3a63ILeOaaeFQHmJXaqpuwAPXJ/rVvxTYLG9xrNqsc8kLj5JEDKyY+6AfpxVbwTrtte69ceaiPHOVXCR4AULkLgdMUWursaqcrskdDp1ittDMbZUVwxZolPVfb+daFnqMNhIVuJMrMMxOW6f7Pvxn8aVJfMspjBbxSGFSqFsg9cAke1ZumafHHIrSRh5UfD7zncSP5cUnGwJ3vcguLm41rU5E02SaPTE4klZd34DjoOB/WrOmaWltoqR25AnhzuWQbGBzjgYyRj8DmrkEsdlcmW6urlIi/lIM7xExJIx65BAzzijVZle5s2vXiZY/wB6CHycEH7+OnTp0oRMh2q30NqgvZ5ke2CkhS2Y8+pyOg449q8P8Z6tLql88m4GVjgNnop/lwQMV2msouvXyJ5hWxhUzzYyiHb6+p5615vfzpeXk9xHGEgZmMQHACjgce/Jql3MZroX/DMUjeWIwoUNvZyM56AfrzXVXwkmubQm53xrtVV4RVC5YliOc54/KsbTtMeOFVEkuY0TcsRwDu5GT37jj0rct7G+v7hriO5cPCxR2BzsHf5sY6Dt61m3dm0Y2ikxbSxu7q5nme6jMSyZ82PO3nBOMjg5OMgevNbX2X7IHjKKyl1iA356jOcn0/rV7SI7aGCWJZY5bjyldiw+6FPG0n1/nT7zyBFmRBukfMgHvjBqGy4ozdS+WeMRSNlcRxsPRRkn8Ov4Vo2VpFZSiVGebbwjkFlJx82TST6ZLbyoZl3PHxgnIJY9x7Cr1wj2dva2ysTFG5+btjGQT/Ko23NFqtC3pwV7eFtiM7qTkr93Ocipvs0jPvg2bDw6Ho2O/wBarQS+YqSxbQoJIUc7T3/WtWxSVreJ4/LMjDOwVO5SK5Bt2aW3YAJhZEU/60Hr+VbNtGZQI5C+3bnAHArNjtbgTKpaNYTnlfmOfpWlCSvmpDKxkTCjPHFSUkXkRdojGCF4z6VMpELbGHPY1DDHDEpBcncMnnJqT/R0YFSzA9yaRSLCEsoOAMcfWorotn5iTxjipUwNwUHnnBprRFhwTkdRUspFe0LbipzV0QFuGQGm2o2OOM7qtbG3D+7U7A3qQqqAMhBUg9KYyrHnbUoRRNnrzUxCgkFeDQBFB+8IzjinFAr8561FCfLlZWHyno1Whhxjg0JCegADotOUEYHfNIo2dc5p45YfWqRLLUhHzZqmD81TXRIDfWq0QY5JzRISWhOX6gVE4HU81IiY680kgznikSMG0VTuQWP1q0TleRxUFwMbQO9Gw1uVomUYBGTntVmZFMfFQKmDkDmiSQkbe3ekW0V9wWUg805FGSynpTSBJN8vQd6kXCI20FhTQ2Vt2WYBSSTxTmwWUEZ+lWNmVUgct1pk4UEAccY4qkJkE4RkLKCMcD6VVmjDRKSRsJxxyasouUkye2ahtwFJPRlPHFWiGUJlaNNqEtC3BXvXN3qmCR3C7hnhDzk9a6/UsOQV+UjHBrndYjQXGS5dT1P4ciqRnI4rUolbUVVzIUceZ8hwVOeSD1qtqa3GnXq3qzSSLCVQTn5sqckrJ7/561f1kpFcwRuiP5i/K8pOVAwcE+n+FWo7OfUrUwwlYZHkYNEsQZFIJIJAxkYxz6GtlsZdRmpzzSWcN+AzpOiGKFYt5iygAfPO4Y6r+Vec69YyRuzBDDNkcjgIfT6HjB967vStSS2sHtbt/s8YlIhTy9yB1PIV+u0nnHv0rP8AE+nLfJBdpGkm4GGR4GwGHUMAenpn9aIysypQujktGW8e5ljZ2yh4DMeMjOR+Rr0Hw9rki2cNlqqSv5ahYX4KtjkD26cV5ldiZS07NIdQt5VAyOGTHB/Guti8QQ6ppiMSYbobQ2VwEYMDwewq2upnTa+FnoerWL39nNPbzQJD5hPmFfmjz1HqeuMio7b+0hfJazr50UgGxrWNduAMnOT8xxk4z1FR6U1rDBbykzwXMbFVnZikTDp9zHPrk1YbVlhgZJYYp7xXZI5wxZCf4cADjj1xSv3Ls9kUZL+zulntS0qJbI0jPOuxpWzjGBkZ7YH4c1yXh3OjeKkDKlrJd7mTcRsRh1U59Rz9RXSQ3tvJfKLuOSJ42WQqoA3lTnPt36+tct42dbzX4Yr2OGMu+5YwmCgJPLe4yOlVF31FNNaHpcV2bqc29uYUi3BpCSdzEdv857VZ1BLJDZy7Yhc24OFVmLOex4H1rnLWSHT7WC2MsY5ByB97AyP61cTVnvPPh07yA8YCmdmxjudo/wDr0X7it2LEdu10FlvmZ4i5IhQ7Id46lmHcVh6xJZ3zSXKSoLlF82NIm37h6gYwB7VoR2sl/piwy3GYnTDrCiruIcKcsT17/wBawfiDrkGjWs9o88NzeShdkaoMxgdASCcCluDdtznPGWuXU0I0/wC0Iod/MuDEM7OAQpx68cVzWkRJcSMJuLaENI7HjJHRR6kk4pbWASWrFv8AXS9QFIGTyeP1zW/omkpLEkJkSFmdVLTYAiXjLHPTPQf/AF6UpW0FCDk7ly1SS4EUZjkiMuFlRfvHJwFUjocZ5+tdLpNpNHJNH5/kRODtQDoQoGCemeelQabZ2yteXj7/ALHZuMnJy0p7/gCcD1JrYlla3haCMRpPKrFVwMgE8j68Vlc6LDJrGbzWnjZltmRIWTjJAGT79zSzBJTpzMG82NTGZBzkAfKT60TTfabNTFHuVMHhcNwoHHrxTbaK7OUieNreJIpoznDkZIP1PH86Vwsb5u5L5pJmUFJnwwx0OMfzGKfbWvSOVgsThsRsuQPTGexqhbyeciRnfAzSbowjAxv6nPX8K1CHWFIiS2wYBNS3fUaVtCtY2H2S4MsbOkZ/1sa8DHTpU9oskLtAIcLjMThuv1NXWWKKKNy/zN94setNeZZYmjAOf4SB3qS0VwzLDI0khUA87afY+bcodgCBhw7ck1DfAsBFghSRkAdcd61oo1ikh2D5D1X0pWKRatI1jAUKOeCT1zV0xK6+WTwo49agldI3Xy/ndjgLSG4eN3MqqCeg7ikNLsWYiQSCclR1pxmRwVBBI6kdaqwK9y4ckxxnjjqamS0RJn8rjI/OkOxasiGy2OlX4wOM9az7ceUhyDTmmO3cp+XNS0Jq7LBC+dyv40Mu4VJbussQc9cU49MU7EkCgAbSOPekQAvwcY461KFyhDdajWNRyBg+9KwyYc4Gam2D5frUAIHA61YjyQPXNUSxl1+tRqpA4p11IAxFIjgDJpPcXQdjaOailfEZNSGTd0qCdCRg0hJdyJJNynjimyDBBPWlTAG3FLHh2OegpFdSKQgAACo3CEAbTnvViRVyAo4702cfISByOOKSKTK33WXAxnpT2DhDxg0qhl2k9vWnxFi7MRx1qhsjGQo7Y61Ul+/jBI9KujOWPbriqM6tkyK3A71SJK8TbdzblP8AsmnK2JMr8x7jtiliWI/K6jGOT6mhikS4xjIxiqArXyxiBiCSdwGT3rC1Xy2LFCWHIBA6Vr6hJEy7V4wM/XFZN+pUO+eMcH61aMpHHeK0ge6hRceSjhCx4Oc81buNQeLTI5HkW0Yb5FjcYLsu4Ag9VOD+vINZ2oQSahf/AGeBQFCtKWZsdFx+GTVPWLwXupWNhcQJZzGOOMyFi6u3Ule2Tke9ap2MrX0KOleI52hlgaG3LzCNS83V9rdcev5Zx0rTttMjn0hFkvoEY7t6bgNuDwQMA/kaW4sUg1rUbLySsU8SMoABIbHJBzxjBzg1YnnjuYEjjjIni2GSR41UDB9cfMMH+VTdXNVF2OQ1a2GWillj89VUJIr53g5yR9B1Fc9JbTWBecBliY5aNhzIhGM+4r0TUNHMmowXfnKY5UMu4RrkA8AYHQHOeeaZrmk3EdpbM1viG3jOB03ZIJGfyq4ztoZzpX1LfhPV47nRvs9tN5MyyKrMzE4ORzknGcetdAsFzprQyRXP2aBnOJJINwQ5GSvJ5IPX8K8buEm0zWmuF32rckCUfewc4YD19a9V8J69bazpoP2ZkfYQY9xdWb0x2ycVTXYmEr6MtGL7MPLFyJZWcsLk4RmPJO7354Fed+I7do9Qa+uGjXyckxKd2VPU5PRia9GuordRMr2bQmQFmmky/lMP4sjPA54HJ/CuH8Vx250JpITm2xvlV0O/f6kn1NC0ZU9Uy54ZvrqWxjiVPMhlJcmdgwYcgEgc9jzXXR2sSWMSXMQ2W6M2VwNxx0z1P0BrkPDTC3h2M8UdxMVkwfQgDB+hyK6RpVWWRDcRyQxBicjKsxx8i9z6k/hTe4orQ5m/1hrW2mS1FvEkkmTLs5fnPQ9D6kYFcbrKeckcrgtc3PMcIbexTnlj13Z/TFb3iu9XU9W2LMjRwgqNgwVJ42gd6zYbGU3ySBjLMMMqIN2VHGT6D8qLpESTk7Glo1oIIrN2jeXDAfKceaRjAHt0rq9P0iee5v2cQrIGJlyBtYY4Qe46bqs+H9CaGxiub1zHcth1KnJCeuBwB3rX03cmpTXNxC62cqMkXykH5ejn64PFYvU6krKyMCydbe+awMPlMQv7sZ+fA6HvuBwc1f04ytrEhnj3PGNok/iVmIOTWnJpMWom6vixju4CotpwB125I+ntWXYwvaw3isZSfMXKICd4PG7PXqOfpSsG5KYXsdXvopnYeWRPFKHIGOhA9jT/APSbXV7aR+beQoOVyFB6cg5xVfWVmk1OW6UyTpblQGcHBXHK+/JrpCrTm1fcux0V0wM5QjjPvQJlKSK4klvcRpHEjeYijoGHYGrsF21xDtjHzNycjoKqScO0Sy73ZGyP7wwcH69qn0qRPKiVSPNVQVHTk9c1IK5pQiEeX0Zh1LevfFT26tPM2CQkfK571UjwJibgfLjAx/OrNpKJEZEBD+p4zSNENnwJXfJ4wNtaNrmWNs8LjII61UaHyt5Y5Jwfar0LLHals8jnPrSKsCxxqcKx2nkHvU8e9golQdeveodMgNxunbqT8vtWisZ3EN3NIYsQ24AHzDmlaRnc7Fw3tTd7RTbuWU8YHanx/NNvjxilZAiRJNsWZVIzUDLzhOR1xWhNH56KvfrVYxtA3K5U9xQEWTWYxGcjFSnJB4x6U2FgfumpCe3WlYliKOgJocDAwc1HJkYK8VFFIxkIagLE2MGpImO4c96YFycg0L94fWmiWPkXMjH3qBg2/wBqsqMuee9GwK2aViUyNcdD1pJ3AXilflzTHUkHAoAjjG4EnvTtuKfGhVakRCe1SyiizkTDI4qWSTEe4DJqaRAWwR0odQ2BjpSBtFPzSVORjNNIIXIbAPGKknt9zjBwDTLjapCg/NTRSs9iJ2YIQo5NZ07NG3I4HvWhKH24XrVJodxYZyw4q0MhcEEbMcjP0onm3dfnP8qivmMKKqkjJANRLIqRbTnHf61QiO8jBlRk+YY4+tZOpuoidA2RgnIFarlQELMQqjn61zmqSZSYZO7JHWqRjMyNMuLe2ub28nwUjRQQT15JxUV1bPqdmrzLxBMbh7dmAOc5bcc/LgcflUU0lpb2oj1KUW9tcTEg5O5gAPlGO5JGK0dOju2s7qSOJlGSWjAxK4z0LH8DjrVt6WFBa3MuC/ub7WhdRJcXMKDy1WIZkCYOc9j279Kva3JbXdkS0+5Q4McMaAgYwTu6bj19MVvaHpBgsElKNDtT5pI3zgn+9z0HpWfqFkL3UvJunjiuZwPM3AAsueNp4IBB+vSouapK4zw/aCT7PbyDaV8qcAHIZRnp7YPI9TWrq9u11NqCTuTBAxkXyjyM4Pzd8AenpTNRgjS5nube6urUW0KuV+UkHJUAEjp0qIWUkzQSXl2XieXDK/yrM3/xPt3xTiKWurON8Sabc6hqkd1iGV1QiF2AGVXJG4dDnA/Aisi1tbrw3NG7ZBj/AOPmFMsNvBDDuB1IPTtXfXEDNL5QRxM5BjK45wduOeg4B+gFZuuaUkLLKrSPKkbLIVZh5h4K5OfmBAYY44rWMrGMo3ehds/EGkXOmq0l9CyxMZFSVgjjjrjqfyrhfGV95jtdyRo+4h9hAIOD8pbsR7Y7Vq6pZ22nhvs8UKQTKPKlUAOpIyFbJwAe3PFc/qdr5+k3l6jQLBM32eMoThztySBjoD3rRK70MZu0Wma+modUlsvsHmgmPcXGF2sfr1HXirGqX14lgtuqRxTMzB5QM/dHO3PPvWd4dmZ7a3niYRssY85TkhVJwHAHXHr7VaaaSTUGkZYpmuirhZDhJPmwHHpnBOOmBSem5om2tCvpmmQ+TdIgZJZE8xhK4YlcjjOOueuMD3rf8NaZLaaa90VUXE3zSoQMBR0GR04/nUtnDLeXI2RKJASMOAdqbcBcemec1uaFZb9PhiAKQsAkq788dD16dDWcndmsYqKL1r5EtqgdTH5zlhGTksnQD6Yx+Rq3dW6yWd5aCSRUWLZESRjdg8Zx9DVS1X7EzSqoka3BR1A3MRnBH1xtNbFtbq9pElwT5bjC49cZqCjKsLW5GhWoEzTSlCrM397rz+OcH881Ukt/nsJg6IsjFT5nBCdRnGc4Nae2a3094oysTeYw3kZAIBAOPfpUD25h+zwSskytHuzg85xuH6E0xPe4otgI9hmErFt+CSAfr+lNhthY2O6PlVGHiXlRk84/nVu0IjkZZG3R79g3dQhwc+/OPzqK/Vo715FYi1dPLCA/xE/K38xUjQ2SIvZwhRmSJi6seoGfX6VZjgjjdQAvkv7cr3FQqsq2gCAJsyjdzj0p3nq1snl+ZLcD73p6c0gJnjP71VByvRfWoYPPhXfjIHXAqdZ7kOjNbquD03ZqaUiNDtXCOMjNBaLcLhmCno4yBT3QTbLdAVZj83sKy7aNopCZJGMajgg8r9Kv2kc8R89nDBzwT1xSKNi1g8kAK2VqeUhm46VFBJtG2TmmLKFlIwWHb2qbDQku4SDbwMc1JbKQ4zSzSRlhtOG69KmjAUZ6kikNvQnt5Myd9ucVamTKZ7dqrQZ2ZA5qeJmxhunp6UJEPyK8StHlWweeKnTBxTpV3KGHWoowd2DQF7kjJmqcsREmQcVbZzSSDIPGTTSFexBnYoGetPiGcHk80yWMgDNSQblI9M07CexMg2se9DkmlGRuOP0oG5+cGpsZkZDYprbgMVK4IHAP5U0hgnQ/lRYaYxQxHFTAmNPekiU+honBI6GpsVfoREk8jqaUfcpAjAEkGgA7TnNAMhmk28DrUAQvL5jADipgodmJUnHtULuwbainmmNO2w24O1GAIFU4xiROc7vTtVueJpANynn2qjcB4mAAOfYVSKRW1CPzHBXqvOKqEZXJwAOSauO7EMQCOxFUpGIDHacCqRLZU1F/3RYsAB/Ce9crqJYMiKNzY6e/pWzfyNJISVbIP61i+XPcXQitw32lgdhGcqe7fgM/pVIyk77EUemfbb1ZpuYoyoQP/q2Ydz6Ddj61r3UlzDJDPp/lC6T/AFscCHy5ADxnkjgfStnT9PSAxFTOkiABiWZhgfXjFXiLlbhPsEPmHOGCYUEepz0FJ6mkVYp+Hp0vt3mDZNG5MkWCMnttHcdeabrNv9p1uCcqivDG2GkPLEjofwyakvIpLIyT3EC+dKfmYZwPZT6n3qO5XKQzXRaFCxG0g7j65b1IP6UikVtahQRq+Wk84LGwzwFzwM9M55zRqqRPbC3nYbfljZCfukn71W9SszNbrBFn5QGHzHHByAf0qlFayTm7eVPMmJD/ALxeQcD5c+gqlqQ9DPW3Rtctfs0sjBYHUgEHaMqBg9uSTUWtwQ2TT5uCyRRFx5kgLA8ce5Hv2NaCRIbyS5tUeFGVdwGSMsc4APT7o6etZUym9jeeaBUimXMoCl2kAJwp/SrIOT1N4fsEXnN543AgFMqkeQdpP4muZ8WXkdxpMKQXLvAhISIrhYwR+XYc96665VpoJBfPNEqKpggVuAp7EY7flXD+KUuYlMdv5gtuq55B9R9Oa1psxxCsrljwldQrp0CDf5+4gAAEE9hnIwD7+9b6DytUiigCBgmQkke5YgeSDnpgjjHY1x/hiC5DxyJAzNG27ZsOGH+PGa7KzSVdTe4Km7t5HJdIwVZ9vOV9wO1FTcMO7xVzqtJuIoIxBc7obsje5cZEgPUgjr+PStbTLyJ/OaNhJPzISrbhGmSMsfb0HWq9tbW97bWc0m9URcIU4YAjr9Ola1tp6RhTDGzKCQJCBhTnPTHT1rGx0NkkUUiyPHbNGwlk3mQt1Y49O9W52uvskkc2yLaFRgD0VjwR6d/yptpElsQs8aCPLeXKqEY9vb29vpS3EDf2lFHjdHON75XqEPT9R+dDGtSJzHp+jSxpL5lrKhIOM7WbjqOvbntVK58yW3gjjV38pyUkQ57YH0HWtK7iaVhFjEbS7uRg7Q+c1XtTdxWk0qojWxkcFduGUZ64HbnNTcprQijcXEMbhAkjqcA9iOoP4c/hTpovOWJ2GWUEnPRhVOeCWGVIYWnfzEBTbwQwplpb3ZULcvKMZATGDx6+xpNiiXTdRi0kSMO7Mw5xxtGM5q1Zwutw1wpRYnG3YOR07mm21v5QKJC5Crkj1HfrVi3tGhaTfJIUbmJcdB6e9AFkrhF2fMpbIOOh9KhuAX/dsOh4yOAfar+0Kq9x3IH86bLGY3O8Er3OOvuKCkZcwd1EfSRmAIHetq3dfL2MACvKg9xVHKTXuASoiGFbaepqxCsiuQ6liBkcdvago0VQOVYH5D29PanxsqO2VyVPPvUEDSE7lQ4HDD+tTW6u25mUgHjGKQDzMNwXAOeealCsclDhutQLD/pC8cfSrxGwYxSBtdBsUzAgMnXuK0IyCM96qIcrjHNSpkL90nFFiGyZlGcqcGoWG05FOBZiMAgH2pjgg4wfypNAmABbqcikPysM9KRdy9P5VJgjG5DimhXEyrcHilj/AHeM880gQHsRUqdQCKols//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30298=[""].join("\n");
var outline_f29_37_30298=null;
var title_f29_37_30299="Class infantile seizures";
var content_f29_37_30299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed classification of infantile seizures (2 to 24 months)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Astatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sudden loss of muscle tone that may be focal (eg, head nod), hemibody or generalized (eg, fall or drop attack)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Behavioral",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abrupt change in behavior without other overt features (usually becomes quiet-hypomotor), occasionally autonomic signs (pallor, cyanosis, etc.)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Clonic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clonic jerking, usually of extremities or eyelids, occasionally followed by tonic posturing.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infantile spasms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       May be myoclonic or brief tonic flexor (adduction of arms with forward flexion of head and trunk) or extensor (abduction of arms with backward extension of head and trunk) spasms. These often occur in clusters.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Tonic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Symmetric or asymmetric posturing (occasional \"fencer posture\"), may be followed by focal or generalized clonic activity.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Versive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A forced and sustained tonic deviation of the eyes that is usually associated with ipsilateral turning of the head and rotation of the trunk.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Unclassified",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted form Nordii, DR, Bazil, CW, Scheur, ML, Pedley, TA, Epilepsia 1997; 38:553 and Acharya, JN, Wylie, E, Luders, HO, et al, Neurology 1997; 48:189.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30299=[""].join("\n");
var outline_f29_37_30299=null;
var title_f29_37_30300="Interferon induced diseases";
var content_f29_37_30300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interferon-induced or exacerbated diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Thyroid diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Asymptomatic thyroid peroxidase antibodies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hashimoto thyroiditis and hypothyroidism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Thyrotoxicosis (Graves' disease)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Destructive thyroiditis without thyroid antibodies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autoimmune hepatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes mellitus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Rheumatic disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Polyarthropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Rheumatoid arthritis-like syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Systemic lupus erythematosus-like syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Psoriatic arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Skin diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Psoriasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sarcoidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Lichenoid and eczematous eruptions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Fixed drug eruption",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Leukocytoclastic vasculitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Pulmonary diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Interstitional pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Bronchiolitis obliterans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sarcoidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pleural effusions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Asthma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Hematologic disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Autoimmune hemolytic anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Autoimmune thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Antiphospholipid antibody syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Neuromuscular diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sensory and sensorimotor neuropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mononeuritis multiplex",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Axonal neuropathies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Demyelinating nervous diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Myasthenia gravis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30300=[""].join("\n");
var outline_f29_37_30300=null;
var title_f29_37_30301="Infant feeding guide";
var content_f29_37_30301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infant feeding guide",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Age (months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        0 to 4",
"       </td>",
"       <td class=\"subtitle2\">",
"        4 to 6",
"       </td>",
"       <td class=\"subtitle2\">",
"        6 to 8",
"       </td>",
"       <td class=\"subtitle2\">",
"        8 to 10",
"       </td>",
"       <td class=\"subtitle2\">",
"        10 to 12",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Breast milk",
"        </p>",
"        <p>",
"         (#feedings)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Frequent feedings",
"        </p>",
"        <p>",
"         (8 to 12)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Frequent feedings",
"        </p>",
"        <p>",
"         (4 to 6)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         On demand",
"        </p>",
"        <p>",
"         (3 to 5)",
"        </p>",
"       </td>",
"       <td>",
"        On demand",
"       </td>",
"       <td>",
"        On demand",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Iron-fortified formula",
"        </p>",
"        <p>",
"         (#feedings)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         16 to 32 oz",
"        </p>",
"        <p>",
"         (8 to 12)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         24 to 40 oz",
"        </p>",
"        <p>",
"         (4 to 6)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         24 to 32 oz",
"        </p>",
"        <p>",
"         (3 to 5)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         16 to 32 oz",
"        </p>",
"        <p>",
"         (3 to 4)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         16 to 24 oz",
"        </p>",
"        <p>",
"         (3 to 4)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Cereals, bread",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        <p>",
"         Infant cereal",
"        </p>",
"        <p>",
"         1 to 4 tbsp twice per day",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Infant cereals",
"        </p>",
"        <p>",
"         Cream of wheat",
"        </p>",
"        <p>",
"         Other plain hot cereals",
"        </p>",
"        <p>",
"         Toast, bagel, crackers",
"        </p>",
"        <p>",
"         2 to 3 servings/day*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unsweetened hot or cold cereals",
"        </p>",
"        <p>",
"         Bread",
"        </p>",
"        <p>",
"         Rice",
"        </p>",
"        <p>",
"         Noodles",
"        </p>",
"        <p>",
"         4 servings/day*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Fruit",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        <p>",
"         Fresh/cooked pur&eacute;ed fruits",
"        </p>",
"        <p>",
"         Mashed bananas",
"        </p>",
"        <p>",
"         Applesauce",
"        </p>",
"        <p>",
"         1/2 cup per day",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Peeled, soft fruit wedges",
"        </p>",
"        <p>",
"         Bananas, peaches, pears, oranges, apples",
"        </p>",
"        <p>",
"         1 to 2 servings/day*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         All fresh fruits, peeled and seeded",
"        </p>",
"        <p>",
"         Canned fruits, packed in water or fruit juice",
"        </p>",
"        <p>",
"         2 servings/day*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Vegetables",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        <p>",
"         Strained or mashed vegetables",
"        </p>",
"        <p>",
"         Dark yellow, orange, or green (avoid corn)",
"        </p>",
"        <p>",
"         1/2 cup per day",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cooked and mashed fresh or frozen vegetables",
"        </p>",
"        <p>",
"         1 to 2 servings/day*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cooked vegetable pieces",
"        </p>",
"        <p>",
"         2 servings/day*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Protein foods",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        <p>",
"         Pur&eacute;ed meats",
"        </p>",
"        <p>",
"         1 to 2 servings per day*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lean meat, chicken, or fish (strained, chopped, or small tender pieces)",
"        </p>",
"        <p>",
"         Egg yolk",
"        </p>",
"        <p>",
"         Cooked dried beans",
"        </p>",
"        <p>",
"         2 servings per day*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Small tender pieces of meat, chicken, or fish (1 to 2 oz)",
"        </p>",
"        <p>",
"         Egg yolk",
"        </p>",
"        <p>",
"         Cheese",
"        </p>",
"        <p>",
"         Cooked dried beans",
"        </p>",
"        <p>",
"         2 to 3 servings per day*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruit juice",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        <p>",
"         Infant juice",
"        </p>",
"        <p>",
"         Vitamin C-fortified adult apple juice",
"        </p>",
"        <p>",
"         Offer from a cup",
"        </p>",
"        <p>",
"         4 oz per day",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         All 100 percent juices",
"        </p>",
"        <p>",
"         From a cup",
"        </p>",
"        <p>",
"         4 to 6 oz per day",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         All 100 percent juices",
"        </p>",
"        <p>",
"         From a cup",
"        </p>",
"        <p>",
"         4 to 6 oz per day",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * One serving size is considered to be one-half cup.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Massachusetts WIC program Nutrition Education Task Force.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30301=[""].join("\n");
var outline_f29_37_30301=null;
var title_f29_37_30302="UGI-SMA syndrome I";
var content_f29_37_30302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper gastrointestinal contrast study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This upper gastrointestinal contrast study (UGI) in an oblique projection demonstrates filling of the stomach and proximal duodenum with contrast (left side of photograph). Distal to this (dark arrowhead), there is compression of the third portion of the duodenum with only a scant amount of contrast in this region. This patient had repair of his scoliosis as evidenced by the hardware (right side of photograph).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30302=[""].join("\n");
var outline_f29_37_30302=null;
var title_f29_37_30303="Sea lice print-Seabather's eruption";
var content_f29_37_30303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sea lice print (Seabather's eruption)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Print of sea lice, Linuche unguiculata, at the contact area under the swimming suit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Junghanss T, Bodio M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright &copy; 2006 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_37_30303=[""].join("\n");
var outline_f29_37_30303=null;
